The antigenic evolution of human influenza A haemagglutinin by Lees, William Dunbar
ORBIT - Online Repository of Birkbeck Institutional Theses
Enabling Open Access to Birkbecks Research Degree output
The antigenic evolution of human influenza A haemag-
glutinin
http://bbktheses.da.ulcc.ac.uk/81/
Version: Public Version
Citation: Lees, William Dunbar (2014) The antigenic evolution of human influenza
A haemagglutinin. PhD thesis, Birkbeck, University of London.
c©2014 The Author(s)
All material available through ORBIT is protected by intellectual property law, including copyright law.
Any use made of the contents should comply with the relevant law.
Deposit guide
Contact: email
 1 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
 
The antigenic evolution of human 
influenza A haemagglutinin 
 
 
William Dunbar Lees 
 
 
 
 
 
 
 
 
 
 
Birkbeck, University of London 
15th September, 2013 
  
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I, William Dunbar Lees, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in the 
thesis. 
  
 3 
 
 
Abstract 
A detailed understanding of the B-cell response to influenza A haemagglutinin is key to the 
accurate matching of vaccines to seasonal strains, and may inform the development of broader 
spectrum vaccines. In this study, I develop techniques for predicting the location of the epitopes 
of protective antibodies by observing the physical locations of amino acid substitutions in 
human wild-type strains.  By linking the understanding gained from this analysis with a large 
body of assay data, I present a model which can predict antigenic distance from HA1 amino 
acid sequences and which meets or exceeds the predictive power of previously developed 
models while retaining generality. 
An interesting conclusion from the epitope analysis discussed above is that antibodies to the HA 
head bind in two regions. The antigenic evolution of influenza H3N2 is more punctuated than 
its genetic evolution.  I propose that the dual regions might contribute to the punctuated nature 
of antigenic evolution, and explore this through the use of a simple simulation. 
Stalk-binding antibodies to HA have attracted much interest in recent years: a number of broad-
binding examples have been isolated, and the slower evolution of the stalk gives hope that these 
may provide broad protection against future strains. Stalk-binding neutralising antibodies to H3 
are known to bind in two regions, and I use data from crystal studies to identify the constituent 
residues of these regions, which I term antigenic sites F and G, in a manner that is consistent 
with previous analyses of the constituent residues of HA1 antigenic sites A-E. I analyse the 
degree of conservation of residues in sites F and G, and conclude that there have been episodes 
of change in the H3 stalk which are consistent with antigenic evolution. 
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1 Introduction 
The global surveillance of influenza, mediated through the World Health Organisation (WHO), 
has yielded a substantial amount of sequence and antigenic information covering the evolution 
of the virus over the past 40 years. In this study I make use of that information to develop a 
deeper understanding of the specifics of antigenic evolution. The key objectives that underlie 
this work are: 
- The prediction of antigenic change 
- A greater understanding of the epitopes of protective antibodies to wild type strains 
- An understanding of the mechanism that gives rise to the clustered antigenic 
development observed in H3N2 antigenic maps. 
I first developed an approach for predicting epitopes of protective antibodies by observing the 
location of amino acid substitutions in successive dominant wild-type strains. An interesting 
result from this study was an indication that such epitopes group in two regions on the 
haemagglutinin monomer.  Consideration of the more membrane-proximal of these two regions 
led to speculation that antigenic activity might occur not just in haemagglutinin’s HA1 
polypeptide chain but also in the HA2 chain, which is not normally considered to be evolving 
antigenically.  My research coincided with an exciting period in which a number of human 
HA2-binding antibodies were isolated and studied in detail. I was therefore able to augment this 
computational study with experimental results from these studies, in order to form a hypothesis 
of antigenic evolution in HA2 that is consistent with rich experimental detail. 
In the course of the study, I developed a number of computational approaches which can 
support influenza surveillance and the research of influenza and other viruses, in particular: 
- Models to predict antigenic escape from sequence analysis, which can provide 
indicative results much more quickly than laboratory assays; 
- The use of large bodies of sequence data in combination with structural information in 
order to identify evolutionary events that are close both in distance and in time; 
- Visualisation tools that can rapidly and conveniently display information from an 
extensive sequence and antigenic database. 
While a number of influenza sequence databases are publicly available, to the best of my 
knowledge there is no equivalent publicly available antigenic database. 
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As both sequencing and antigenic surveillance become ever more pervasive, computational 
techniques such as the above will become applicable to a wider set of organisms, and, 
correspondingly, their use will become increasingly necessary in order to draw conclusions 
from the large amount of available data. The amount of data available for influenza itself is 
continuing to increase, putting a strain on existing analytical methods and creating new 
opportunities for research. I discuss the implications for the future in the concluding chapter. 
1.1 Influenza Structure 
Influenza A is an enveloped negative-sense RNA virus (Figure 1.1). It has two surface 
glycoproteins: haemagglutinin (HA), and neuraminidase (NA). HA carries the receptor binding 
site (RBS), which attaches to sialic acid located on proteins on the surface of the host cell. NA 
is a sialidase which removes the sialic acid, allowing budding virions manufactured by the cell 
to escape. The viral envelope consists of a lipid membrane, given strength and shape by an inner 
‘matrix’ protein, M1. A further matrix protein, M2, forms an ion channel through the envelope. 
The segmented genome consists of eight genes, each encapsulated in the nucleocapsid protein 
NP. Also present in the envelope are the proteins NEP, which mediates export of protein from 
the cell’s nucleus during assembly; NS1, which has various roles in circumventing the cell’s 
antiviral responses; and the proteins comprising the viral polymerase, PA, PB1, PB1-F2 and 
PB2. A final protein, N40, was discovered recently and is believed to have a role in viral 
replication (Wise et al., 2009). Detailed descriptions of structure and lifecycle may be found in 
Fields Virology (Palese et al., 2007) and Flint et al. (2009). 
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(this figure is not included in the public version) 
 
 
 
 
Figure 1.1: Structure of the Influenza A virion, adapted from Flint et al. (2009). It is not clear whether the recently 
discovered protein N40 is present in the envelope or merely synthesized during viral replication. It is shown in this 
figure for completeness. 
 
HA is a trimeric molecule in which each monomer is composed of two protein chains, HA1 and 
HA2 (Figure 1.2). The RBS is located in the globular head of HA1, towards the membrane-
distal tip of the protein. The RBS binds to sialic acid at the terminal end of sugar chains on the 
surface of host cells. In humans, on the cells in question, most sialic acid present has an α-2,6 
linkage, while in avian species, it mostly has an α-2,3 linkage. For an avian strain of influenza to 
reproduce efficiently in humans, adaptions to the RBS are required. Pigs have both receptors, 
and may present a bridge for such adaption (Klenk, Garten, and Matrosovich, 2011). 
HA is the major antigenic component of the virus (Wright, Neumann, and Kawaoka, 2007): the 
primary mechanism through which human hosts gain immunity to an influenza A strain is 
through the development of antibodies which neutralise the virus by binding to HA in the 
vicinity of the RBS and hence block host cell attachment. In addition to its role in host cell 
attachment, HA also undergoes a conformational change during the process of endocytosis. The 
conformational change enables fusion of the endosomal membrane with the viral envelope, 
releasing viral RNA and protein into the cytoplasm (Wiley and Skehel, 1987). The virus can be 
neutralised by antibodies which interfere with the process of membrane fusion by binding to the 
stem in the neighbourhood of the fusion peptide. The action and prevalence of such antibodies 
is discussed in Chapter 5. 
Influenza A HA and NA are divided into antigenic subtypes, determined by serology. Currently 
there are 17 subtypes of HA (1-17) and 9 of NA (1-9).  Structurally and phylogenetically, the 
HA and NA subtypes both fall in to two groups. For HA, group 1 consists of subtypes H1, 2, 5, 
6, 8, 9, 11, 12, 13, and 16, while group 2 consists of subtypes H3, 4, 7, 10, 14, and 15 (Skehel, 
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2009). The recently isolated H17 is thought to be closer to group 1 than group 2, but definitive 
phylogenetic analysis of this subtype has not completed (Tong et al., 2012).  
Through the breeding of escape mutants to mouse monoclonal antibodies, it was established that 
neutralising antibodies to human H1 and H3 strains bound to defined regions in the HA head 
(Wiley, Wilson, and Skehel, 1981; Caton et al., 1982; Wiley and Skehel, 1987; Wilson and Cox, 
1990). These are known as the antigenic sites. In H1, there are five sites, named Sa, Sb, Ca1, Ca2 
and Cb. In H3, there are also five sites, named A-E. Bush and co-workers subsequently 
compiled a list of amino acid residues comprising the five antigenic sites in H3 (Bush et al., 
1999), which I describe in greater detail in Section 5.6. This has been widely adopted in 
bioinformatics studies of H3 antigenicity and evolutionary pressure, and I shall describe it in 
this work as the ‘canonical list’ of H3 antigenic residues. 
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Figure 1.2: Spacefill view of  H3 haemagglutinin, from the crystal structure derived by Sauter et al., (1992), rendered 
in Jmol. One monomer is shown in white (HA1) and light brown (HA2), with the RBS shaded yellow and the 
fusogenically active region, consisting of the N-terminal residues of HA2 shaded dark red. The other two monomers 
are shaded grey. 
A subtype of influenza A is named according to its HA and NA subtypes, for example H3N2. 
The name of an influenza strain carries its type, host organism, place of isolation, strain number, 
and subtype, for example A/Human/Hong Kong/1/1968 (H3N2).  The host designation is often 
dropped in works, such as this, where the host is clear from the subject and context. 
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1.1.1 Epidemics and Pandemics 
In humans, influenza A HA undergoes rapid evolution under the selective pressure of 
neutralising antibodies. As a result of this evolution the virus can escape antibody action and re-
infect hosts that gained immunity to previous strains. This process of antigenic drift leads to 
regular epidemics, infecting 5-15% of the population each year. Drift variants typically persist 
for 2-5 years. In the US, influenza epidemics are estimated to cause on average of 20,000 deaths 
per year (Wright, Neumann, and Kawaoka, 2007). Influenza epidemics occur in the winter 
season in temperate regions, and as a result this disease is known as seasonal influenza. 
Influenza A infects a large variety of mammalian and avian species. Pigs and waterfowl in 
particular can act as reservoirs of different strains. Where a host becomes infected with multiple 
strains, the segmented genome lends itself to reassortment, occasionally resulting in the 
emergence of a novel strain. These novel strains, created by the process of antigenic shift, can 
cause pandemics in humans and other species. Since the beginning of the 20
th
 century, there 
have been five human pandemics: 1918 (H1N1), 1957 (H2N2), 1968 (H3N2), 1977 (H1N1) and 
2009 (H1N1). Of these, the most severe was the 1918 pandemic, which is estimated to have 
caused 25 million deaths in the first 12 months (Johnson and Mueller, 2002). Subsequent 
pandemics have been less severe. A definitive report on the 2009 pandemic is awaited from the 
WHO, but, in an initial study, global excess mortality in the first 12 months has been estimated 
at approximately 250,000 deaths, of which 80% were of individuals aged 65 or less (Dawood et 
al., 2012). In contrast to epidemic influenza, pandemic influenza is not seasonal. 
Pandemics can result in the displacement of one circulating human subtype by another. The 
H1N1 subtype circulated from 1918 until the 1957 pandemic, when it was displaced by H2N2. 
H2N2 circulated until 1968, when it was displaced by H3N2. In 1977 the H1N1 subtype was 
reintroduced: 1977 strains were closely related to those circulating in the late 1950s. From 1977 
to 2009, the H1N1 and H3N2 subtypes co-circulated. The 2009 pandemic strain is an H1N1 
subtype but antigenically more similar to 1918 strains than those isolated more recently. It 
replaced previously circulating H1N1 strains and continues to co-circulate with H3N2. Its 
subtype is usually written as H1N1pdm or pH1N1, to distinguish it from the seasonal strains 
which it displaced. 
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1.1.2 Influenza Vaccination 
Most vaccines today are based on the split-virus technique, licensed in 1968. In this technique, 
influenza virus is cultured in pathogen-free embryonated hen’s eggs. HA and NA are split from 
the intact virion using detergents, and separated via ultracentrifugation. The seasonal vaccine 
consists of HA from three strains, selected to be representative of the currently circulating 
strains of A/H1N1, A/H3N2 and influenza B (Osterholm, Kelley, Manske, et al., 2012). This 
vaccine is known as the trivalent inactivated vaccine (TIV). It is delivered via intramuscular 
injection. Because the influenza B strains have split into two antigenically different clades, 
quadrivalent forms, containing two influenza B strains, are currently under development (Barr 
and Jelley, 2012). 
An alternative vaccine, also available in many countries but much less widely used, uses cold-
adapted live attenuated influenza virus (LAIV). The strains are cold-adapted so that they will 
infect the upper respiratory tract only. Again, the vaccine contains three strains as for TIV, and 
the strains are cultured in embryonated chicken eggs. This vaccine is administered as a nasal 
spray (Carter and Curran, 2011).  
The strains used in seasonal vaccines must be regularly updated to allow for antigenic drift. The 
WHO conducts global surveillance of influenza strains through a network of national 
laboratories and regional collaborating centres. It issues recommendations for vaccine 
composition twice annually: in February for the Northern Hemisphere, and in September for the 
Southern Hemisphere. The timing allows approximately six months for national governments to 
review the recommendation and for manufacturers to create high-growth strains that will culture 
well in eggs, conduct trials, and ready stocks for the next season. In making the 
recommendation, the WHO’s advisory panel has to exercise judgement to predict the 
antigenicity of strains that will be circulating in 6-12 months’ time. They must balance the need 
to update a strain because of antigenic drift against possible manufacturing difficulties in 
culturing a new strain in eggs. The influenza vaccine is the only vaccine requiring annual 
review, update and administration to retain effectiveness. 
The development timeframe for the seasonal vaccine provides a window during which the virus 
may develop unexpectedly: hence the vaccine is not always well matched against circulating 
strains. The time needed to develop a pandemic vaccine may be longer, because of the need to 
conduct additional safety trials in order to comply with national licensing requirements. Limited 
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supplies of the single vaccine against the H1N1 pandemic strain became available in the US in 
October 2009, and full stocks were available there in January 2010 – 5 and 8 months 
respectively after vaccine development started (Singleton et al., 2010). 
A number of factors make it hard to determine vaccine effectiveness with accuracy. It is 
difficult to establish infection categorically. Some cases of influenza are asymptomatic. Where 
symptoms do occur, they are similar to those of other common infections such as rhinovirus, 
coronavirus and respiratory syncytial virus. Serology does not allow the effects of vaccination 
to be distinguished categorically from those of infection (McDonald and Andrews, 1955; 
Osterholm, Kelley, Manske, et al., 2012). Finally, the expected variation in vaccine 
effectiveness from year to year due to vaccine strain mismatch means that an extended trial is 
necessary for categorical results. A recent meta-analysis estimated the effectiveness of TIV in 
adults aged 18-65 at 59%. No studies meeting the criteria of the meta-analysis were available 
for other age groups. Effectiveness of LAIV in children aged 6 months to 7 years was estimated 
at 83%. Again no studies meeting the criteria were available for other age groups (Osterholm, 
Kelley, Sommer, et al., 2012). Even the higher of these two figures is below the likely level 
required for herd immunity, and it is notable that no figure is available for protection of the over 
65 age group, which is the most vulnerable to seasonal infections. 
A key goal in current influenza design is the elicitation of more effective, longer lasting 
antibodies. The stalk of HA is a potential target antigen, which we shall consider in this study 
(Pica and Palese, 2013).    
This study is focussed on the humoral response of the human immune system. The response of 
the innate immune system and the cellular immune response are also important. The innate 
response alone is not able to clear influenza infection in experimental animals, but both CD4+ 
and CD8+ cells are able to clear infection independently (Wright, Neumann, and Kawaoka, 
2007). 
1.1.3  Determination of Antigenic Distance 
Influenza surveillance requires a means of determining the extent to which antigenic drift has 
occurred. The assay generally used for this purpose in surveillance laboratories is the 
haemagglutination inhibition (HI) assay. The assay determines the extent to which serum taken 
from a host exposed to one strain of influenza is capable of neutralising the binding activity of a 
second strain (World Health Organization, 2011). 
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HA will bind multiply to erythrocytes in solution. In the well of a test tube or tray, this forms a 
dispersed red pattern. In the absence of such binding, the cells fall to the bottom of the well, 
forming a sharply defined ‘button’ shape. Antibodies binding to HA will inhibit this 
agglutination, and this inhibition forms the basis of the assay. 
In a haemagglutination assay, two-fold serial dilutions of a viral sample are mixed with a 
specified amount of erythrocyte and placed in successive wells. The maximum dilution at which 
agglutination occurs is determined by observing the point at which the pattern in the well 
changes from diffuse red to button. This maximum dilution is known as the ‘titre’: a dilution of 
1:128, for example, corresponds to a titre of 128. 
For a haemagglutination inhibition assay, antiserum is collected by infecting a laboratory 
animal, typically a rabbit or ferret, and waiting for the infection to pass before collecting the 
serum. Reference antisera for well-known strains, such as vaccine strains, are kept in stock for 
use when required. In the assay, two-fold dilutions of antiserum are mixed with a fixed amount 
of viral sample and erythrocyte. The maximum dilution of antiserum that prevents agglutination 
is noted: this is known as the ‘HI titre’ and in this study we will refer to the titre between viral 
strain   and antiserum   as   . We distinguish between homologous titres   and 
heterologous titres   . 
The ‘HI Distance’     between strain   and antiserum   is defined as follows: 
     (
   
   
) 
  (Burnet and Lush, 1940) 
For the purposes of vaccine selection, an antibody is typically considered potent against a 
sample strain if     is 4 or less (Schild et al., 1973). 
Lapedes and Farber (2001) demonstrated that a ‘shape space’ of low dimensionality can be 
constructed in which antisera and antigens are treated as points, with the distance between them 
(the 'antigenic distance') being linearly related to the logarithm of the concentration ratio. The 
equation 
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) 
defines the antigenic distance   between the samples.  
The terms HI distance (   ) and antigenic distance (   ) as defined above will be used in this 
study. The literature is not consistent in terminology, with some authors referring to    as the 
antigenic distance, and others using the term for    .  
1.2 Outline 
In Chapter 2, I summarise the sources of data used for this study, and provide an analysis of 
assay data quality.  
Chapter 3 describes an analysis of H1N1 and H3N2 sequences directed towards understanding 
the binding location of human antibodies to wild-type strains. From this analysis, I derive a set 
of locations participating in H3 antigenic clusters, compare it with sets derived by other 
researchers through other means, and use it to develop a model that predicts the antigenic 
distance between two strains via amino acid sequence analysis.  
An interesting conclusion from this work is that human antibodies to wild-type strains are found 
to bind in two regions of HA1. In Chapter 4 I develop a simple simulation model of antigenic 
distance in order to explore the influence that such two-region binding might exert on antigenic 
maps. I demonstrate that it is a possible cause of the clustered nature of the H3 antigenic map 
determined by Smith et al., (2004). 
In Chapter 5, I examine possible roles of HA2 in the antigenic evolution of HA. I look first at its 
contribution to the antigenic clusters found in Chapter 3, identifying a limited role for HA2 in 
both H1 and H3. I discuss the identified stalk-binding epitopes of H1 and H3, and, using a 
database of HA2 sequences, make a case that the HA stalk, while more highly conserved than 
the globular head, is capable of antigenic evolution to escape antibody binding, and argue that 
evolution of the H3 stalk, as evidenced by substitutions and fixations, is compatible with such 
evolution. 
In Chapter 6 I summarise some general conclusions from this work, and discuss future 
directions of research.  
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Examination of the ratio of non-silent to silent nucleotide mutations is a frequently used 
technique for identifying regions of a protein under positive or negative selective pressure. 
While not part of the main body of this work, in Appendix A I provide a brief comparison of 
this approach with the techniques used in the analysis above. 
In Appendix B, I describe a website which brings together a number of analysis tools created for 
this work.  
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2 Assay and Sequence Data Quality 
2.1 Analysis of HI data quality 
2.1.1 Sources of Error 
Because the biochemical properties of human influenza strains – such as binding specificity and 
avidity – have changed over time, experimental protocols have not remained constant. The 
Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (World Health 
Organization, 2011) defines current standard methods for surveillance laboratories, including a 
standard protocol for the HI assay. A number of issues relating to sources of experimental error 
are noted, as are the following points, which relate more to variation of biochemical and 
biological properties: 
- Adaption of the viral strain to the culture medium, particularly in those strains cultured 
in eggs; 
- Varying reactivity to specific red blood cells; 
- High sensitivity of some viral strains to nonspecific inhibitors of haemagglutination. 
These points are considered in more detail in following sections. 
The repeatability of HI assays when conducted according to a defined standard operating 
procedure was studied in an H5N1-specific context by Noah et al. (2009), who concluded that 
reliable results could be obtained provided that experimental practice was carefully followed 
and appropriate controls were employed to allow issues to be identified and addressed. In 
particular, strict assay acceptance criteria must be observed, based on the results of assay 
controls. Assessment of haemagglutination must be based on standardised protocols, with 
variation between operators eliminated via training and assessment. 
2.1.2 Viral Adaption in Culture 
De Jong et al. (1988) observed that H3N2 viral specimens isolated from human subjects were 
heterogeneous: they contained a ‘major’ antigenic variant, and one or more ‘minor’ variants, 
with the minor variants being present in fractions between 10
-1
 and 10
-3
. Culture of the sample 
in eggs or mammalian cells could be accompanied by changes in HI assay results as the 
proportion of variants adapted to the culture medium. Because samples cloned in mammalian 
cells were found to be stable upon further passage, while those cultured in eggs could take a 
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number of passages to stabilise, they argued that mammalian cultures should be preferred, and 
in recent years it has become customary in surveillance applications to culture strain samples in 
mammalian cells. Antisera, however, are typically raised from egg-cultured viral strains. 
Passage histories are not always provided in assay reports, but, for example, in the WHO UK 
Collaborating Centre’s report of March 2000, approximately 50% of viral strain samples are egg 
passaged and 50% passaged in Madin-Darby canine kidney (MDCK) cells. In the WHO UK 
Collaborating Centre’s report of February 2005, all viral strain samples are MDCK passaged. 
The implications of the above for this work are, firstly, that both egg and mammalian cultured 
samples of a strain may be reported in the database, with potentially different antigenic results, 
and, secondly, that the amino acid sequence recorded for a strain may not match that of the 
variant that has been assayed.  
2.1.3 Red Blood Cell Binding Avidity 
Traditionally, the HI assay has employed chicken red blood cells, although turkey red blood 
cells are sometimes favoured as they provide a shorter settling time and inhibition patterns are 
clearer (World Health Organization, 2011). In the 1990s, however, a number of H3N2 strains 
emerged which were unable to agglutinate chicken red blood cells, and, subsequently, turkey 
red blood cells (Medeiros et al., 2001). Guinea pig red blood cells were able to agglutinate 
strains throughout this period, and are now recommended for the assay of all novel strains 
(World Health Organization, 2011). Published assay results through this period do not appear to 
have suffered quality problems as a result, although the variable avidity of red blood cells 
employed in successive assays, even when drawn from genetically similar animals, is a key 
source of variability between assays of the same viral strain against the same reference 
antiserum (private discussions with Dr John McCauley and Dr Rodney Daniels, UK WHO 
Collaborating Centre for influenza surveillance, November 2012). The red blood cell type used 
in preparing surveillance data is not routinely published. 
A more serious problem developed in the early 2000s when it became apparent that a number of 
‘low reacting’ MDCK cultured H3N2 strains would not develop high titres, even homologous 
titres against their egg-grown antisera, or could be made to do so only with great difficulty (see, 
for example, the summary of H3N2 activity in the introduction to the UK WHO Collaborating 
Centre interim report for March 2007). The cause of this problem was identified by Lin et al. 
(2010). Surprisingly, it results from an amino acid substitution in neuraminidase, which allows 
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neuraminidase to bind to red blood cells and hence cause agglutination in an antiserum-
insensitive manner. Luckily this binding has proved to be oseltamivir-sensitive, and the addition 
of oseltamivir carboxylate to the assay restores the expected specificity.  
In previous work (Lees, 2009), it proved necessary to exclude post-2003 assays with low-
reacting homologous titres in order to obtain acceptable predictive results through these years. 
While that practice is now fully justified by the identified cause, it may be better to examine the 
neuraminidase sequence for the implicated substitution.  
2.1.4 Non-Specific Inhibitors of Haemagglutination 
Non-specific inhibitors of influenza virus haemagglutination are naturally occurring 
components of serum. Three types have been identified: the alpha class, which are sialyated 
glycoproteins that, while inhibiting haemagglutination, do not neutralise viral activity; the beta 
class, which are lectins that bind to mannose-rich glycoproteins on the head of HA and hence 
interfere sterically with the binding to red blood cells and inhibit viral activity; and the gamma 
class, which are similar to the alpha class, but also inhibit viral activity (Ryan-Poirier and 
Kawaoka, 1991; Anders, Hartley, and Jackson, 1990). While steps are taken in the WHO 
protocol to inactivate non-specific inhibitors, some residual activity may remain. This can affect 
the assay results of strains that are particularly sensitive to their presence, usually resulting in 
high titre values to multiple antisera.  
2.2 Mathematical Treatment of HI Assay Results 
The large volume of data in the HI assay database, and particularly the large number of 
measurements available for some reference strains and antisera, provides an opportunity to 
examine the repeatability of assay results.  
2.2.1 Normalization of the Assay Data 
Archetti and Horsfall (1950) introduced a ‘two-way’ measure of antigenic distance between two 
strains in order to normalise assay results against variations in experimental conditions. This 
measure is calculated from ‘cross titres’ of each strain against the other strain’s antiserum. 
Ndifon (2011) formalised this as follows. 
Suppose that    is the titre obtained with isolate i against antiserum raised from isolate j. Then 
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where    is the concentration of antibodies in the serum,    is the average affinity of the 
antibodies for the virus, and    is a constant representing a range of factors such as the affinity 
between the virus and red blood cell.  
We can see from this that the classical one-way distance, 
        (
   
   
)     (
     
     
) 
eliminates    but has a dependency on    and   . The two-way distance removes all unwanted 
dependencies: 
     
 
 
   (
      
      
)  
 
 
    (
      
      
) 
Unfortunately it has not proved possible to determine a way of eliminating the dependence on    
and    in the one-way measurements: instead, variation due to the underlying factors must be 
controlled as much as possible through experimental standardisation and treated as experimental 
error. On this basis, we may expect more variation in one-way assay results than in derived 
Archetti/Horsfall distances. 
In this work, unless otherwise stated, the antigenic distance is defined as the log to the base 2 of 
the titre ratio. As the experimental procedure requires the titre ratio to be successively halved, 
using base 2 will generally yield integral distances. 
2.2.2 Analysis of Errors 
The HI assay data includes many multiple assays of the same strain/antiserum pair. Data to 
2008 includes 39 pairs of H3N2 strains for which 10 or more assays are available. H1 data is 
more limited, but 6 or more assays are available for a total of 33 strains (Tables 2.1 and 2.2). 
For two-way Archetti/Horsfall data, where we have to combine two one-way measurements 
from the same HI table, the available data is more limited. In the same period, we can find 19 
H3N2 strain pairs with 10 or more assays, and 16 H1 assays with 6 or more assays (Tables 2.3 
and 2.4). In this section I shall consider the characteristics of the data sets listed in these four 
tables.  
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2.2.3 Distribution of Measurement Results 
Figure 2.1 shows normal probability plots for the strain/antiserum or strain/strain pair for which 
there is most data. In the plots, the straight line represents the best fit of a normal distribution 
onto the data. The points should lie close to the line without any obvious skew or trend, and the 
mean and standard deviations calculated from the fit should be in agreement with the observed 
values. Mean and median values should be in near agreement. 
Observed and calculated values of mean, standard deviation and median are provided in Table 
2.5.  
The relatively low number of measurements, and the low precision of the dataset (one-way 
measurements are typically integers between 1 and 8) limit the conclusions that can be drawn 
from this analysis, but the results are consistent with a normal distribution of results. Some 
estimated standard deviation values differ significantly in percentage terms from the calculated 
value, but the difference is small in absolute terms considering the precision of the 
measurements. 
 
Figure 2.1: Normal Probability Plots for selected strain pairs from each dataset (H1N1/H3N2, one-way and two-way) 
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Strain Antiserum Assays Log 
Distance 
Std 
Dev 
Std 
Err 
95% 
conf 
+/- 
A/Beijing/262/1995 A/New Caledonia/20/1999 14 1.29 0.61 0.16 0.33 
A/New Caledonia/20/1999 A/Beijing/262/1995 14 1.93 0.62 0.16 0.33 
A/New Caledonia/20/1999 A/Thessaloniki/24/2005 10 1.70 0.67 0.21 0.43 
A/Thessaloniki/24/2005 A/New Caledonia/20/1999 9 0.33 0.50 0.17 0.33 
A/Johannesburg/82/1996 A/Beijing/262/1995 8 3.38 0.92 0.32 0.65 
A/Hong Kong/2652/2006 A/New Caledonia/20/1999 8 3.75 1.16 0.41 0.82 
A/New Caledonia/20/1999 A/Egypt/96/2002 8 0.38 0.52 0.18 0.37 
A/Egypt/96/2002 A/New Caledonia/20/1999 8 0.75 0.46 0.16 0.33 
A/New Caledonia/20/1999 A/Hong Kong/2652/2006 8 3.38 0.52 0.18 0.37 
A/New Caledonia/20/1999 A/Johannesburg/82/1996 8 6.50 0.76 0.27 0.53 
A/Beijing/262/1995 A/Johannesburg/82/1996 8 5.38 0.92 0.32 0.65 
A/Johannesburg/82/1996 A/New Caledonia/20/1999 8 3.88 0.83 0.30 0.59 
A/Solomon Islands/3/2006 A/Hong Kong/2652/2006 7 1.14 0.69 0.26 0.52 
A/New Caledonia/20/1999 A/Fujian/156/2000 7 1.29 0.76 0.29 0.57 
A/Hong Kong/2652/2006 A/Solomon Islands/3/2006 7 1.29 0.95 0.36 0.72 
A/Hawaii/15/2001 A/New Caledonia/20/1999 7 4.86 0.69 0.26 0.52 
A/Fujian/156/2000 A/New Caledonia/20/1999 7 1.43 0.79 0.30 0.59 
A/New Caledonia/20/1999 A/Hawaii/15/2001 7 1.29 0.76 0.29 0.57 
A/Beijing/262/1995 A/Fujian/156/2000 7 2.14 0.69 0.26 0.52 
A/New Caledonia/20/1999 A/Solomon Islands/3/2006 7 3.57 1.62 0.61 1.22 
A/Hong Kong/2652/2006 A/Thessaloniki/24/2005 7 5.14 1.07 0.40 0.81 
A/Fujian/156/2000 A/Beijing/262/1995 7 3.00 0.00 0.00 0.00 
A/Beijing/262/1995 A/Hawaii/15/2001 6 2.33 1.03 0.42 0.84 
A/Hawaii/15/2001 A/Beijing/262/1995 6 4.33 0.82 0.33 0.67 
A/Chile/8885/2002 A/New Caledonia/20/1999 6 1.83 0.98 0.40 0.80 
A/New Caledonia/20/1999 A/Fukushima/141/2006 6 3.17 0.75 0.31 0.61 
A/Thessaloniki/24/2005 A/Solomon Islands/3/2006 6 3.50 1.52 0.62 1.24 
A/New Caledonia/20/1999 A/Chile/8885/2002 6 0.67 0.52 0.21 0.42 
A/Thessaloniki/24/2005 A/Hong Kong/2652/2006 6 2.83 0.41 0.17 0.33 
A/Hong Kong/2652/2006 A/Fukushima/141/2006 6 0.83 0.41 0.17 0.33 
A/Solomon Islands/3/2006 A/Thessaloniki/24/2005 6 3.83 0.41 0.17 0.33 
A/Fukushima/141/2006 A/Hong Kong/2652/2006 6 1.17 0.41 0.17 0.33 
A/Solomon Islands/3/2006 A/New Caledonia/20/1999 6 3.33 1.03 0.42 0.84 
MEAN    0.75 0.28 0.56 
Table 2.1: H1N1 one-way assays for which 6 or more results are available (data to 2008) 
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Strain Strain Assays 
Log 
Distance 
Std 
Dev 
Std 
Error 
95% 
conf +/- 
A/Beijing/262/1995 A/New Caledonia/20/1999 14 1.39 0.49 0.13 0.26 
A/Thessaloniki/24/2005 A/New Caledonia/20/1999 9 0.72 0.51 0.17 0.34 
A/Johannesburg/82/1996 A/New Caledonia/20/1999 8 4.88 0.23 0.08 0.16 
A/New Caledonia/20/1999 A/Egypt/96/2002 8 0.44 0.18 0.06 0.12 
A/Johannesburg/82/1996 A/Beijing/262/1995 8 4.38 0.44 0.16 0.31 
A/Hong Kong/2652/2006 A/Solomon Islands/3/2006 7 0.57 0.35 0.13 0.26 
A/Fujian/156/2000 A/New Caledonia/20/1999 7 0.36 0.24 0.09 0.18 
A/Hawaii/15/2001 A/New Caledonia/20/1999 7 2.57 0.45 0.17 0.34 
A/Fujian/156/2000 A/Beijing/262/1995 7 1.86 0.24 0.09 0.18 
A/Hong Kong/2652/2006 A/New Caledonia/20/1999 7 3.29 0.49 0.18 0.37 
A/Solomon Islands/3/2006 A/New Caledonia/20/1999 6 2.67 0.82 0.33 0.67 
A/Hawaii/15/2001 A/Beijing/262/1995 6 3.25 0.42 0.17 0.34 
A/Chile/8885/2002 A/New Caledonia/20/1999 6 0.5 0.32 0.13 0.26 
A/Thessaloniki/24/2005 A/Solomon Islands/3/2006 6 3.25 0.69 0.28 0.56 
A/Hong Kong/2652/2006 A/Fukushima/141/2006 6 0.67 0.41 0.17 0.33 
A/Hong Kong/2652/2006 A/Thessaloniki/24/2005 6 3.92 0.74 0.3 0.6 
MEAN    0.44 0.17 0.33 
Table 2.2: H1N1 two-way assays for which 6 or more results are available (data to 2008) 
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Strain Antiserum Assays 
Log 
Distance 
Std 
Dev 
Std 
Error 
95 % 
conf 
+/- 
A/Wyoming/3/2003 A/Panama/2007/1999 21 1.95 0.74 0.16 0.32 
A/Panama/2007/1999 A/Wyoming/3/2003 21 3.33 1.28 0.28 0.56 
A/California/7/2004 A/Wyoming/3/2003 17 2.35 0.93 0.23 0.45 
A/Wyoming/3/2003 A/California/7/2004 17 0.94 1.14 0.28 0.55 
A/California/7/2004 A/Wisconsin/67/2005 17 1.88 0.99 0.24 0.48 
A/Wisconsin/67/2005 A/California/7/2004 17 2.18 0.88 0.21 0.43 
A/Panama/2007/1999 A/Moscow/10/1999 15 2.17 1.51 0.39 0.78 
A/Moscow/10/1999 A/Panama/2007/1999 15 1.6 0.51 0.13 0.26 
A/Moscow/10/1999 A/Sydney/5/1997 14 1 0.39 0.1 0.21 
A/Panama/2007/1999 A/Sydney/5/1997 14 2 0.88 0.23 0.47 
A/Sydney/5/1997 A/Moscow/10/1999 14 1.93 1.44 0.38 0.77 
A/Sydney/5/1997 A/Panama/2007/1999 14 1.86 0.77 0.21 0.41 
A/Wellington/1/2004 A/Wyoming/3/2003 13 1.54 0.88 0.24 0.49 
A/Hiroshima/52/2005 A/California/7/2004 12 2.67 0.49 0.14 0.28 
A/Wyoming/3/2003 A/Wellington/1/2004 12 1.33 1.15 0.33 0.67 
A/Hong Kong/4443/2005 A/California/7/2004 12 3.58 0.9 0.26 0.52 
A/New York/55/2004 A/California/7/2004 12 0.67 0.65 0.19 0.38 
A/California/7/2004 A/New York/55/2004 12 1 1.04 0.3 0.6 
A/Panama/2007/1999 A/Fujian/411/2002 12 4.67 0.78 0.22 0.45 
A/Fujian/411/2002 A/Panama/2007/1999 12 4.08 1.62 0.47 0.94 
A/Shantou/1219/2004 A/Wyoming/3/2003 11 4.18 0.75 0.23 0.45 
A/Hong Kong/4443/2005 A/Wisconsin/67/2005 11 2.82 1.08 0.33 0.65 
A/California/7/2004 A/Hong Kong/4443/2005 11 1.73 0.47 0.14 0.28 
A/Wellington/1/2004 A/Panama/2007/1999 11 3.64 1.21 0.36 0.73 
A/Shantou/1219/2004 A/Panama/2007/1999 11 5.18 0.87 0.26 0.53 
A/Hiroshima/52/2005 A/Wisconsin/67/2005 11 0.45 0.69 0.21 0.41 
A/Wisconsin/67/2005 A/Hong Kong/4443/2005 11 0.18 0.4 0.12 0.24 
A/Wyoming/3/2003 A/Shantou/1219/2004 10 1.1 0.74 0.23 0.47 
A/California/7/2004 A/Hiroshima/52/2005 10 3.3 0.82 0.26 0.52 
A/Wellington/1/2004 A/California/7/2004 10 0.7 0.67 0.21 0.43 
A/New York/55/2001 A/Panama/2007/1999 10 0.4 0.7 0.22 0.44 
A/New York/55/2004 A/Wyoming/3/2003 10 2.5 0.85 0.27 0.54 
A/Wyoming/3/2003 A/New York/55/2004 10 2.4 0.97 0.31 0.61 
A/Wisconsin/67/2005 A/Hiroshima/52/2005 10 0.9 0.57 0.18 0.36 
A/California/7/2004 A/Panama/2007/1999 10 5.7 1.06 0.33 0.67 
A/Panama/2007/1999 A/Shantou/1219/2004 10 4.7 0.95 0.3 0.6 
A/Panama/2007/1999 A/California/7/2004 10 5.5 1.18 0.37 0.75 
A/Panama/2007/1999 A/Wellington/1/2004 10 3 0.82 0.26 0.52 
A/California/7/2004 A/Wellington/1/2004 10 2 0.82 0.26 0.52 
MEAN    0.89 0.25 0.51 
Table 2.3: H3N2 one-way assays for which 10 or more results are available (data to 2008) 
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Strain Strain Assays 
Log 
Distance 
Std 
Dev 
Std 
Error 
95% conf 
+/- 
A/Wyoming/3/2003 A/Panama/2007/1999 21.00 2.62 0.65 0.14 0.28 
A/Wisconsin/67/2005 A/California/7/2004 17.00 1.82 0.58 0.14 0.28 
A/California/7/2004 A/Wyoming/3/2003 17.00 1.32 0.53 0.13 0.26 
A/Moscow/10/1999 A/Panama/2007/1999 15.00 1.18 0.80 0.21 0.42 
A/Moscow/10/1999 A/Sydney/5/1997 14.00 0.93 0.92 0.25 0.49 
A/Sydney/5/1997 A/Panama/2007/1999 14.00 1.25 0.51 0.14 0.27 
A/New York/55/2004 A/California/7/2004 12.00 0.62 0.57 0.16 0.33 
A/Wellington/1/2004 A/Wyoming/3/2003 12.00 1.42 0.60 0.17 0.34 
A/Panama/2007/1999 A/Fujian/411/2002 12.00 3.71 0.66 0.19 0.38 
A/Hong Kong/4443/2005 A/California/7/2004 11.00 1.77 0.26 0.08 0.16 
A/Hong Kong/4443/2005 A/Wisconsin/67/2005 11.00 0.68 0.25 0.08 0.15 
A/Shantou/1219/2004 A/Panama/2007/1999 10.00 4.00 0.85 0.27 0.54 
A/California/7/2004 A/Wellington/1/2004 10.00 1.00 0.47 0.15 0.30 
A/Hiroshima/52/2005 A/California/7/2004 10.00 3.00 0.53 0.17 0.33 
A/Wellington/1/2004 A/Panama/2007/1999 10.00 3.25 0.54 0.17 0.34 
A/Shantou/1219/2004 A/Wyoming/3/2003 10.00 1.60 0.52 0.16 0.33 
A/Hiroshima/52/2005 A/Wisconsin/67/2005 10.00 0.55 0.37 0.12 0.23 
A/New York/55/2004 A/Wyoming/3/2003 10.00 2.30 0.42 0.13 0.27 
A/California/7/2004 A/Panama/2007/1999 10.00 5.65 1.33 0.42 0.84 
MEAN    0.60 0.17 0.34 
Table 2.4: H3N2 two-way assays for which 10 or more results are available (data to 2008) 
 
Strain Pair Measurement 
Mean Median Standard Deviation 
    
Calculated Estimated % Calculated % Calculated Estimated % 
 A/Wyoming/3/2003 vs.  
A/Panama/2007/1999 
One-Way 1.95 1.94 0.55 2 2.44 0.74 0.88 18.5 
Two-Way 2.62 2.62 0 2.5 4.55 0.65 0.68 5.13 
A/Beijing/262/1995 vs. 
A/New Caledonia/20/1999 
One-Way 1.29 1.23 4.67 1 22.2 0.61 0.89 45.3 
Two-Way 1.39 1.39 0 1.5 7.69 0.49 0.53 9.12 
Table 2.5: Calculated and estimated values from selected strain pairs in the four data sets. Calculated values are 
derived directly from the dataset. Estimated values are estimated from the ‘best fit’ normal distribution according to 
the Normal Probability Plot. As mean and median values are equal for a normal distribution, the estimated mean 
value is also used as the estimated median. 
 
2.2.4 Independence of the Observations 
Surveillance laboratories often publish several HI assay tables in a season, utilising very similar 
sets of reference antisera. The question arises as to whether the titres between reference strains 
and antisera are determined de novo in each assay, or simply carried forward from one table to 
the next. Because of the dependency of results on red blood cell avidity, the assay will certainly 
be repeated anew when the supply of blood is changed (private discussions with Dr John 
McCauley and Dr Rodney Daniels, UK WHO Collaborating Centre for influenza surveillance, 
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November 2012). The supply is changed on a weekly basis, and inspection of the published 
tables in the database reveals them to be separated by at least this amount of time. Each assay 
recorded in the database can therefore be regarded as the result of a distinct laboratory 
experiment, or, more likely, the average of several such results obtained at the same time and 
under the same conditions.  The viral samples used in the experiment are not, however, 
necessarily derived de novo from wild type viral specimens. 
The antisera used in the HI tests collected in the database are predominantly ‘reference antisera’ 
prepared and distributed by the WHO Collaborating Centres, located in the US, UK, Japan, 
China and Australia. These are used in the reports of those centres, which form the very large 
majority of assays published since 2001, and are also used in many other assays published both 
since and before that date. Novel strains are typically isolated and cultured for a specific assay: 
however the Collaborating Centres provide reference strain cultures, which mirror the reference 
antisera. Assays of the reference strains against reference antisera are typically provided in each 
report of results, alongside assays of novel strains against the reference antisera, to act as a 
control. The reference strains and antisera are highly represented in the datasets of frequently-
occurring measurements that we have been examining, particularly in the two-way datasets.  
While there is a significant degree of independence, since each Collaborating Centre develops 
its own reference material, and will develop several batches of a widely used strain over time, a 
degree of interdependence should be noted. For example, the Collaborating Centre in London 
published 5 H3N2 HI tables undertaken at different times between January and September 
2006. The reference strain A/California/7/2004 was represented in each of these tests, and the 
assays of that strain against its antiserum from those 5 tables are recorded in the database as 
separate measurements. The note against the antiserum in each table (F31/05) indicates that the 
same source of antiserum was used in each case (that is, drawn from the same ferret). 
In conclusion, the observations are independent in that they are separate observations in the 
laboratory. There is a degree of dependence in that antiserum from the same source is used in 
multiple experiments, particularly in those experiments for which there are large numbers of 
results. The conclusions that we draw from these results, and predictions that we make, are valid 
within the framework of the experimental system from which the data was drawn. We cannot 
guarantee their validity outside that framework. 
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2.2.5 Heteroscedasticity 
Figure 2.2 shows plots of variance against log2 distance. Some outliers can be observed but 
there is no apparent dependence of variance on distance.  
 
Figure 2.2: Plots of variance against log2 distance for the four data sets. Outliers are numbered. 
The two-way measurements display generally lower variance than the one-way measurements, 
supporting the principle of normalisation underlying the Archetti-Horsfall calculation discussed 
in the opening section.  
Nine outliers were identified in the plots. These are listed in Table 6. In most cases, the high 
variance was caused by one or in some cases two outliers in the underlying assay results, 
indicated by ‘O’ in the Notes column.  
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Outlier Strain Strain/Antiserum Variance 
Notes 
1 A/New Caledonia/20/1999 A/Solomon Islands/20/2006 2.62 O 
2 A/Thessaloniki/24/2005 A/Solomon Islands/20/2006 2.31 O/S 
3 A/New Caledonia/20/1999 A/Solomon Islands/20/2006 0.67 O 
4 A/Hong Kong//2652/2006 A/Thessaloniki/24/2005 0.55 O 
5 A/Thessaloniki/24/2005 A/Solomon Islands/20/2006 0.48 O/S 
6 A/Fujian/411/2002 A/Panama/2007/1999 2.62 P/S 
7 A/Panama/2007/1999 A/Moscow/10/1999 2.28 O 
8 A/Sydney/5/1997 A/Moscow/10/1999 2.07 O 
9 A/California/7/2004 A/Panama/2007/1999 1.77 S 
Table 2.6: Variance Outliers identified in the Variance/Log Distance Plots of Figure 2. In the Notes column, O 
denotes that variation is probably attributable to outliers in the results. S denotes variation that can probably be 
attributed to antiserum variability, and P to possible variations in experimental protocol (see text for discussion). 
The presence of outliers in the underlying data suggests that a robust metric such as the median 
or  M-estimate (Huber, 2005) will provide a better estimate of the log distance than would be 
provided by the mean. As an example, the data series for outlier 1 is 2.5, 4, 4, 4, 4.5, 4.5. The 
value of 2.5 appears to be an outlier. The mean is 3.92, which is below the value of the other 
data points. The M-estimate of the location using the R function huberM with default 
parameters is 4.09, which is more in keeping with the data set taken as a whole. 
In outlier 9, the high variance appears to be caused by a change in the reference antiserum. Log 
distance values of 4, 4.5, 5, 5, 5, 5, 5.5 were obtained in 2005 using UK-supplied antiserum to 
A/Panama/2007/1999 reference F2/01. Values of 7.5, 7.5, 7.5 were obtained in 2006 using 
antiserum to the same strain with reference F7/06. All assays except for one assay in the 2005 
series were performed by the same laboratory, and we are fortunate that the antiserum reference 
was quoted on all assays, including the single assay performed at another laboratory, as it is not 
usually included in the HI results. The likely cause of high variance in this case is noted as S in 
the table, for ‘serum-related’. 
The observation of the impact of the change in antiserum on this particular strain pair provides 
evidence that the consistency of the HI assay can be affected by variation in the immune 
responses of the animals from which antisera are drawn. On the other hand, the overall 
consistency of results obtained from different laboratories, for example the WHO Collaborating 
Centres in the UK and the US, which generally derive their own antisera independently, 
demonstrates that this is not the norm. In this particular case, the variation represented a 
relatively small (onefold or twofold) change in the result obtained for a strain/antiserum pair of 
two antigenically different strains. It may be that variation of this nature is more likely at high 
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antigenic distance, due to the correspondingly large differences in the antibodies likely to be 
raised against them. 
Another interesting outlier is outlier 6 (strain A/Fujian/411/2002 vs. antiserum 
A/Panama/2007/1999), which has a wide spread of values (2, 2, 2, 3, 3, 4, 5, 5, 5, 6, 6, 6) in 
which the lower results (2-4) appear to be derived from US/Australian-originated antiserum and 
the higher values (5-6) from UK-originated antiserum. However, in this case the divergence 
may well be related to differences in protocol. The mutations between these strains included 
changes in the RBS, and Fujian-like viruses proved difficult to work with, often providing low 
reactivity even in homologous titres as noted in the introductory section.  The note against this 
outlier is ‘P/S’, indicating either a possible protocol difference, or a serum-related difference as 
for outlier 9. 
Outliers 2 and 5 (both involving A/Thessaloniki/24/2005 and A/Solomon Islands/20/2006) 
exhibit a wide range of values (e.g. 1, 3, 3, 4, 5, 5 for outlier 2). These may be related to 
differences in antisera as the lower values were determined in 2007, and the higher in 2008, 
however in this case the reference antisera are not identified specifically and so one cannot be 
sure: another explanation would simply be that the value of 1 is an outlier. These lines are 
therefore marked ‘O/S’ in the table.  
2.3 Analysis of sequence quality 
An overall assessment of sequence quality was presented in previous work (Lees, 2009). In 
particular, I assessed the extent to which sequences of human strains may have been influenced 
by egg adaption in culture. In the database, I attempt to address this issue, and others impacting 
sequence quality, by deriving consensus sequences where multiple sequences are available for a 
strain, which is frequently the case for strains of interest such as vaccine strains and dominant 
wild-type strains. One important factor here is the standardisation of place names, such as South 
Australia/S. Australia. Again, this topic is addressed in detail in previous work. 
For this study, I required full-length H1N1 and H3N2 HA1 and HA2 sequences for as many 
strains as possible, and in particular for prevalent wild-type strains. I wished to confirm high 
data quality for the prevalent strains, particularly in the early years. As described in detail in my 
previous work, viral sequences were extracted mainly from the NCBI’s Influenza Virus 
Resource (Bao et al., 2008) and from the Influenza Research Database (Squires et al., 2012). 
These two resources provide curated, searchable databases of influenza sequences extracted 
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from GenBank (Benson et al., 2008). I found little variation in the human H1N1 and H3N2 
sequences available from the two sources. Some sequences, particularly for early strains of 
interest, were not available from these sources and were extracted from published papers where 
available.  
Another important resource, GISAID (http://platform.gisaid.org), provides strains to researchers 
under terms which do not allow for subsequent publication without explicit permission from the 
original contributing researchers. I elected not to download sequences in bulk from GISAID 
because of the possibility that we might wish to make the database publicly available at some 
point in the future. I did, however, consult GISAID for particular sequences of interest that were 
not available elsewhere, but did not obtain any hits. 
2.3.1 Full-Length Sequences of Dominant Strains 
The prevalent subtypes and circulating strains are reported periodically in the Weekly 
Epidemiological Record.  The description is typically couched in terms of antigenic relatedness 
to reference strains. A typical example is shown in Figure 2.3. WHO vaccine strain 
recommendations are provided in the same journal. 
 
 
(this figure is not included in the public version) 
 
 
 
Figure 2.3: An extract from a report of influenza activity in the Weekly Epidemiological Record (No 9, 3 March 
2006) describing the antigenic characteristics of influenza strains circulating in the previous season: in this case the 
Northern Hemisphere 2005/2006 season. 
As will be noted in the cited characterisation of H3N2 strains, some seasons see a transition 
from one antigenic type to another, which will usually then become the prevalent antigenic type  
in the subsequent season (for brevity, I shall refer to the prevalent antigenic type, as 
characterised by a reference strain, as the prevalent or dominant strain). While the progression is 
clear (strains related to reference strain x are replaced by strains related to reference strain y), 
 40 
 
 
the exact point at which a transition occurs is not always easy to pin down, and is known to 
occur at different times in different parts of the world (Russell et al., 2008).  In Table 2.7 I show 
the prevalent circulating strains and recommended vaccine strains for each Northern 
Hemisphere season since 1968, as reported in the Weekly Epidemiological Record. I have 
necessarily made some simplifications in order to arrive at a single reference strain for each 
season, but the account accurately follows the progression of prevalent strains, and is in 
accordance with the account and approach taken by other researchers (Gupta, Earl, and Deem, 
2006). 
I conducted an analysis of sequences available for H3N2 predominant strains to 2005 (both 
partial and complete), identifying the source of each one and comparing multiple sequences 
where available. A total of 95 sequences were considered in this analysis, and multiple 
sequences were available for each strain. Generally, correspondence between sequences was 
good, with little variation between samples (typically 3 or fewer amino acid differences across 
the full-length protein), and I therefore have confidence in the consensus sequences. A number 
of sequences of early strains determined by Kostolanský et al. (2000) were found to vary 
significantly from those determined by other researchers (amino acid differences in 7-10 
positions in HA1), and I therefore eliminated sequences from this source in this study. It should 
be noted that these sequences, which I feel to be misleading, have been utilised by other 
researchers. Russell et al. (2008) submitted sequences to GenBank which are identical to those 
of Kostolanský in the course of publishing their work, which I believe to be duplicates.   
I found full-length sequences of A/England/42/1972 and A/Port Chalmers/1/1973, contributed 
by the NIAID Influenza Genome Sequencing Project, which were misnamed in GenBank as 
A/England/72 and A/Port Chalmers/73 (other sequences of these isolates covered HA1 only). I 
was able to confirm this error (private communication with Dr Yiming Bao, September 2012) 
and have requested the NCBI to correct the GenBank records. In the course of this work, I also 
identified 16 H3N2 sequences with an isolation date of 1968 which were categorised by 
GenBank and the Influenza Virus Resource as human wild-type strains, but turned out on 
examination to be laboratory-induced mutations of A/Hong Kong/1/1968 from a mouse 
adaption study. Again, I have requested the NCBI to correct the records of these strains.  
The data quality issues described above emphasise the importance of careful curation if the 
correct results are to be obtained from a study of HA sequences, particularly those of early 
strains. I believe that this has received inadequate attention in a number of bioinformatics 
 41 
 
 
studies that have used influenza HA sequences. It is worth noting that, thanks to the effort of 
mass sequencing initiatives, new full-length HA sequences (and, indeed, full viral genome 
sequences) for a number of early strains have been deposited with the NCBI during the period 
of this research.
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Northern 
Hemisphere 
Season 
H1N1 H3N2 Notes Incidence in  season 
W - widespread 
P - partial 
L - low or none 
Prevalent Vaccine Prevalent Vaccine H1N1 H3N2 B 
1968-69   A/Hong Kong/1968      
1969-70   A/Hong Kong/1968      
1970-71     mainly influenza B, isolated HK68    
1971-72   A/Hong Kong/1968  antigenically distinct strains reported, en72 
emerging 
   
1972-73   A/England/42/1972      
1973-74   A/Port Chalmers/1/1973 A/England/42/1972   W W 
1974-75   A/Port Chalmers/1/1973 A/Port Chalmers/1/1973 A/Port Chalmers/1/1973 types emerging  W L 
1975-76   A/Victoria/3/1975 A/Port Chalmers/1/1973 also A/Scotland/840/1974  W L 
1976-77   A/Victoria/3/1975 A/Victoria/3/1975   P L 
1977-78 A/USSR/90/1977  A/Texas/1/1977 A/Victoria/3/1975  P W L 
1978-79 A/USSR/90/1977  A/Texas/1/1977 A/Texas/1/1977 also A/Brazil/11/1978 (H1N1) P L P 
1979-80 A/Brazil/11/1978 A/USSR/90/1977 A/Bangkok/1/1979 A/Texas/1/1977 also A/Bangkok/2/1979 P W P 
1980-81 A/Brazil/11/1978 A/Brazil/11/1978 A/Bangkok/1/1979 A/Bangkok/1/1979  P W P 
1981-82 A/England/333/1980 A/Brazil/11/1978 A/Bangkok/1/1979 A/Bangkok/1/1979 little H3N2 activity L L L 
1982-83 A/England/333/1980 A/Brazil/11/1978 A/Philippines/2/1982 A/Bangkok/1/1979 A/Philippines/2/1982 (H3N2) emerging L P L 
1983-84 A/Chile/1/1983 A/Brazil/11/1978 A/Philippines/2/1982 A/Philippines/2/1982  P L P 
1984-85 A/Chile/1/1983 A/Chile/1/1983 A/Philippines/2/1982 A/Philippines/2/1982  L P L 
1985-86 A/Chile/1/1983 A/Chile/1/1983 A/Mississippi/1/1985 A/Philippines/2/1982 A/Christchurch/4/1985 (H3N2) also 
emerging 
L W P 
1986-87 A/Singapore/6/1986 A/Chile/1/1983 A/Mississippi/1/1985 A/Christchurch/4/1985  W L L 
1987-88 A/Singapore/6/1986 A/Singapore/6/1986 A/Mississippi/1/1985 A/Leningrad/360/1986 A/Leningrad/360/1986 (H3N2) emerging L P P 
1988-89 A/Singapore/6/1986 A/Singapore/6/1986 A/Sichuan/2/1987 A/Sichuan/2/1987  W W P 
1989-90 A/Singapore/6/1986 A/Singapore/6/1986 A/England/427/1988 A/Shanghai/11/1987 A/Beijing/353/1989 (H3N2) also emerging L W P 
1990-91 A/Singapore/6/1986 A/Singapore/6/1986 A/Beijing/353/1989 A/Guizhou/54/1989  P P P 
1991-92 A/Singapore/6/1986 A/Singapore/6/1986 A/Beijing/353/1989 A/Beijing/353/1989  P W L 
1992-93 A/Singapore/6/1986 A/Singapore/6/1986 A/Beijing/32/1992 A/Beijing/353/1989  L P P 
1993-94 none A/Singapore/6/1986 A/Beijing/32/1992 A/Beijing/32/1992  L W P 
1994-95 A/Singapore/6/1986 A/Singapore/6/1986 A/Johannesburg/33/1994 A/Shangdong/9/1993  L P P 
1995-96 A/Singapore/6/1986 A/Singapore/6/1986 A/Johannesburg/33/1994 A/Johannesburg/33/1994 A/Wuhan/359/1995 emerging W W L 
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1996-97 A/Bayern/7/1995 A/Singapore/6/1986 A/Wuhan/359/1995 A/Wuhan/359/1995  L W P 
1997-98 A/Beijing/262/1995 A/Bayern/7/1995 A/Sydney/5/1997 A/Wuhan/359/1995  P W L 
1998-99 A/Bayern/7/1995 A/Beijing/262/1995 A/Sydney/5/1997 A/Sydney/5/1997  L W W 
1999-2000 A/New Caledonia/20/1999 A/Beijing/262/1995 A/Moscow/10/1999 A/Sydney/5/1997 also A/Panama/2007/1999 (H3N2) P W L 
2000-01 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/Moscow/10/1999 A/Moscow/10/1999  W L P 
2001-02 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/Moscow/10/1999 A/Moscow/10/1999  P W W 
2002-03 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/Fujian/411/2002 A/Moscow/10/1999 A/Fujian/411/2002 (H3N2) emerging L P W 
2003-04 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/Fujian/411/2002 A/Moscow/10/1999  L W L 
2004-05 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/California/7/2004 A/Fujian/411/2002 A/California/7/2004 (H3N2) emerging L W P 
2005-06 A/New Caledonia/20/1999 A/New Caledonia/20/1999 A/Wisconsin/67/2005 A/California/7/2004 A/Wisconsin/67/2005 (H3N2) emerging L W P 
2006-07 A/Solomon Islands/3/2006 A/New Caledonia/20/1999 A/Wisconsin/67/2005 A/Wisconsin/67/2005 A/Solomon Islands/3/2006 (H1N1) 
emerging 
L P L 
2007-08 A/Brisbane/59/2007 A/Solomon Islands/3/2006 A/Brisbane/10/2007 A/Wisconsin/67/2005 A/Brisbane/59/2007 (H1N1) emerging W P L 
2008-09 A/Brisbane/59/2007 A/Brisbane/59/2007 A/Brisbane/10/2007 A/Brisbane/10/2007  P P L 
2009-10 A/California/7/2009 A/Brisbane/59/2007 A/Perth/16/2009 A/Brisbane/10/2007  W L P 
2010-11 A/California/7/2009 A/California/7/2009 A/Perth/16/2009 A/Perth/16/2009  P P P 
Table 2.7: Vaccine recommendations and circulating strains for each North Hemisphere season since 1968, as extracted from the Weekly Epidemiological Record.  
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3 Predicting Naturally Occurring Epitopes in Influenza A HA1 
3.1 Aims and Overview 
Given the amino acid sequences of the haemagglutinins of two influenza strains, one of which is 
a descendant of the other and known to be antigenically different, we would like to identify the 
amino acid substitutions in the descendant that are associated with antigenic escape. In this 
study, I examine the size, shape and composition of known epitopes, and develop a 
computational method for identifying HA1 substitutions between strains which match those 
properties. I apply this method to predict the likely epitopes in selected wild-type H1 and H3 
strains, and derive a set of ‘immunoactive1’ H3 amino acid locations from this analysis, which is 
broadly consistent both with sets of locations derived via other techniques (discussed below in 
Section 3.4) and with the locations of known H3 epitopes. I develop a predictive model of 
antigenic distance based on this set of immunoactive locations, and demonstrate that it has 
improved specificity compared to models developed in previous studies.  
The work in this chapter has been published: Lees WD, Moss DS, Shepherd AJ. (2011). 
Analysis of antigenically important residues in human influenza A virus in terms of B-cell 
epitopes. Journal of Virology 85, no. 17 (September): 8548–8555; although here I present an 
updated analysis of known epitopes using information added to the Protein Data Bank since 
publication. 
3.2 B-cell Epitope Sizes in Influenza A 
A recent structural analysis of a non-redundant set of 53 antibody-antigen complexes in the 
Protein Data Bank (PDB) (Berman et al., 2002) found that 75% of the epitopes consisted of 
between 15 and 25 amino acids and covered a contact surface area on the antigen of between 
600 and 1,000Å
2
 (Rubinstein et al., 2008). Previous mutation studies have demonstrated that a 
small number of the epitopic residues – typically between three and five (Novotny, 1991) – can 
contribute a majority of the binding energy, with the mutation of just a single key residue being 
sufficient in some cases to inhibit binding (Air, Laver, and Webster, 1990). 
                                                     
 
1
 I use the term ‘immunoactive locations’ to refer to those locations in the molecule at which an amino 
acid substitution is likely to lead to antigenic change. 
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I conducted an analysis of all crystal studies of influenza A / antibody complexes in the PDB as 
of January 2013. The contact surface areas on the antigen, as reported by the authors, ranged 
from 631 to 984Å
2
.  The methods used to determine the epitope were often unreported, and, 
given the considerable scope for variation in such approaches – both in the overall approach 
taken, and in the determination of cutoff values for significance (Sivalingam and Shepherd, 
2012), for consistency, I used protein-protein interactions inferred by PDBsum 
(http://www.ebi.ac.uk/pdbsum/) to derive surface areas and epitopic residues in each structure.  
In PDBsum, hydrogen-bonded atomic contacts are inferred by appropriate distance and bond 
angle between donor/acceptor pairs, and non-bonded contacts (involving either a carbon or 
sulphur atom) by distance (Laskowski, 2009). The results (Table 3.1) are in agreement with the 
above-described more general analysis: the number of identified epitopic residues ranges from 
14 to 22.  
In order to understand the approximate dimension of an HA epitope, I determined the longest 
distance between constituent residues, as measured between Cα atoms. This ranged from 25Å to 
58Å.  The latter figure is high in comparison to measurements from other structures, the next 
highest distance being 45Å. It is associated with the complex of a broadly-binding antibody to 
an H3 strain in PDB structure 3ZTJ. The same antibody is shown in complex with an H1 strain 
in 3ZTN. This antibody’s primary contacts are in the heavy chain variable region HCDR3 (no 
other HCDRs are involved). The conformation of HCDR3 in the H1 and H3 complexes is 
remarkably similar (Figure 3.1). Approximately two thirds of the interaction (in terms of buried 
surface area) is with the HA2 chain. The antibody light chain has an interaction with the HA2 of 
an adjacent monomer in the H3 complex, but not in the H1 complex. The difference may arise 
from an N-glycosylation site at HA1 38 present in H3 strains but not in H1 strains (Corti et al., 
2011). Given the similarity of the heavy chain interaction between the two structures, it is likely 
to contribute the majority of the binding energy in both structures; however it is possible that 
the outlying residues are important in order to achieve the necessary orientation of the antibody 
in the presence of the oligosaccharide. From this description and the associated figures, it will 
be seen that this exceptionally large longest distance arises from the disjoint epitopic residues 
present in the H3 structure but not the H1 structure. 
In the above analysis of longest distance, the distance between Cα atoms is measured directly, 
rather than across the protein surface. Arguably the latter might provide more realistic 
measurements in regions of the protein that are markedly ridged: however, examination of 
influenza A epitopes, which is confirmed in wider structural studies of B-cell epitopes (Laver et 
al., 1990; Kringelum et al., 2013), reveals them to be relatively flat. 
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Figure 3.1: Partial structures of HA from PDB 3ZTJ (H3 subtype) (A) and 3ZTN (H1 subtype) (B): spheres indicate 
Cα atoms of amino acids constituting the HA protein. Red spheres indicate those identified by PDBsum as forming 
the epitope of antibody FI6V3 which binds to strains in both subtypes. HA1 is shown in light grey and HA2 in dark 
grey. In the H3 complex (A), an adjacent HA2 monomer is shown in light blue. The antibody binds across to this 
monomer, as well as employing outlying residues at both the membrane-distal (top of picture) and membrane-
proximal sides of the core. These features are not observed in the H1 complex (B), although the structure of the core 
is quite similar 
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PDB Code Subtype Binding 
Region 
Haemagglu
-tination 
Inhibiting 
Antibody 
Origin 
Notes HA Epitope (from PDBsum) 
Reported 
S.A. (Å2) 
Longest 
Dist. (Å) 
No. of 
Residues 
HA1 locations HA2 locations 
2VIR  H3 Head Yes Mouse Binds in sites A and B 631 25 17 129-137, 155-159, 
190, 193, 194 
 
1KEN H3 Head Not Stated Mouse Binds across 2 HA 
monomers. Fusion inhibiting 
884 29 18 128, 135-137, 156, 
158, 165, 186, 187, 
189, 190, 192-194, 
222, 225-227 
 
1QFU H3 Mid Yes Mouse  922 42 18 48-50, 59, 60, 62, 63, 
74, 75, 78, 79, 90, 92, 
94, 143, 271, 273, 274 
 
1EO8 H3 Mid Yes Mouse Epitope substantially overlaps 
with 1QFU 
787 28 15 50, 59, 60, 62, 63, 74, 
75, 78, 79, 82, 90, 92, 
94, 271, 273 
 
3GBN H1 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
827 30 18 38, 40-42, 291, 292 19-21, 38, 41, 42, 45, 
46, 49, 52, 53, 56 
3GBM H5 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
799 30 19 38, 40-42, 291-293, 
318 
19-21, 38, 41, 42, 45, 
46, 49, 52, 53 
3FKU H5 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
723 29 14 32, 34, 292 18-21, 38, 41, 42, 45, 
49, 52, 53 
3SDY H3 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
900 25 16 325 15, 16, 18, 19, 25, 30, 
32-36, 38, 150, 153 
3SM5 H1 Head Not Stated Human Binds across RBS itself 775 30 20 134-137, 153, 155, 
156, 158-160, 187, 
189, 190, 192-194, 
222, 225-227 
 
3ZTN H1 Stalk No Human Binds to H1 and H3 strains – 
same antibody as in 3ZTJ 
911 30 19 28, 29, 289, 316 18-21,38, 39, 41-43, 
45, 46, 49, 53, 56, 57 
3ZTJ H3 Stalk No Human See above. H3 form binds 
across two monomers of HA 
984 58 19 38, 277, 278, 318 18, 20, 21, 38, 39, 42, 
43, 45, 46, 49, 53, 56, 
57 (1st monomer); 7, 
11 (2nd monomer) 
3LZF H1 Head Not Stated Human  946 31 18 125, 126, 128, 129, 
157-163, 165-167, 
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169, 197, 246, 248 
4FQI H5 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
782 32 19 38, 40, 41, 42, 291, 
292, 293 
18, 19, 20, 21, 36, 38, 
41, 42, 45, 46, 48, 49 
4FQV H7 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
791 33 17 38, 291, 292 18, 19, 20, 21, 38, 41, 
42, 45, 46, 48, 49, 52, 
53, 56 
4FQY H3 Stalk No Human Fusion inhibiting 
Binds across HA1, HA2 
819 32 17 291, 318 18, 19, 20, 21, 37, 38, 
41, 42, 45, 46, 48, 49, 
52, 53, 56 
4FP8 H3 Head 
(RBS) 
Yes Human Broadly binding 626 22 18 98, 131, 133, 134, 
135, 136, 137, 145, 
153, 155, 156, 186, 
189, 190, 192, 193, 
194, 226 
 
4GMS H3 Head 
(RBS) 
Yes Human Broadly binding.  893 45 19 90, 131, 134, 135, 
136, 137, 153, 155, 
156, 157, 158, 159, 
189, 193, 194, 196, 
226 
 
 Mean 824 32.4 17.7   
Table 3.1: HA/antibody X-ray studies in the Protein Data Bank, showing the HA epitope surface area (i.e. the area buried on the surface of HA) and the longest distance between HA 
amino acids comprising the epitope. Surface areas and epitopic residues are calculated by PDBsum. Longest distances are derived from the protein structure, visualised in Jmol, and are 
measured between the Cα atoms of the corresponding residues. 
  
 
 49 
 
3.3 Identified Clusters in H1 and H3 HA 
I developed an algorithm to search for amino acid substitutions which ‘cluster’ within a specific 
distance of each other. The algorithm requires, as input, amino acid sequences of the two strains 
to be compared and a distance, hereafter referred to as the “cluster distance”. The largest 
possible set of substitutions is found such that the Cα atoms of all substitutions in the set lie 
within the cluster distance from each other.  
The first step in the calculation is to identify the substitutions between the two sequences. I then 
compute a distance matrix containing the distance between the Cα atoms of each pair of 
substitutions. Distances between Cα atoms are inferred from the X-ray structures of 
A/Aichi/2/68 (PDB code 1HGD) (Sauter et al., 1992) for H3N2 strains and A/Puerto Rico/8/34 
(PDB code 1RU7) (Gershoni et al., 2007) for H1N1 strains. These structures were selected as 
being representative of the subtypes concerned, and, in contrast to many other available 
structures, because the HA is shown unbound from antibodies which might deform the gross 
structure. In the case of 1HGD, the HA is complexed with a synthetic construct in the RBS, but 
this is unlikely to cause more than small local deviations. Recently published crystal structures 
of 2004 and 2005 H3N2 HAs have revealed little change in backbone structure in H3 from 1968 
to 2005 and validate the approach of using a single representative structure to locate and assess 
antigenic differences between strains (Lin et al., 2012). 
The largest subset of substitutions meeting the required criterion – that the distance between any 
two substitutions in the set should be less than or equal to the cluster distance – is then 
discovered via a traversal of all possible permutations.  If there are n substitutions, the algorithm 
will first check whether the set containing all n meets the criterion. If not, all permutations of n-
1, n-2, … are successively checked, until, if necessary, all permutations containing at least three 
substitutions have been tested. If a conforming subset is identified, it is assigned to a cluster and 
the process is repeated with any remaining substitutions (i.e., discounting those that have 
already been assigned to a cluster). The process terminates when no further clusters can be 
identified. 
Valid clusters are required to contain at least three substitutions, as ‘clusters’ of two 
substitutions are too common for those of significance to be distinguished. Both effective 
substitutions (i.e. those that become fixed in the viral population) and ineffective substitutions 
are considered for inclusion in clusters. In this work, they are distinguished following the 
approach and terminology of Shih et al. (2007): in summary, a substitution is classed as 
‘effective’ provided that the newly dominant amino acid is present in at least 99% of samples 
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for a period of at least one year: an ‘ineffective’ substitution, by contrast, is one in which an 
amino acid becomes dominant at a location but never achieves 99% penetration in a year before 
ceasing to be dominant. It should be noted that a substitution classed as ineffective in this 
terminology, while not persisting in the long term, may nevertheless contribute to antigenic 
evolution in the shorter term, before being displaced by a more effective substitution. 
The predominant circulating strains of influenza A H1N1 and H3N2 viruses in each year 
between 1972 and 2009 were identified from the annual and semi-annual influenza virus 
activity reports in the Weekly Epidemiological Record (http://www.who.int/wer/en/). The 
algorithm described in the above paragraphs was applied to each successive change in the 
predominant circulating strain in order to identify substitution clusters. Where multiple clusters 
were identified in substitutions between adjacent circulating strains, and where sequences of 
intervening strains were available, phylogenetic trees derived from sequence data using PhyML 
(Guindon and Gascuel, 2003) were used in conjunction with HI assay results compiled from 
data from journals and other sources to determine antigenic intermediates between the two 
epidemic strains. This allowed the evolutions of some multiple clusters to be separated. 
Identified clusters, using a cluster distance of 35Å, are shown in Figures 3.2 - 3.4. The cluster 
distance of 35Å was determined to be appropriate in this analysis (see Figure 3.8 and ensuing 
discussion), and is in good agreement with the crystallographically determined epitope 
dimensions described in the previous section and with the results of other studies (Rubinstein et 
al., 2008; Kringelum et al., 2013). 
Interestingly, the H1 strains A/New Caledonia/20/1999 and A/Egypt/39/2005 are antigenically 
similar, although being separated by 6 years and 7 HA1 amino acid differences. There are a 
further 5 amino acid differences in HA1 between A/Egypt/39/2005 and A/Solomon 
Islands/3/2006, but the antigenic distance (shown in the diagram as a titre ratio rather than a log 
ratio) between these two strains is 7. In view of the low antigenic distance between A/New 
Caledonia/20/1999 and A/Egypt/39/2005, the six substitutions between these strains identified 
as a cluster in the diagram may represent successive dead ends on the path to eventual antigenic 
escape.  
A question arises as to whether substitutions at ‘buried’ locations should be eliminated from 
consideration. Even if a location is identified as being buried in the reference structure, it is 
possible that a substitution could result in it becoming exposed: likewise, antibody binding 
could cause a local rearrangement resulting in the exposure of a buried location and its 
subsequent participation in the epitope. For these reasons, I did not discount buried locations 
when deriving clusters. Analysis of the structures 1HGD (H3) and 1RU7 (H1) using PISA 
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(Krissinel and Henrick, 2007) reveals a total of 21 buried locations in the H3 HA1 monomer 
and 27 in the H1 HA1 monomer. Two of these are identified as cluster members: H257Y in the 
H1N1 transition from A/USSR/90/1977 to A/Brazil/11/1978, and V202I in the H3N2 transition 
from A/Moscow/10/1999 to A/Hong Kong/1550/2002. The first is in a 5-location cluster and 
the second in an 11-location cluster: hence eliminating these two substitutions would not 
materially affect the results. Additional HA locations on the inward face of the monomer may 
not be accessible to antibodies in the trimeric structure, however few such locations are 
identified in my results (see Section 3.4 and Figure 3.7). 
The predicted epitopes lie within closely defined regions of the monomer. All but three of the 
21 H3N2 clusters and all but four of the 15 H1N1 clusters lie close to the RBS, with centroids 
positioned at 25Å or less from the membrane-distal end of the monomer. The exceptions are 
grouped in a region closer to the viral membrane, with centroids positioned between 40 and 55Å 
from the extreme membrane-distal end. I shall refer to these regions as the “RBS region” and 
the “mid region” in this work (Figure 3.5). Of the 76 amino acid locations participating in 
clustered substitutions between the H3N2 strains considered (both the series shown in Figure 
3.3 and the series shown in Figure 3.4), 61 occurred within RBS clusters, and 18 occurred 
within mid region clusters, with three locations occurring in both clusters (Table 3.2). 
Between successive H3N2 strains, I observed a number of substitutions in the mid region that 
did not meet the criteria for clusters developed above. I postulated that substitution clusters may 
develop in this region at a slower rate than in the RBS, in which case a snapshot between 
successive wild-type strains might not allow a sufficient window for a full cluster to develop. 
To take a coarser-grained view, I examined substitutions between representative strains of the 
11 “antigenic clusters” identified by Smith et al. (2004), using the vaccine candidates identified 
in that work as being representative of each antigenic cluster. 
The results are shown in Figure 3.4, and identify mid region clusters in 6 out of 10 cases. A 
possible seventh candidate can be seen in the transition from Wuhan/359/1995 to 
Sydney/5/1997, where the substitution at position 121 could potentially be a member of either 
predicted epitope but has been assigned to the RBS region due to the order in which the 
algorithm examines sets of substitutions. 
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Region Amino Acid Identifiers  
RBS 62, 75, 78, 80, 82, 83, 94, 96, 121, 122, 124, 126, 131, 133, 135, 137, 138, 139, 
142, 143, 144, 145, 146, 155, 156, 157, 158, 159, 160, 163, 164, 182, 185, 186, 
188, 189, 190, 192, 193, 194, 196, 197, 199, 201, 202, 207, 208, 213, 214, 216, 
217, 219, 222, 223, 225, 226, 227, 233, 242, 244, 248 
Mid 47, 50, 53, 54, 57, 62, 63, 82, 83, 172, 174, 260, 262, 275, 276, 278, 299, 308 
Both 62, 82, 83 
Table 3.2: Locations participating in H3 clusters identified in this study, classified by the region in which the cluster 
occurs 
 
 
 
 
 
Figure 3.2: Clusters on the HA1 monomer calculated with a cluster distance of 35Å, for substitutions between 
selected H1N1 strains. Effective substitutions are shown in blue, and other substitutions in red. The Receptor Binding 
Site is shown in yellow. Clusters are designated by the light grey spheres. Predominating strains are listed in red text 
and intermediates in black text. The antigenic distance between the strain/serum on the left and the strain on the right 
is given in the arrow between the strain names where known from published results as the ratio between the 
homologous and heterologous HI titre. A value of 4 or more is generally regarded as immunologically significant 
(Schild et al., 1973). The number of substitutions in each cluster is given by the number near the cluster. The 2009 
pandemic strain is shown for comparison, with amino acid differences compared to A/Brisbane/59/2007, although no 
cluster analysis has been performed given the large number of substitutions. 
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Figure 3.3: Clusters on the HA1 monomer calculated with a cluster distance of 35Å, for substitutions between 
selected H3N2 strains. Legend and colour coding as for Figure 3.2. 
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Figure 3.4: Clusters on the HA1 monomer calculated with a cluster distance of 35Å, for substitutions between H3N2 
'antigenic clusters' (Smith et al., 2004). Legend and colour coding as for Figure 3.2. 
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Figure 3.5: The centroids of identified clusters lie in two distinct regions of the H3 molecule, one close to the 
membrane-distal tip, and one at an axial distance of 40-55Å from the tip.  In this study, these regions are termed the 
RBS and mid region respectively. The figure shows, for all H3N2 clusters identified in this study, the distribution of 
axial distance from the tip of the molecule to the cluster centroid, superimposed onto a single monomer of the global 
head of H3N2 (PDB structure 1HGD) for reference. Canonical H3 antigenic sites are shown in colour: A (red), B 
(blue), C (green), D (yellow), E (orange). 
 
3.4 Comparison with H3 Canonical Sites 
Table 3.3 lists the amino acid identifiers at which clustered substitutions were observed in the 
H3N2 strains considered, classified in terms of the canonical H3N2 antigenic sites. In previous 
work (Lees, 2009), we identified additional locations that should be considered members of 
these antigenic sites, in light of sequences not available at the time when the original list (Bush 
et al., 1999) was drawn up. Five locations are allocated to antigenic sites on the basis of this 
additional classification. 
Of the 63 locations identified previously by Shih et al. (2007) as undergoing frequency 
switches, 57 are represented in the list of 76 substitutions identified in clustered substitutions. 
Twenty-three of the 25 locations identified by Yang (2000) as being under selective pressure 
(95% level, all models with listed locations) are included. Of the 45 locations identified 
previously by Smith et al. (2004) as being cluster differentiating, 41 are included, as are all 6 
locations forming the decision tree constructed by Huang et al. (2011). These results give 
confidence that the regions identified by this technique are indeed those that are key to antigenic 
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differentiation, indicated both by evidence of selective pressure and by their importance in 
antigenic cluster differentiation (Figure 3.6).  
Antigenic 
Site 
Amino Acid Identifiers  
A 122*, 124*, 126, 131*, 133*, 135, 137*, 138, 142, 143*, 144*, 145*, 146* 
(13/19) 
B 155*, 156*, 157, 158*, 159, 160*, 163, 164*, 186, 188*, 189*, 190*, 192, 
193*, 194, 196*, 197*, 199 (18/22) 
C 47, 50*, 53*, 54*, 275, 276*, 278*, 299, 308 (9/27) 
D 96, 121, 172*, 174*, 182, 201*, 207*, 208, 213*, 214, 216, 217*, 219, 
222*, 223, 225*, 226, 227, 233, 242, 244*, 248 (22/41) 
E 57, 62*, 63, 75*, 78, 80, 82*, 83*, 94, 260*, 262* (11/22) 
Unclassified 139, 185, 202* (3/0) 
Table 3.3: Locations participating in H3 clusters identified in this study, classified by canonical antigenic site (Bush 
et al., 1999). Locations in italics are additional locations not classified in that work but assigned subsequently to the 
cluster by virtue of their position (Lees, Moss, and Shepherd, 2010). Locations classified by Shih et al. (2007) as 
carrying effective frequency switches are in bold. Locations identified by Smith et al. (2004) as cluster differentiators 
are starred. Figures in brackets show the number of substitutions observed in the site in this study, and the total 
number of locations in the canonical H3 site. 
 
The list is roughly half the size of the canonical list of varying locations in antigenic sites A to 
E. While this approach may miss some immunogenic locations (for example, in some cases 
escape may have occurred with substitutions of fewer than three residues), this significant 
reduction in number and the broad agreement with residues identified by other techniques 
suggest that not all of the canonical locations are immunogenically important. 
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Figure 3.6: Comparison of Substitution Clusters with other sets of key residues. (A) Clustered substitutions observed 
in H3N2 strains considered in this study, superimposed onto one HA1 monomer (in white). (B) Locations undergoing 
effective frequency switches (Shih et al., 2007). (C) Canonical antigenic sites (Bush et al., 1999). Locations are 
coloured according to the antigenic site: A (red), B (blue), C (green), D (yellow), E (orange), or unclassified (black). 
The remaining two HA1 monomers in the complex are shown in light grey, and the three HA2 monomers are shown 
in dark grey. Some key residues are obscured in this view, and, indeed, obscured in the trimeric structure – see Figure 
3.7 for a reverse view. 
Some solvent-exposed residues in the HA1 monomer are not accessible to antibodies in the 
trimeric form, as they are occluded by HA2, or by other monomers. The exact extent of this 
occlusion cannot be determined with certainty, because the structure contains deep clefts and 
pockets: the extent to which antibodies can penetrate these is not known. To form an 
approximate view of the extent of the occluded region, I identified all HA1 residues whose Cα 
atom lay at a distance of 10Å or less from the Cα atom of a residue in HA2 or in another 
monomer, taking these to form the boundary of a region of potentially occluded residues. I then 
examined this region in spacefill view in Jmol, and removed from it all residues with apparent 
surface exposure in the trimeric form, leaving the set of occluded residues shown in Figure 
3.7A. The set of 76 substitutions identified in this study includes three that lie in this occluded 
region (Figure 3.7B): all lie on the edge of the region closest to the membrane-distal tip. It is 
possible that residues in this location could contribute to antibody binding, either directly, via a 
minor conformational change, or indirectly (see Section 5.5 for a discussion of the role of buried 
residues in antibody escape). By contrast, the canonical set of 131 residues includes 11 which 
are distributed throughout the obscured region (Figure 3.7C).  This is expected, as the authors 
considered solvent exposure but did not consider the blocking effect of the trimer as a whole. 
The low number of buried locations included in the set produced by my analysis provides some 
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confidence that the use of a directly measured cluster distance (as opposed to surface path) is 
not introducing structurally questionable predictions. 
Figure 3.7: Substitutions identified in this study lying on the inward face of the HA monomer, compared with those 
in canonical antigenic regions. (A) Residues shaded in grey are occluded in the trimeric structure. (B) Three residues 
identified in this study lie within the occluded region: residues 213 and 216 in antigenic site D, shown in yellow, and 
residue 202, which lies outside the canonical sites and is largely obscured in this view. (C) A total of 11 residues from 
the canonical set lie within the occluded region (Legend and colour coding as for Figure 3.2).   
 
3.5 Cluster distance versus epitope size  
To obtain an understanding of the sensitivity of this approach to the cluster distance, I examined 
the proportions of total and effective substitutions lying within calculated clusters for cluster 
distances of between 20Å and 60Å. The results are presented in Figure 3.8. With a cluster 
distance of 35Å, approximately 80% of the substitutions between the strain transitions 
illustrated in Figures 3.2-3.4 were contained within clusters. An increase of the cluster distance 
from 35Å to 60Å does not increase the percentage significantly, indicating that the remaining 
substitutions are sufficiently distant from clusters that they are unlikely to form part of a 
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common region. I therefore consider a distance of 35Å to be a reasonable trade-off between 
inclusion and specificity: however, in the spirit of the method, this is not a highly optimised cut-
off. Interestingly, the same pattern can be seen both for total substitutions and for effective 
substitutions.  
To understand the significance of these results, I compared them with simulated results obtained 
by distributing substitutions at random on the H3 monomer, considering all possible locations in 
HA1. The H3 series contained 19 strain transitions with between 3 and 16 substitutions in each 
transition. I used bootstrap tests to examine the significance of the clusters of substitutions 
obtained compared to those expected from a random distribution of substitutions across the 
HA1 monomer. In these tests, 1,000 batches of 19 simulated strain transitions were created, 
with the number of substitutions reflecting the distribution of the number in the H3 series and 
with the substitutions positioned randomly across the monomer. I observed a significant 
increase in the number of substitutions in a cluster at all diameters between 25Å and 60Å (p < 
0.01) compared to a random distribution of substitutions. Even if the randomly assigned 
substitutions were chosen just from the 131 canonical residues in the five antigenic sites, this 
level of significance was found for H3 cluster distances of between 25Å and 45Å (the mean 
number of substitutions in an H3 cluster at 35Å was 6.8 in my results, compared to 5.3 in the 
random simulation with substitutions selected from the 131 locations). The clusters obtained 
from the analysis contain a significantly higher number of residues than would be expected 
from a random distribution, and are therefore unlikely to be just an artefact of sample size. 
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Figure 3.8: Proportion of substitutions lying within calculated clusters of various sizes. Effective substitutions follow 
the definition described previously by Shih et al. (2007). 
3.6 Comparison of Cluster Locations with Locations of Known Epitopes 
Okada et al. (2010) isolated and cloned 98 antibodies to wild-type H3 HA from a single 
volunteer born in 1960. These antibodies were found to divide into three sets: one set that bound 
to strains isolated between 1968 and 1973, a second set that bound to strains isolated between 
1977 and 1993, and a third set that bound to strains isolated between 1993 and 2003. This 
experimental study used a chimeric approach in which various regions of the HA1 protein of a 
strain of interest are replaced by equivalent regions from a known antigenic variant. By this 
means, it is possible to test if the epitope of an antibody known to bind to the strain of interest 
contains critical residues in the replaced regions. The replacement regions varied in length from 
5 to 32 amino acids. The technique is not able to identify the specific location of critical 
residues, but can isolate them to the substitutions within any replacement region found to elicit 
antigenic escape. 
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I compared the residue locations obtained by Okada et al. with 35Å clusters calculated from a 
predominant strain transition at or just after the end of each of the three identified periods of 
antibody binding, reasoning that substitutions in this transition would have led to escape. 
Okada et al. isolated 11 antibodies binding to viral strains isolated between 1968 and 1973: I 
compared their binding locations with clusters calculated for the transition between 
A/England/42/1972 and A/Port Chalmers/1/1973. Nine of the antibodies bound across antigenic 
sites B and D in a location that is consistent with that identified in this analysis. The remaining 
two bound in the RBS region, inside the cluster identified by my results (Figure 3.9A). In the 
period of 1977 to 1993, most of the isolated antibodies bound in a region close to a mid region 
cluster that was calculated for the transition between A/Beijing/32/1992 and 
A/Wuhan/359/1995. The remainder bound in site E and site B. The set of locations identified in 
site E lie within the calculated mid region cluster, while those identified in site B lie within the 
calculated RBS cluster. My analysis predicts an epitope in the RBS region in this period: 
although such an antibody was not isolated from the experimental subject, it is possible that 
such antibodies were present in the wider population (Figure 3.9B). 
In the period of 1993 to 2004, most antibodies isolated in the study showed binding activity in 
site B. Two of the substitutions in the cluster that were calculated for the transition from 
A/Fujian/411/2002 to A/Wellington/1/2004 are included in the set of residues from the study. 
The remaining antibodies from the study bound in the mid region; no substitutions in this region 
were observed for this strain transition. The experimental study also identified some binding 
activity in site A: the identified locations lie within the calculated cluster (Figure 3.9C). 
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Figure 3.9: Comparison of clusters obtained in this analysis with data from an experimental study of antibodies 
isolated from a single individual (Okada et al., 2010). In each case, panel (i) shows the clusters that were obtained 
from a transition between the predominant wild-type strain and panel (ii) shows those residues identified in an 
experimentally defined chimeric approach, at least some of which disrupt the binding of an antibody that became 
ineffective after that transition. (A) Transition of A/England/42/1972 to A/Port Chalmers/1/1973; (B) transition of 
A/Beijing/32/1992 to A/Wuhan/359/1995 (B(ii) shows the mid region only); (C) transition of A/Fujian/411/2002 to 
A/Wellington/1/2003. Substitutions are in blue, and the receptor binding site is in yellow. 
The antibody complexes in the PDB, summarized earlier in Table 3.1, include nine H3 
structures, with epitopes spanning the head, mid and stalk regions. Some interesting 
comparisons can be drawn between these structures, my results, and the results reported by 
Okada et al. Turning first to the four H3 structures displaying head-region epitopes, the 
structure 2VIR binds in antigenic sites A and B, and in terms of location, is typical of many of 
the clusters that I have identified in H1 and H3 strain transitions and the RBS binding antibodies 
identified previously by Okada et al. The structure 1KEN binds across antigenic sites A, B, and 
D in one HA monomer and sites A and B in another. The binding location is again typical, but 
this technique and that reported previously by Okada et al. do not specifically address cross-
monomer binding.  The antibodies in structures 4FP8 and 4GMS bind across the RBS, with 
contacts in antigenic sites A, B and D. These antibodies are broadly binding to H3 strains and to 
other subtypes. Interestingly, though, their epitopes include many locations identified in Table 
3.3: 14 out of the 18 residues in the 4FP8 epitope are in this list, as are 12 out of the 19 residues 
in the 4GMS epitope. Other residues in these two epitopes are strongly conserved, and may 
form the critical contacts allowing for their broad spectrum action.  
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Figure 3.10: Comparison of H3 epitopes deduced from structures reported under PDB codes 1QFU (A), 1EO8 (B), 
3ZTJ (D), and 3SDY (E) compared to the locations identified in this analysis in canonical antigenic sites C and E (C) 
(site E in yellow, site C in green). As in Figure 3.1, spheres indicate Cα atoms of amino acids constituting the HA 
protein. Yellow and green spheres in (A) and (B) show those locations in the epitope that are also found in (C). Red 
spheres in (A),(B),(D) and (E) indicate those identified by PDBsum as forming the epitope of the respective antibody 
that are not identified in (C). All epitopes highlighted on structure 1EO8.  
Figure 3.10 compares two mid region and two stalk-region epitopes identified from H3 
structures in the PDB with the antigenic locations identified from this analysis in canonical sites 
C and E. There is good correspondence between the mid region epitopes and the identified 
locations, with both epitopes encompassing the two antigenic sites. The same 6 HA1 locations 
in each epitope are included in the set of immunoactive locations identified by my technique: 
location 50 in antigenic site C, and 62, 63, 75, 78, 94 in antigenic site E. The five locations 
identified in the mid region in the Okada study (Figure 3.9, Bii , HA1 locations 
50,53,54,276,278), at least some of which are escape locations for antibodies isolated in that 
study, are all locations identified by my technique.  
The two stalk-region epitopes identified from H3 structures shown in the figure bind close to the 
viral membrane, although in 3ZTJ, the outlier at HA1 278 is included in the antigenic locations 
in site C identified by cluster analysis. Given the preponderance of HA2 locations in these two 
epitopes, it is not surprising that they do not coincide with locations identified by cluster 
analysis, as that analysis was confined to HA1. The H1 and H5 stalk-binding epitopes identified 
in crystallographic studies lie in equivalent locations between those of the two H3 epitopes, and 
again have a preponderance of HA2 residues. A further, final, H3 stalk-binding antibody, 
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identified in PDB structure 4FKY, binds in a similar region to that of 3ZTJ (see Section 5.6 for 
further discussion of stalk binding antibodies to H3). 
An interesting question arises as to whether the orientation of the antibody isolated by Okada et 
al. whose antigenic escape region is depicted in Figure 3.9B(ii) is closer to that of the two H3 
mid region epitopes 1EO8 and 1QFU, or to that of the stalk-binding epitope of 3ZTJ. The 
Okada study did not assess HA2 locations for antigenic escape, but the antibody was found to 
be neutralising and not haemagglutination inhibiting. These points suggest an orientation for 
this antibody closer to the viral membrane than that of the mid region antibodies, firstly as the 
latter are still sufficiently close to the RBS to inhibit haemagglutination, and also because, in the 
absence of steric interference with the RBS, the neutralisation mechanism is likely to be 
inhibition of the fusogenic transition, which requires binding to the HA2 chain in the stalk 
(Yewdell, 2011) . From Table 3.1 it can be seen that, for the set of known structures, antibodies 
binding exclusively to HA1 are haemagglutination inhibiting, while those binding also to HA2 
are not, presumably because their increased distance from the RBS prevents steric interference 
with binding.  
To obtain a wider comparison between the antigenically active regions identified in this study 
and those obtained by other researchers, I conducted a search of the Immune Epitope Database 
(http://www.immuneepitope.org/) (Vita et al., 2010) for conformational epitopes on human H1 
and H3 HA1. Antibodies raised against synthetic peptides were excluded. I obtained references 
for a total of 16 additional studies (Table 3.4). Epitopes in the region of the RBS were found in 
15 of those studies, and the locations identified were in good agreement with the locations 
identified in this work. Mid region epitopes were found in three of those studies. Two of these 
mid region epitopes lie across HA1 and HA2; the third is confined to HA1 in the same region as 
that identified by my analysis and by Okada et al. and shown in Fig. 6C. One study identified an 
epitope that is distinct from those identified in cluster analysis; interestingly, this epitope is from 
an antibody isolated from a human volunteer which was found to bind to a relatively conserved 
region of H3 HA at positions 173 to 181 (Kubota-Koketsu et al., 2009). 
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Subtype Host Strain RBS Mid Other Ref 
H1 mouse 1977-1986, various strains Y     Yamada et al. (1991) 
H3 mouse X31 Y Y   Smith et al. (1991) 
H1 mouse A/PR/8/34 Y     Stark and Caton (1991) 
H1 mouse A/PR/8/34 and escape variants Y     Meek et al. (1989) 
H3 mouse 1968-1977, 5 strains Y   Y Underwood (1984) 
H1, H2, H3 mouse Various   Y   Okuno et al. (1993) 
H3 mouse X31 Y     Laeeq et al. (1997) 
H1 mouse Beijing 262/95, New Caledonia 20/99 Y     Morrissey and Downard (2006) 
H3 mouse Panama 2007/99,Shangdong 9/93,Kiev 301/94, Y Y   Morrissey et al. (2007) 
H3 mouse A/Kamata/14/91(H3N2) Y     Nakajima et al. (2007) 
H1 human Pandemic 1918 Y     Yu et al. (2008) 
H3 mouse Panama 2007/99,Shangdong 9/93,Kiev 301/94, Y     Morrissey and Downard (2008) 
H1,H3 human Various Y   Y Kubota-Koketsu et al. (2009) 
H1 mouse A/New Caledonia/20/99 Y     Schwahn and Downard (2009) 
H1 human Pandemic 1918 Y     Krause et al. (2010) 
H1 human Pandemic 1918 and 2009 Y     Xu et al. (2010) 
Table 3.4: H1 and H3 HA1 B-cell epitopes identified from references extracted from the Immune Epitope Database (search conducted on 22nd May 2011). For each one, the epitope’s 
location, derived from locational information provided in the database, is listed. Typically the database identifies a small number of locations experimentally determined to lie within the 
epitope. 
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3.7 Predictive Models of Antigenic Escape Based on Identified Cluster Participants 
A viral strain of influenza A is considered to be antigenically different to antiserum raised from 
a different strain if the antigenic distance rises above a certain threshold, typically 2 
(corresponding to a titre ratio in excess of 4). The appearance of strains that are antigenically 
different to the vaccine antiserum is an indication that the vaccine strain may require updating 
(Schild et al., 1973; Smith et al., 2004; Carrat and Flahault, 2007). 
Researchers have previously noted an approximately linear relationship between the antigenic 
distance separating two H3N2 strains and various counts of their HA1 amino acid differences 
(Lee and Chen, 2004; Liao et al., 2008). They have utilised this relationship to build predictive 
models of antigenic difference or similarity. Such models are potentially useful for vaccine 
selection, and, being binary classifiers, are simple to evaluate. Lee and Chen (2004) obtained 
best performance by counting differences at the canonical set of 131 locations lying close to 
known antigenic sites and known to exhibit variation (Bush et al., 1999). Liao et al. (2008), in 
their most successful predictive model, improved overall performance by introducing two 
refinements. Firstly, amino acid differences were ignored unless the type of amino acid 
(classified as polar, nonpolar, positively charged, or negatively charged) changed. Secondly, 
multiple regression was used to select immunoactive locations from the full set of 131 locations 
used by Lee and Chen, and only changes at these locations were considered. Using the training 
and validation data assembled by Lee and Chen, and introducing these refinements, they 
achieved an agreement rate in the validation data set of 92% compared to Lee and Chen’s 83%, 
yielding a sensitivity of 84% and specificity of 94% (Lee and Chen did not provide sensitivity 
or specificity scores).  
In previous work (Lees, Moss, and Shepherd, 2010), we widened the canonical set of 131 
locations to include a further 110 locations neighbouring the known antigenic sites and 
exhibiting variation in later years than those considered by Bush et al. in 1999. To incorporate 
locational information in our model, we developed a novel approach in that work, in which 
these locations were divided in to bands according to their distance from the membrane-distal 
tip of the protein, with the count of the number of substitutions in each band being used as the 
explanatory variables of a linear model. We also incorporated terms in the model to account for 
changes in N-glycosylation between the two strains. With our models, we were able to exceed 
the sensitivity of the models of Liao et al. but obtained generally poorer specificity. On the 
training and validation sets used in that study, which varied from those of Liao et al. and in 
particular strictly separated the strains used in training and validation sets, our best model 
obtained a sensitivity of 97% and specificity of 57%, compared to the approach of Liao et al. 
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which achieved sensitivity 83%, specificity 73%. Our models have an advantage in terms of 
generality, in that they do not rely on multiple regression to narrow the locations of interest to 
those evidenced in the training set, but the low specificity suggests that substitutions that do not 
relate to antigenic change are being included. In our models, we did not observe an 
improvement through discounting substitutions that did not change amino acid type. 
3.8 Predictive Models Based on Cluster Participation 
I reasoned that those locations identified in this study as participating in antigenic clusters might 
form a useful and relatively generalised set of locations on which to base a predictive model. To 
provide a representation of the spatial distribution of the amino acid differences, analogous to 
the bands in previous work, I superimposed a three-dimensional grid onto the HA1 molecule, 
using the reference coordinates from the X-ray structure of A/X-31 (PDB code 1HGD) (Sauter 
et al., 1992). Each amino acid was assigned to the cell of the grid in which its Cα atom is found. 
Changed amino acids were counted in each cell; for example, if, between two strains, there were 
three amino acid substitutions within a cell, the “difference” count for that cell would be 3. I 
tested models with a range of cell sizes, as described later. 
The counts obtained were used as explanatory variables in a linear model of the form 
   
   ∑    
  
 
   
where    
  is the antigenic distance between the strains i and j as calculated by the model; the 
sum is over all cells in the grid,   
  
 is the count of the number of amino acid differences 
between the strains in cell n, and the variables     and k are parameters to be determined by 
minimizing the least-squares residual given by  
   ∑    
      
    
calculated over a training set, where    
  is the observed distance (from HI assay data) between 
the strains as reported in the training set. The R module lm() (http://www.R-project.org) was 
used to perform calculations. 
The ability of the model to correctly predict antigenic similarity or difference (i.e., antigenic 
distance  <=2 or >2), was tested on a validation data set. In order to provide a benchmark 
comparison of performance, I used the training and testing pairwise data set reported by Liao et 
al. (2008). The training set consists of 181 antigenic distances measured between 45 viruses 
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isolated between 1971 and 2002, and the validation set consists of 96 measurements between 19 
viruses isolated between 1999 and 2003. Two commonly used reference strains 
(A/Panama/2007/99 and A/Fujian/411/2002) are included in both datasets. While the inclusion 
of measurements against these strains in both training and validation sets is not ideal, this 
dataset was used in order to allow comparison of results with previous studies. I present results 
based both on the distances used in that study and on an extended set, in which the strain pairs 
considered are maintained but the quality of the distance measurements is improved by 
including additional titres from published studies not considered by Liao et al.  
Being conscious that the selection of a particular cell size could lead to over-fitting, I reviewed 
the impact of cell size on predictive properties. Results are presented for grids with cubical cells 
with edge lengths varying between 2Å and 22Å. At 8Å, 47 cells of the grid were occupied, 
giving an average of 1.6 residues per cell. At 22Å, 10 cells were occupied, giving an average of 
7.6 residues per cell. The predictive quality of the models was assessed by calculating the 
Matthews correlation coefficient (MCC) (Matthews, 1975). Figure 3.11(A) shows the predictive 
performance of the model at various cell sizes. I was interested to know the extent to which 
substitutions in the mid region contributed to predictive performance. I therefore constructed a 
second model, in which only the 61 identified residues in the RBS region were considered. 
Results for this model are presented in Figure 3.11(B). 
 
Figure 3.11: Performance of the predictive model based (A) on substitutions at all 76 identified locations, and (B) on 
the 61 locations in the RBS region only. Each graph shows predictive performance of the model using the set of HI 
assay titres used in a previous study (Liao et al., 2008), and also when using an extended set, incorporating assay 
results from additional studies in order to obtain greater precision. When used with the model developed for this 
study, the improved precision of the extended set leads to improved performance. 
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Both models provide relatively consistent performance across a broad range of cell sizes in 
which the residue density varied considerably. This indicates robustness in the underlying 
approach. The falloff in the predictive power in the validation set at cell sizes below 12Å in the 
76-location model and 8Å in the RBS-only 61-residue model suggests that, at these small cell 
sizes, the model is over-fitting to the training set by overweighting those locations that are 
significant in that set. The RBS-only model provides significantly improved results in the cell 
size range of 6Å to 10Å without significant degradation at a larger cell size. While this could be 
caused by over-fitting in the 76-location model, the result is interesting in view of the discovery 
by Okada et al. (2010) of wild-type antibodies binding in the mid region which are not 
haemagglutinin inhibiting, as such antibodies would be overlooked by the HI assay. 
Table 3.5 compares the performance of the models discussed in this section with the best results 
obtained by Liao et al. (2008) and with the best results from our previous work, demonstrating 
that the identification of immunoactive sites through discovery of antigenic clusters can be used 
to overcome the weak specificity of our previous approach. 
Model Sensitivity 
(%) 
Specificity 
(%) 
MCC 
Complete 76 locations – average scores 87.5 79.9 0.57 
Complete 76 locations – best result 90.0 89.5 0.73 
RBS only – average scores 86.5 80.6 0.60 
RBS only – best result 90.0 92.1 0.77 
Multiple regression, GM4 (Liao et al., 2008) 83.2 93.5 n/a 
Banded model M4 (Lees, Moss, and Shepherd, 
2010) 
97 57 0.55 
Table 3.5: Comparison of the sensitivity and specificity of models based on identified cluster participants when 
tested against the extended HI titre data set compared to the best models from two previous studies. For the models 
developed for this study, both the average figures (averaged across 8 cell sizes from 8Å to 22Å) and the best result 
obtained (at 12Å for the complete 76 location model and 8Å for the RBS only model) are shown. 
3.9 Sensitivity of the Model to Grid Orientation 
While the employment in the analysis above of grids with multiple cell sizes provides some 
assurance that the results are not overly biased by selection of a favourable grid configuration, I 
also examined sensitivity to grid orientation by changing the grid origin. In this analysis, the 
origin was progressively shifted along the x-, y- and z- axes simultaneously (i.e., along the 
major diagonal) by an increasing percentage of the cell size. The MCC value (averaged across 8 
cell sizes from 8Å to 22Å) was determined at each orientation (Figure 3.12).  The results 
confirm a lack of bias to grid configuration (overall mean MCC 0.57, standard deviation 0.04).  
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Figure 3.12: Mean Matthews correlation coefficient obtained by the predictive model based on substitutions at 76 
locations and cubical cell sizes ranging from 8Å to 22Å in 2Å steps. The x, y, and z co-ordinates of the origin of the 
grid were progressively shifted by a percentage of the cell size, with ‘0% grid offset’ coinciding with the grid origin 
used in section 3.10.  
3.10 Alternative Predictive Models Considered 
Liao et al. (2008) considered several predictive methods, reporting the best performance with a 
multiple-regression approach in which substitutions at roughly 20 locations were selected by the 
model during the analysis of the training set. To attempt to reduce noise induced by 
substitutions unlikely to prove effective, amino acids were categorised into groups using one of 
six different approaches of increasing complexity (the simplest having three groups: polar, non-
polar and charged; and the most complex distinguishing additionally between aliphatic and 
aromatic non-polar amino acids and introducing additional groups for cysteine and glycine), 
with only substitutions that caused a switch of groups being considered significant. With the 
models developed for this study, I found that grouping approaches such as those reported by 
Liao et al., or the introduction of additional explanatory variables based on properties such as 
charge or hydrophobicity, did not improve performance significantly. I believe that this reflects 
the relatively low level of noise in difference scores at the locations selected.  
 
3.11 Discussion 
A key challenge in building predictive models of antigenic escape is to separate those amino 
acid substitutions related to escape from those that occur for other reasons. The ‘antigenic 
clustering’ approach addresses this challenge by seeking patches of multiple substitutions that 
are spatially co-ordinated and occur together as part of a known antigenic transition. The 
technique is similar to that used by earlier researchers to infer the binding location of 
monoclonal antibodies by studying substitutions in escape mutants (Wiley, Wilson, and Skehel, 
 71 
 
1981), but here it is applied computationally to wild-type strains, introducing the requirement 
for spatial co-ordination to eliminate at least some of the substitutions arising from other causes. 
The extent to which the antigenic clusters identified match genuine epitopes could only be 
established categorically via experimentation. At the time of writing there has only been limited 
study of the epitopes of human antibodies, and studies have focussed on unusual and rare 
properties, such as broad-spectrum binding, rather than reviewing what is typical in the 
population as a whole. In this chapter I have compared in some detail the results of one 
experimental study which is particularly relevant to this work, and in which I have established 
several correspondences. Beyond experimental evidence, some other factors give confidence. 
Firstly, the antigenic clusters identified lie within the range of identified H3N2 antigenic sites. 
Secondly, the set of 76 locations identified as participating in clusters is to a large extent a 
superset of sets of locations other researchers have identified as having undergone periods of 
selective pressure, or determining membership of antigenic clusters. Finally, I have 
demonstrated that counts of substitutions at the 76 locations can be used in predictive models, 
and can overcome the problems of specificity associated with our previous models, which were 
based on larger numbers of locations.  
Given that the survey of antigenic clusters utilised strains isolated across a period of 34 years, 
models based on substitutions at the identified locations are likely to have greater generality 
than those based on much smaller numbers of locations (Liao et al., 2008; Huang and Yang, 
2011), which have been necessary until now in order to obtain acceptable predictive 
performance. 
While examples of atypical antibody binding exist (Kubota-Koketsu et al., 2009; Barbey-Martin 
et al., 2002), my results lend support to the dogma that anti-HA1 antibodies generally bind in 
the region of the five antigenic sites. At first sight, the restriction to these sites is surprising, 
particularly as the antibodies used in the experiments from which the sites were deduced were 
of mouse origin rather than human. Indeed, it is perhaps surprising that one observes a general 
consistency in antigenic escape across a population, as evidenced by the consistency of HA 
assay results discussed in the previous chapter. The underlying reasons are likely to be a 
combination of genetic and structural factors. While V-region gene rearrangement and ensuing 
secondary diversification allow for a very large gene repertoire, there is evidence that the typical 
antibody response to influenza can, in practice, be more limited in diversity (Kavaler et al., 
1990; Clarke et al., 1990; Lingwood et al., 2012). That conformational epitopes themselves 
have structural and compositional features, making some parts of a protein more immunogenic 
than others, is discussed in Rubinstein et al. (2008). 
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This analysis suggests that, in H3N2 in particular, antibody binding to HA1 takes place in two 
distinct regions: the RBS region and the mid region, with evolution and escape taking place 
more rapidly in the former than the latter region. This led us to speculate that the clustered 
nature of the H3N2 antigenic map observed by Smith et al. (2004) might be caused by interplay 
between antigenic escape in the two regions. This possibility is explored in Chapter 4. It should 
be noted that an epitope is sufficiently large to span multiple antigenic sites. The RBS region 
includes sites A and B, while the mid region includes sites C and E. Substitutions in site D are 
present in both RBS and mid region clusters. 
The analysis in this chapter, and that of the experimental study quoted, are both confined to the 
HA1 chain. One antibody identified in the experimental study, which was found to bind in the 
mid region, was neutralising but not haemagglutination inhibiting. This suggests an orientation 
remote from the RBS, and a neutralisation action through fusion inhibition rather than steric 
interference with receptor binding, both factors which would make it likely that the epitope 
would extend into the HA2 chain, given its location and its role in membrane fusion. The ready 
isolation of such an antibody from a human volunteer would have important implications for 
vaccine selection and epidemic forecasting: the human stalk-binding antibodies that have been 
the subject of X-ray crystallographic studies were specifically selected for their broad-spectrum 
affinity and are, by contrast, extremely rare: Corti et al., for example, isolated ‘a few’ broadly 
binding plasma cell derivatives from a single donor, having screened 104,000 cells from 8 
donors. This possibility – and the possibility that other mid-range clusters might also have 
epitopes extending into HA2 – led us to examine variation in HA2 in more detail. This work is 
described in Chapter 5 
.  
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4 Exploring the clustered behaviour of antigenic distance in Influenza A H3N2 
Haemagglutinin 
4.1 Introduction and Motivation 
The antigenic evolution of influenza A H3N2 Haemagglutinin, as revealed by antibody binding 
assays, is known to be punctuated. When antigenic distances between H3N2 strains are used to 
construct two dimensional antigenic maps (see the following section for a discussion of 
antigenic mapping), this behaviour gives rise to a clustered behaviour (Figure 4.1). 
 
 
 
 
 
(this figure is not included in the public version) 
 
 
 
 
 
 
 
 
 
Figure 4.1: Antigenic Map of selected H3N2 strains showing clustered behaviour (Smith et al., 2004). The position 
of each strain is shown in colour, antisera are shown in outline. The size and shape of each data point represents 
uncertainty in the calculated position. Strains are assigned to clusters in the map by k-means clustering. Clusters are 
named after a vaccine strain considered representative of the cluster in terms of its position and isolation year. Each 
square represents one unit of antigenic distance. 
Studies of conformational antibody binding in general have indicated that, of the 15-22 residues 
typically comprising a B-cell epitope, a small subset of 5-6 contribute most of the binding 
energy (Laver et al., 1990). In antibody/haemagglutinin complexes, cases have been found in 
which mutation of just 1 or 2 residues will give rise to antigenic escape (Smith et al., 2004; Jin 
et al., 2005). 
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In Chapter 3, we saw that antigenic evolution in HA1 in wild type human H3N2 strains is 
associated with mutations that cluster in two regions: one region surrounding the RBS at the 
membrane-distal end of the haemagglutinin stalk, and the second (the ‘mid region’) lying closer 
to the HA1/HA2 interface. These regions coincide with, but are more restricted than, the 
antigenic sites A-E identified in in vitro studies based on monoclonal mouse antibodies (Wilson 
and Cox, 1990). 
I was interested to explore the potential of these two phenomena (variation in binding strength 
between residues in an epitope, and multiple regions associated with antigenic evolution) to 
give rise to punctuated evolution of antigenic distance. To facilitate this, I developed a model to 
simulate antigenic evolution. 
4.1.1 Antigenic Maps 
Edelstein and Rosen (1978) introduced the concept of shape space as a means to model protein-
protein interaction. The nature of the two interacting surfaces, for example those of an epitope 
and paratope, are considered to be represented by two co-ordinates in multidimensional space, 
where the dimensions describe both the geometric shape of the surfaces, and also the other 
physical and chemical characteristics relevant to binding. The molecular affinity observed 
experimentally is assumed to be a monotonic function of the distance between the two co-
ordinates in shape space. 
Perelson and Oster (1979) used experimental data to estimate the dimensionality of shape space, 
finding it to be approximately five-dimensional. Lapedes and Farber (2001) applied ordinal 
multi-dimensional scaling (MDS) to antigenic distances derived from several small sets of 
influenza HI assay data. They confirmed that this data could be represented accurately in five 
dimensions, but no fewer. An important result from this work was the discovery that 
logarithmic antigenic distance is linearly related to distance in shape space. 
Smith et al. (2004) used metric MDS to model a large set of H3N2 HI data, covering the period 
1968 – 2002. Interestingly, in view of the above results, they found that antigenic distances 
could be recalled from the model without appreciable loss of precision even if the shape space 
was restricted to two dimensions, thus allowing for the construction of conveniently viewable 
antigenic maps, such as the map illustrated above in Figure 4.1. 
A complication arises from the definition of antigenic distance, which is normally defined as the 
logarithm of the ratio of a homologous titre to a heterologous titre (Section 2.2.1). In some, 
relatively rare, cases, the heterologous titre exceeds the homologous titre, leading to a negative 
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antigenic distance under the above definition. In other cases (as was the case with some 
experimental data used by Smith et al.), homologous titre values are not available. Smith et al. 
adopted a modified definition of antigenic distance, in which the numerator is the highest 
observed titre in that column of the assay table, rather than the homologous value. Another 
complication seen in HI data is the reporting of threshold values, often denoted by ‘<’ in the 
assay table. Here the antibody reactivity was too low to be observed within the limits of the 
assay. The reported result is a lower bound on antigenic distance rather than a specific value.  
MDS algorithms are typically based on matrix transformations: however this approach requires 
a complete matrix (Borg and Groenen, 1997). Matrices of antigenic data tend to be sparse, 
particularly when, as in the case of Smith et al., many assay tables are brought together in order 
to create a dataset covering an extensive period.   
Smith et al. derived co-ordinates in the antigenic map by minimising an error function using 
conjugant gradient optimization (Flannery, Teukolsky, and Vetterling, 1988). In the case of 
numerical assay values, the error function took the form 
 (       )   (       )
 
 
where      is the antigenic distance between antigen i and antiserum j as measured in the assay, 
and     is the Euclidean distance as represented in the map. In the case of threshold values, the 
function is modified to 
 (       )   (       )
 
 (         ) 
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and     is the reported lower bound on antigenic distance. In this modified function,      is a 
‘squashing function’ which ensures that the reported error is close to zero when           
Smith et al. tested the effectiveness of their maps by utilising them to predict HI values that 
were missing from the data used to construct the maps, and then determining those values 
experimentally. They noted that prediction error decreased ‘only slightly’ as the number of 
dimensions was increased from 2 to 5. This result may reflect noise or lack of precision in the 
data set rather than inherent low dimensionality of shape space. 
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Prediction of missing data could be beneficial to surveillance, allowing the number of assays to 
be reduced, or the number of reported strains to be increased. Cai et al. (2010) noted that this 
problem of data completion is similar that set in the Netflix Challenge: a problem that received 
much attention as a result of the large prize offered by Netflix Corporation for a satisfactory 
solution (Bennett and Lanning, 2007). They developed an approach to predicting HI assay data 
termed MC-MDS, which brings together these advances in matrix completion with MDS.  
Cai et al. suggested also that novel emerging strains would tend to be antigenically different to 
all of those observed previously in the population, over some window roughly coincident with 
herd immunogenic memory. They introduced a further term into the MDS error function to 
account for this tendency. This phenomenon of ‘temporal bias’ essentially introduces a 
preferred direction of evolution into the map. Such a preferred direction is seen in assay data 
when comparing an antiserum with a strain whose isolation date differs by up to 5-10 years: 
antigenic distance tends to increase over time. Beyond that point, antibody reactivity is typically 
too low for an antigenic distance to be determined, and whether temporal bias exists beyond that 
point is therefore not deducible from the data. In my simulation I examine the effect of preferred 
directionality in antigenic maps in one simulation run (see Figure 4.9), but otherwise do not 
include a directional preference. I demonstrate that introducing a biologically reasonable degree 
of preference does not impact the overall conclusions.  
4.1.2 Determination of Cluster Quality 
In developing the antigenic map shown in Figure 4.1, Smith et al. (2004) used k-means 
clustering (MacQueen, 1967) to identify clusters. k represents the number of clusters into which 
the data set should be divided, and must be provided as an input to the algorithm. The algorithm 
also requires an initial assignment of the data to clusters (which may be random). The algorithm 
proceeds through successive optimisation steps, in each step determining the centroid of each 
cluster (the means), and then assigning each data point to its closest mean. The algorithm 
terminates when no assignments change during an optimisation step. 
While this method is widely used, the requirement for the user to provide a value for the 
parameter k has disadvantages. An optimal value of k has to be identified, typically by running 
the algorithm with various values of k, so that the best value can be selected. The results of k-
means clustering also depend critically on the initial assignment to clusters: ideally, therefore, 
the algorithm should also be run with multiple initial assignments. Antigenic map simulation 
experiments require the creation of a large number of antigenic maps. The need to run the 
clustering algorithm multiple times on each one would therefore introduce significant overhead.  
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The selection of a ‘best’ value of k and the best set of input conditions can be made by 
reviewing the resulting clusters, either by eye, or algorithmically. In initial simulations using k-
means clustering, I found that the act of partitioning a map into a certain number of coloured 
clusters had a powerful influence on perception, making it hard to determine objectively the 
optimum number to use: a computational assessment is therefore to be preferred. The value of k 
in the map shown in Figure 4.1 was set to 11. The determination of that value is not discussed 
by the authors.  
Computational approaches for determination of the best k include evaluation of the average 
Silhouette (Rousseeuw, 1987), and information theoretic methods (Sugar and James, 2003). The 
selection of suitable criteria raises an important point for this work: while most observers would 
agree that the map shown in Figure 4.1 displays a degree of clustering, what exactly do we 
mean by clustering in this context, and can the ‘degree’ to which a map is clustered be 
quantified (Jain, 2010)? 
In the case of antigenic maps, the key quality exhibited by a clustered map is that of density: the 
surprising observation is that antigenic distance evolves discontinuously rather than 
continuously, so that there are regions of low density in the map. Algorithms have been 
developed to derive clusters directly from density analysis: in particular DBSCAN (Ester et al., 
1996) and its derivatives.  
The DBSCAN algorithm requires two initial parameters: Ɛ, and MinPts. Ɛ is a distance, defining 
the extent of a neighbourhood around a point. In a two-dimensional map such as ours, the 
neighbourhood is typically defined as a circle with radius Ɛ. MinPts represents the minimum 
number of points required to form a cluster. The algorithm starts by considering the 
neighbourhood around an arbitrarily selected data point. If at least MinPts data points are found 
in the neighbourhood, a cluster is started, otherwise any points in the neighbourhood are 
provisionally marked as ‘noise’. If a cluster is started, each point assigned to the cluster is then 
examined in turn, and the cluster widened to incorporate that point’s neighbourhood, provided 
that the MinPts criterion is met for the neighbourhood. The cluster widening continues as long 
as suitable data points are identified. Once all suitable points have been processed, an as-yet 
unvisited point is selected for examination. The algorithm terminates once all points have been 
visited. 
Density-based algorithms have limitations in handling high-dimensional data (Jain, 2010), and 
DBSCAN will not work well with clusters of widely varying density (an issue that addressed in 
a later algorithm, GDBSCAN (Jörg et al., 1998)). Neither of these limitations raise concerns in 
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this context. More complex variants are available which will infer a cluster hierarchy, but such a 
hierarchy is not relevant to this work. 
For this work, DBSCAN was selected for cluster determination. The advantages of this 
algorithm over k-means clustering are: 
- The density-based search algorithm fits naturally with the concept of antigenic 
clustering; 
- In contrast to k, the parameters Ɛ and MinPts do not require tuning for individual maps 
in a series; 
- It will classify outlying points as noise rather than allowing them to influence cluster 
partitioning; 
- It is simple to implement; 
- It is determinate: there is no dependence upon an initial cluster assignment. 
Use of DBSCAN requires values to be selected for Ɛ and MinPts. Empirically, I selected 
Ɛ=0.10 and MinPts=3 as suitable parameter values for the simulated antigenic maps 
generated in this study (Figure 4.2). Sensitivity to these settings is discussed later. 
Figure 4.2: Clusters derived by DBSCAN for selected values of Ɛ and MinPts. Ɛ effectively defines the minimum 
boundary between clusters. Selecting a low value of Ɛ leads to the identification of many small clusters, while a high 
value will cause cluster boundaries to become overlooked. A value in the region of 0.10 is reasonable for this data 
(top row). The selection of MinPts is less sensitive: low values may allow noise to blur the boundary between 
clusters, while high values will cause small clusters to be classed as noise. A value of approximately 5 appears 
reasonable for this data (bottom row). The scales on x and y axes show deviation (in antigenic units) from the initial 
strain.  
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4.1.3 Measurement of the ‘Degree of Clustering’ 
In order to compare maps produced with different parameter settings, we require a metric of 
cluster quality. For this purpose I employed Silhouette scores (Rousseeuw, 1987). Silhouette 
scores have performed well in evaluation by a number of researchers against other measures 
such as the Dunn index (Dunn, 1973), the Davies-Bouldin index (Davies and Bouldin, 1979), 
and the Rand index (Rand, 1971) as a reliable measure of cluster quality (Clifford et al., 2011; 
Grafahrend-Belau et al., 2008; Lovmar et al., 2005; Pearson et al., 2007) and have been used in 
a wide variety of contexts.  
The Silhouette score for a single point i is calculated from two metrics a(i) and b(i). a(i) is a 
measure of the average dissimilarity of point i to other points in the same cluster. While any 
metric of dissimilarity may be used, in this case I use the average Euclidean distance between 
point i and the other points in the cluster. b(i) is the lowest average dissimilarity of point i to 
points in another cluster: the average dissimilarity to each cluster (apart from that cluster 
including point i) is calculated and the lowest value is taken. Again, although any measure may 
be used, I use the average Euclidean distance as the measure of dissimilarity. From a(i) and b(i), 
the Silhouette score for point i, s(i), is calculated as 
      
         
    {         }
 
and the Silhouette score S for the entire map is the mean of s(i) for all points in the map that are 
cluster members (in other words, excluding points classified by the clustering algorithm as 
noise). 
From the definition, it will be seen that values of s(i) can range between -1 and 1. Values close 
to 1 indicate strong clustering, while values close to 0 indicate little clustering. Negative values 
indicate an erroneous assignment of points to clusters, and are not found in simulated antigenic 
maps when classified by DBSCAN. In the degenerate case of just a single cluster, I assign the 
map a Silhouette score of 0. Figure 4.3 shows Silhouette scores obtained for a number of 
simulated antigenic maps. 
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Figure 4.3: Simulated antigenic maps created with a range of model parameters in order to demonstrate the 
Silhouette score S as a measure of cluster quality. In these maps, and other maps in this chapter, each cluster is shown 
in a separate colour, and data points classified as noise are shown in black. 
 
 
4.1.4 Model Principles 
The model presented in this chapter is intended to be a simple simulation that incorporates just 
sufficient functionality to simulate the two phenomena of interest. The model portrays antigenic 
evolution on a two dimensional antigenic map. It starts with a single strain, which is evolved 
through a number of generations. In each generation, there is a chance of antigenic evolution. If 
antigenic evolution occurs, a new strain is created at a random distance from its parent within a 
predefined range, at a random bearing on the map (the random bearing reflects the lack of 
temporal bias in the model, discussed in the previous section).  The newly spawned strains are 
considered fitter than their parents with respect to the host population, as a result of the 
antigenic distance, and, over a number of generations, ancestor strains are retired from the 
population once newer strains exist that are separated by more than a threshold antigenic 
distance. 
To simulate the significant change in antibody binding energy occasionally provoked by a 
mutation at one of small number of locations, the model provides a chance for a mutation to 
cause an elevated antigenic distance, over and above the normal predefined range. This elevated 
distance is associated with the relatively rare substitution of one of these key residues. 
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To simulate the contribution from mutations in two independent regions, the model provides for 
two chances of antigenic evolution in each active strain per generation, with the antigenic 
parameters for the two chances being set separately. In this way, I can model the relatively 
lower mutability of the mid region compared to the RBS region and can determine the effect of 
greater or lower contributions to antigenicity from the two regions. 
4.1.5 Model Parameters 
The following parameters, for each site, can be set by the experimenter: 
     - The probability that an antigenically different strain will be created in a generation; 
          – The new strain will be created with an antigenic distance of at least     from the 
parent strain, and, unless the antigenic distance is elevated by the mutation of a key residue, a 
distance no greater than       
       - The probability that an antigenically different strain will have an elevated antigenic 
distance, caused by the mutation of a key residue; 
  - The multiplier to be applied in the case of an elevated antigenic distance; 
In each generation, each extant strain is provided with the opportunity to create antigenically 
dissimilar new strains. The antigenic distance     between the parent strain and the new strain 
is determined as follows. For each of the two sites, four random numbers,          and    are 
generated. Each of these can take a value from 0 to 1.  
If         no new strain is created.  
If        and         , a new strain is created, and 
                         
If        and         , a new strain is created, and 
                                      
To simulate the two independent sites, in each generation, I allow for the creation of two strains 
at independent antigenic distances      and      , using independently generated random 
numbers and independent parameters. The two sets of parameters are distinguished by using a 
numbered suffix, e.g.           . Representative values are discussed in Section 4.2.1. 
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In addition to the above, the model requires values for three values which apply to strains 
created at either site: 
Fitness Threshold – The antigenic distance that must separate two strains in order for the newer 
to be considered fitter. 
Parent Survival Time – The number of generations that a prior strain should survive a newer 
strain that is at a sufficient antigenic distance to be considered fitter. 
Target Strains – The number of child strains to be generated in this simulation. 
Pseudocode for the simulation is given below: 
Create a single strain at co-ordinates (0,0), mark as ‘active’ 
LOOP until we have created the required number of strains 
  FOR EACH active strain 
    FOR EACH site in the strain 
      assign random values between 0 and 1 to rG, rL, rH, rD 
      IF rG < pAD THEN 
        IF rH >= pHigh THEN 
          deltaAD = deltaMin + rL*(deltaMax-deltaMin) 
        ELSE 
          deltaAD = deltaMin + rL*(deltaMax-deltaMin) 
                      +h*deltaMax + rD – 0.5   
        END IF 
        create new active strain at a distance deltaAD and at a random bearing  
      END IF 
    END FOR 
  END FOR 
 
  FOR EACH active strain 
    IF a more recent strain exists  
      AND distance between them > fitnessThreshold THEN 
      decrement strain lifetime 
      IF strain lifetime <= 0 THEN 
        mark strain as inactive 
      END IF 
    END IF 
  END FOR 
END LOOP 
     
4.1.6 Parameter Values 
In this report I present a range of results to illustrate model sensitivity to particular parameters, 
but I regard the following values as being representative of current experimental data. In the 
simulations to follow, one parameter is generally varied while others are held at the values listed 
in this section. 
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The model is relatively insensitive to the absolute value of the mutation chance, as this only 
affects the parent survival time relative to the development of new strains.  In the previous 
chapter, I found that transitions in the RBS region were roughly correlated with the need to 
update the H3N2 vaccine strain, which occurred 16 times between 1972 and 2005. I found 
transitions in the mid region roughly correlated with antigenic cluster transitions, of which there 
were 9 in the same period, providing a ratio between the two of approximately 1:2. 
                        
Smith et al (2004) found that a single residue mutation caused on average 0.37 units of antigenic 
change.  A single mutation in a Beijing/1992-like strain was found to cause 2.5 units of change. 
The      and      settings provide a range around the average value, and   extends this to the 
level found in the exceptional single mutation. 
             
16 HA1 residues differ between A/Panama/2007/1999 and A/Wyoming/03/2003. Of these, the 
mutations at two locations were found to cause significant antigenic drift with mutations at 
other locations being relatively insignificant (Jin et al., 2005).  The value of 0.125 (1/8) reflects 
this distribution. 
Fitness Threshold=0.2, Parent Survival Time=1 
Varying Fitness Threshold and Parent Survival Time did not alter the character of the models 
unless they were set sufficiently high to swamp the results with numerous extant strains. The 
values are set to reflect the fact that, in general, there is just one dominant strain of H3N2 at any 
time. 
4.2 Implementation 
The antigenic map simulator, including DBSCAN for cluster determination and Silhouette for 
cluster quality evaluation, was implemented in PHP on the web site described in Appendix B. 
Simulations can be run interactively from the web site. Further PHP code (not accessible from 
the web site) was developed to carry out long-running simulations with varying simulation 
parameter values. 
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4.3 Model Results 
With a single active mutation region and        , cluster quality is generally low and does 
not vary with     , except at very low values, comparable to the value of the Fitness Distance 
(Figure 4.4). At such low values of     , ‘parent’ strains are less likely to be removed from 
circulation, altering the pattern of antigenic development. 
Figure 4.4: Results with a single mutable region and         show antigenic movement but little differentiation 
into clusters. The graph shows variation of S (averaged over 1000 simulations, SE < 0.01) with     . The plots show 
typical simulated maps obtained with the settings shown. These illustrations of typical maps and those in subsequent 
figures were created by selecting parameter values from the graph likely to give the required value of S. 
If        , a higher cluster quality is achieved, with the quality increasing with increased   
(Figure 4.5). Clusters obtained typically show much greater differentiation than those obtained 
with        , even at a comparable Smean. 
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Figure 4.5: With a single mutable region, the degree of clustering increases as h is increased. For values at or below 
1, there is effectively no ‘exceptionally elevated’ contribution and cluster quality remains low. Results for Smean are 
averaged over 1000 simulations, SE < 0.01. 
  
 86 
 
Figure 4.6: With two mutable regions and                 , cluster quality increases as       and       
diverge. A higher cluster quality is observed if the mutation chance    differs in the two regions (compare the 
maximum value of Smean achieved in this figure (0.7) with that achieved in Figure 4.4 (0.55): in the latter case     
was set to 0.3 in both regions. Results for Smean are averaged over 1000 simulations, SE < 0.01. 
 
When        , cluster differentiation is observed with two active mutation regions provided 
     differs from      . Cluster quality increases as the values diverge (Figure 4.6).  Cluster 
quality is higher if the mutation chance     of the two regions differ (this can be seen by 
comparing the graph in Figure 4.6 with the lower line in Figure 4.7: the probabilities differ in 
the former case and are equal in the second, while other parameters are identical). 
From Figures 4.5 - 4.7, we can see that both the introduction of a chance of a nonzero       and 
the introduction of a second active region can elicit high quality clustering that is not observed 
in the absence of both factors. The effect is cumulative: with two active regions, introducing a 
nonzero       increases cluster quality (Figure 4.7). 
Figure 4.8 shows the distribution of S values obtained from runs of 1000 simulations at typical 
settings with two active regions and        . If, with reference to Figure 4.2, we define the 
threshold of acceptable cluster quality to be S = 0.5 in order to consider maps of a similar cluster 
quality, then at Smean = 0.6, 80% of simulations yield a score at or above the threshold, while at 
Smean = 0.7, the proportion rises to 92%. It should be noted that cluster quality does not of itself 
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have biological significance. Here we are interested in the proportion of maps that have at least 
a similar quality to that seen in Figure 3.5. 
Figure 4.7: With two mutable regions, introducing a nonzero       increases cluster quality. 
Figure 4.8: Distribution of S values obtained from runs of 1000 simulations employing two active regions, using 
parameter values selected from those of Figure 4.7 to provide Smean values of 0.6 and 0.7. Results for Smean are 
averaged over 1000 simulations, SE < 0.01. 
 
In the simulations used above, a new and antigenically different strain is introduced at a random 
bearing from its ‘parent’ strain. As discussed in Section 4.1.1, an element of directional bias 
might more closely reflect antigenic evolution, in that, at least over a short to medium 
generational window, a strain is likely to be antigenically different to all its successors. I 
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examined the impact of directional bias on cluster quality by restricting the range of the bearing 
of child strains (Figure 4.9).  With two active regions, and parameter settings that achieve Smean 
= 0.65, bearing ranges of 135
o
 or higher produce a comparable Smean and comparable antigenic 
maps. Smaller bearing ranges produce antigenic maps with distinctly pronounced linearity, and 
somewhat lower values of Smean, probably as a result of the elongated, somewhat one-
directional, clusters. 
Figure 4.9: Restricting the bearing of new strains from their parents has little effect on the Smean obtained at typical 
parameter settings taken from those of Figure 4.6, until the bearing range is reduced below 135o. Below that value, 
antigenic maps take on a linear character, and the achieved Smean is reduced. Results for Smean are averaged over 
1000 simulations, SE < 0.01. 
Figure 4.10 shows the sensitivity of the achieved Smean value to variations in the DBSCAN 
parameters MinPts and Ɛ. Overall, these demonstrate a linear trend, in which a clear distinction 
is preserved between the achieved Smean for a high quality and a low quality cluster: hence the 
analysis above is not unduly sensitive to the selected values. As MinPts increases, the number of 
points classed as ‘noise’ increases, and this increases the quality of the residual clusters. This 
has a greater impact on low scoring clusters: hence at high MinPts, the scores start to converge. 
As Ɛ increases, DBSCAN will require points to be further apart in order to be sorted into 
separate clusters. For a given map, this will result in larger clusters and hence reduce overall 
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cluster quality. The impact is greater for lower quality clusters, as these will tend to be separated 
by a smaller distance.  
Figure 4.2 demonstrated that the values we selected for these parameters provide good results 
with few outliers classed as ‘noise’. From Figure 4.10, we can see that electing other reasonable 
values for these two parameters would alter the precise values obtained in the analysis but 
would not alter the overall qualitative conclusions. 
Figure 4.10: Sensitivity of Smean to variation in the DBSCAN parameters MinPts and Eps (Ɛ) from the values used 
in this analysis (bracketed in red).  Results for Smean are averaged over 1000 simulations, SE < 0.01. 
 
 
4.4 Discussion 
In this analysis, I have demonstrated the applicability to antigenic maps of DBSCAN as a 
clustering algorithm, and of Silhouette as a cluster quality score. These tools could prove useful 
in other antigenic mapping applications, and either separately or in combination could be used 
to provide a firmer foundation for the division into clusters. On the basis of density distribution, 
some cluster boundaries in the H3N2 map shown in Figure 4.1, such as that between BK79 and 
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SI87, are questionable: density mapping may identify more biologically relevant clusters than k-
means clustering. 
The simulations suggest that the influence of some mutations with exceptionally high antigenic 
effects can produce the clustered behaviour seen in H3N2 antigenic maps. The existence of such 
mutations has been demonstrated experimentally, but it is not known whether mutations of 
sufficient strength occur frequently enough to explain the observed antigenic cluster transitions 
as there are examples where the binding energy is relatively evenly distributed (Lee and Air, 
2002; Venkatramani et al., 2006). I have demonstrated that another factor, the interplay between 
antigenic activity at two independent regions, could also produce antigenic clusters, and have 
shown in simulation that it is possible for the two phenomena to work in combination. 
If clustering activity is indeed caused by one or both of the above phenomena, we might expect 
to see periods in the H3N2 antigenic evolution when such activity is at a reduced level, for 
example when antigenic activity is focussed on one site, and the antibodies involved have 
relatively evenly distributed binding energy across their epitopes. More generally, we might 
expect clustering activity to fluctuate as a function of these effects. Figure 4.1 does suggest a 
fluctuation in clustering activity – for example the clusters for WU95 and SY97 are clearly 
separated, while those for SI87 and BE89 are much less so – but such observations could easily 
be affected by sample bias.    
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5 Antigenic Escape in Influenza A HA2 
5.1 Introduction and Motivation 
In Chapter 3, I developed techniques for predicting HA antibody binding locations in wild-type 
human H3N2 strains. The analysis was confined to HA1, which is typically considered to 
include the antigenically active regions of the protein. 
The identification of several predicted antibody binding locations in the ‘mid’ region, a region 
somewhat distant from the tip, and a region in which HA1 overlaps with HA2, suggested the 
possibility of HA2 participation in B-cell epitopes. Also, although first reported some years 
previously (Okuno et al., 1993), this work coincided with the announcement of a number of 
broad-spectrum antibodies binding in the HA2 stalk (Table 5.1). As well as understanding 
whether HA2 residues could contribute to epitopes in the mid region, I therefore also wished to 
apply the techniques to an analysis of the stalk.  
Reference Subtypes Bound Epitope determined by 
Okuno et al., (1993) H1, H2 Generation of escape mutants 
Throsby et al. (2008) H1, H2, H5, H6, H8, H9 Inference, substitutions, modelling 
Sui et al., (2009) H1, H2, H5, H6, H9, H11, 
H13, H16 
Crystallography 
Ekiert et al., (2009) H1, H5 Crystallography 
Wang et al., (2010) H1, H3, H5 Ab induced via vaccination with HA2-
based protein 
Wei et al., (2010) H1, H2, H5 Competition assay with stem mutant 
Kashyap et al., (2010) H1, H5 Prediction based on results of Sui et al. 
and Ekiert et al. 
Clementi et al., (2011) H1, H2, H5, H9, some H3 Alanine mutagenesis 
Ekiert et al., (2011) H3, H7, H10, H15 Crystallography 
Corti et al., (2011) H1, H2, H3, H4, H5, H6, 
H7, H9, H10, H13 
Crystallography 
Dreyfus et al., (2012) H1, H2, H3, H4, H5, H6, 
H7, H9, H10, H12, H13, 
H14, H15, H16, type B 
Crystallography 
Table 5.1: Studies of stalk-binding antibodies discussed in this chapter. 
 
A broad-spectrum vaccine is a key objective of influenza vaccine research, and the induction of 
broadly-binding anti-stalk antibodies has been advocated as a possible approach (Wang and 
Palese, 2009). Such an approach would depend on the stalk being unable (or slow) to achieve 
antigenic escape. To date, stalk-binding antibodies isolated for structural study have been 
specifically selected for their reactivity against a broad range of strains. The stalk has a low rate 
of evolution compared to other regions of HA, in particular the region close to the RBS. 
Nevertheless, as we shall see later in this chapter, fixations and periods of polymorphism do 
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occur in the stalk, and escape mutants to neutralising stalk binding antibodies have been 
cultured in vitro. Studies of recently isolated stalk-binding antibodies are necessarily 
retrospective. The extent to which broad-binding properties may be preserved across future 
strains, and, in particular, whether evolutionary pressure might elicit escape following antibody 
emergence, is the subject of this chapter. 
5.2 Availability of HA2 Sequences 
The sequence database contains full length sequences for approximately 1,300 H1N1 strains and 
3,000 H3N2 strains isolated between 1968 and 2008 (Figure 5.1).  
Figure 5.1: Number of unique strains isolated between 1968 and 2008 for which full-length sequences exist in the 
database. 
The H3N2 record provides a more consistent set of samples over a longer period – not only 
because H1N1 was not in circulation until 1977, but also because a higher number of sequences 
are available in most years between 1977 and 2000: 823 unique full-length sequences for H3N2 
strains are available in that period, compared to 262 H1N1 sequences.   
To examine the contribution of HA2 residues to clusters identified in Chapter 3, we require full 
length HA sequences (i.e., including HA2 in its entirety) for the dominant strains used in that 
analysis as listed in Figures 3.2-3.4. As some strains were missing from the database, I reviewed 
publicly available sources including GenBank (http://www.ncbi.nlm.nih.gov/GenBank), Uniprot 
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(http://www.uniprot.org/), NCBI’s Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html), the Influenza Research Database 
(http://www.fludb.org) and the GISAID database (http://www.gisaid.org) in order to obtain as 
many as possible. Although sequencing efforts are reducing the number of gaps, some required 
full length HA sequences are not available. I therefore constructed ‘hybrid’ sequences for these 
strains by combining the consensus HA1 sequence of the strain with the consensus HA2 
sequence taken from the full sequence strain differing from the target strain in the lowest 
number of HA1 residue positions (Table 5.2).  
Required Strain Selected HA2 hybrid strain Differing 
HA1 
locations 
A/Texas/1/1977 (H3N2) A/Memphis/1/1977 (H3N2) 3 
A/Mississippi/1/1985 (H3N2) A/Hong Kong/14/1983 (H3N2) 3 
A/Sichuan/2/1987 (H3N2) A/Hong Kong/7/1987 (H3N2) 2 
A/Beijing/352/1989 (H3N2) A/Beijing/353/1989 (H3N2) 1 
A/Wuhan/359/1995 (H3N2) A/New York/631/1996 (H3N2) 2 
A/Hong Kong/1550/2002 
(H3N2) 
A/Hong Kong/CUHK23162/2002 
(H3N2) 
2 
A/Fujian/411/2002 (H3N2) A/Hong Kong/CUHK5316/2003 (H3N2) 0 
A/Bayern/7/1995 (H1N1) A/New York/643/1995 (H1N1) 1 
Table 5.2: Dominant strains required for cluster analysis for which no full-length sequence could be obtained, and the 
full-length strain selected from the database for hybridisation. The third column shows the number of locations in 
HA1 at which the hybrid strain’s residue differs from that of the required dominant strain. 
To provide an indication of likely accuracy of these hybrid sequences, I analysed all full-length 
sequences whose HA1 sequence differed from one of the strains in this survey with a known 
HA2 in three or less locations (three being the highest difference amongst the hybrid 
candidates). The analysis suggests that, on average, the ‘hybrid’ HA2 may be expected to differ 
from the desired HA2 in one position or less, and that a difference in two positions is unlikely 
(Table 5.3). 
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Target Strain Number of 
full length 
strains with 
HA1 varying 
in 3 locations 
or less 
Number of 
such strains 
with an HA2 
sequence 
differing 
from the 
target 
Total 
number 
of 
residues 
at 
variance 
Maximum 
residues at 
variance in 
any one 
strain 
Average 
residues at 
variance 
per strain 
A/Hong Kong/1/1968 24 8 8 1 0.33 
A/Port Chalmers/1/1973 5 0 0 0 0.00 
A/England/42/1972 5 0 0 0 0.00 
A/Victoria/3/1975 0 - - - - 
A/Bangkok/1/1979 5 0 0 0 0.00 
A/Philippines/2/1982 1 1 1 1 1.00 
A/Leningrad/360/1986 3 3 3 1 1.00 
A/Beijing/353/1989 9 3 3 1 0.33 
A/Beijing/32/1992 0 - - - - 
A/Johannesburg/33/1994 16 0 0 0 0.00 
A/Sydney/5/1997 1 0 0 0 0.00 
A/Moscow/10/1999  25 8 12 2 0.48 
A/Wellington/1/2004 291 228 254 3 0.87 
A/California/7/2004 131 14 14 1 0.11 
A/Wisconsin/67/2005 2 0 0 0 0.00 
A/Perth/16/2009 205 28 29 2 0.14 
(TOTAL) 723 293 324 3 0.30 
Table 5.3: Analysis of sequences with an HA1 which is close to that of required H3N2 strains, showing the variation 
of that HA2 of those strains compared to the known HA2 of the required strain. Across all 723 strains in this sample, 
only 1 differed from the target HA2 sequence in more than two locations. 
 
5.3 HA2 Participation in Mid Region Clusters 
H1N1 
The clusters inferred in two of the transitions shown in Figure 3.2 are changed as a result of the 
inclusion of HA2 substitutions. In the transition A/Brazil/11/1978-A/Chile/1/1983, a 
substitution at HA2 57 is added to the mid region cluster (Figure 5.2A).  In the transition 
A/Chile/1/1983-/Singapore/6/1986, HA2 residues 57 and 77 are added, as a result of which the 
mid cluster moves lower and the fixation at HA1 58 is dropped (Figure 5.2B). 
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Figure 5.2: Clusters in the H1N1 series which are altered as a result of considering HA2 substitutions. A - 
A/Brazil/11/1978-A/Chile/1/1983. B - A/Chile/1/1983-/Singapore/6/1986. As in Figures 3.2-3.4, each cartoon 
indicates positions on a single HA monomer at which substitutions occur between two dominant strains. Those 
substitutions that become fixed in the population are shown in blue; others in red. The RBS is coloured yellow. Other 
HA1 residues are white, and other HA2 residues grey. The number of substitutions in each cluster is shown as a 
single number. The location code of substitutions of interest is given as a number followed by the subscript 1 or 2 to 
indicate HA1 or HA2 respectively.  
H3N2 
Clusters deduced for three transitions in the H3N2 series outlined in Figures 3.3 and 3.4 are 
affected by consideration of HA2 substitutions. In the transition A/Beijing/32/1992-
A/Johannesburg/33/1994 (Figure 3.3), a new mid region cluster is formed, incorporating HA2 
56 and two HA1 substitutions (Figure 5.3A). 
In A/Johannesburg/33/1994-A/Wuhan/359/1995 (Figure 3.3), HA2 46 and 56 are included in 
the mid region cluster, which moves closer to the membrane as a result, and a new cluster of 
three residues is inferred on the HA head, away from the RBS (Figure 5.3B). HA1 124 is within 
35Å of either cluster on the head, but is assigned to the cluster closest to the RBS as the 
algorithm seeks the largest possible clusters. 
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In A/Bangkok/1/1979-A/Sichuan/2/1987 (Figure 3.4), a new mid cluster is formed from HA2 
55 and 66, and HA1 307. All three residues are buried in the trimeric structure, making it 
unlikely that this inferred cluster is indicative of antigenic escape (Figure 5.3C). 
Figure 5.3: Clusters in the H3N2 series which are altered as a result of considering HA2 substitutions. A - 
A/Beijing/32/1992-A/Johannesburg/33/1994. B - A/Johannesburg/33/1994->A/Wuhan/359/1995. C - 
A/Bangkok/1/1979-A/Sichuan/2/1987 (showing the side of the monomer facing in to the trimer). Colouring and 
legend as in Figure 5.2.  
Conclusion 
Excluding the additional mid region cluster inferred in the transition A/Bangkok/1/1979-
A/Sichuan/2/1987, in which all the residues are buried, and which therefore does not seem 
indicative of antigenic escape, HA2 substitutions play a part in just two H1N1 and two H3N2 
transitions. Only one includes a fixation in an HA2 residue. Participation of HA2 residues in 
mid region clusters may occur, but it is at most limited, and consideration of HA2 residues does 
not significantly change the number or size of inferred clusters in the analysis of Chapter 3. 
5.4 The Action and Activity of Stalk Binding Antibodies 
From analysis of the binding activity of panel of seven monoclonal antibodies to proteolytic 
fragments of HA2, Varecková et al. (2003) identified four linear peptide regions on HA2 to 
which antibodies bound. Antibodies binding to three of these regions provide protection against 
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lethal challenge in mice, but only antibodies binding close to the N-terminus of HA2, which is 
known to be associated with the pH-induced structural transformation that occurs during the 
process of membrane fusion (Skehel and Wiley, 2000), are virus neutralising (Varecková et al., 
2003; Staneková et al., 2012). 
Among the neutralising anti-HA2 antibodies, very broad-spectrum examples are rare (Corti et 
al., 2011), but studies suggest that less broad-spectrum types are widely present in the adult 
human population (Sui et al., 2011; Staneková et al., 2012). Hu et al. (2013) reported the 
isolation of stalk-binding neutralising antibodies from a 2009 pandemic H1N1 vaccine 
recipient. Wrammert et al. (2011) found that, in 9 individuals infected with the H1N1 pandemic 
strain, a majority of neutralising antibodies were stalk-binding and broadly cross-reactive. They 
contrast this with the vaccination response to annual strains, in which the proportion of such 
antibodies is much lower. Staneková et al. (2012) report a negligible increase in anti-HA2 
antibody levels after conventional vaccination, compared to an approximately twofold increase 
following a natural infection with a seasonal H3N2 strain: hence a comparison of antibody 
levels in natural infection on one hand and in vaccination on the other may be misleading.  
Although researchers have hypothesised that stalk-binding antibodies are induced by the 
appearance of novel strains (Palese and Wang, 2011; Chiu et al., 2013), results to date do not 
provide a conclusive picture of their prevalence in seasonal infections.  
Results from several studies suggest that antibodies binding in the stalk may be more frequent in 
those subjects that have been subjected to repeated infections. Children have a restricted 
antibody response to HA compared to adults, with the response typically focusing in the area of 
the RBS (Natali, Oxford, and Schild, 1981; Nakajima, Nobusawa, and Nakajima, 2000). 
Repeated exposure of mice to different influenza strains can induce a broader response 
including the elicitation of stalk-binding antibodies (Vanlandschoot et al., 1998; Wang et al., 
2010; Krammer et al., 2012). The global influenza surveillance program, which focuses in large 
part on the immune response of serologically naïve animals, may therefore underestimate the 
role of such antibodies in conferring protection to the adult human population. Until recently, 
the programme has also relied almost exclusively upon the HI assay, which is not sensitive to 
the neutralisation mechanism of stalk-binding antibodies. 
Stalk-binding antibodies specific to group 1 influenza subtypes isolated to date, as well as the 
group 1/group 2/Influenza B antibody CR9114, have a common germline descent from the 
variable heavy chain gene IGHV1-69 (Throsby et al., 2008; Sui et al., 2009; Dreyfus et al., 
2012), possibly as a result of the unusual ability of antibodies descended from this germline to 
bind to conserved hydrophobic pockets (Sui et al., 2009). 
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Concerns have been raised that the stalk region of HA on the intact virion may not be readily 
accessible to antibodies: however a recent study using cryoelectron microscopy to examine 
H1N1pdm virions incubated with C179 IgG antibody found that 75% of the HA trimers were 
complexed with at least one antibody particle, with a random distribution of bound and unbound 
trimers on the viral surface (Harris et al., 2013).  A modelling study based on measurement of 
single HA fusion events suggests that six HA trimers must undergo the fusogenic transition in 
order to achieve membrane fusion (Blumenthal et al., 1996). On that basis, the antibody density 
found by Harris et al. would be sufficient to inhibit membrane fusion. 
5.5 The Limits of Broad-Spectrum Stalk Binding Antibodies 
The ability or otherwise of the broad spectrum antibodies cited in Table 5.1, which are known to 
be rare, to neutralise any strain in the group(s) to which they are specific is of interest. If they 
are indeed completely effective against a subtype, we would not expect them to elicit mutations 
in that subtype, since no escape from their action would be possible. If, on the other hand, 
escape or partial escape by certain strains is possible despite the structural constraints exerted by 
the fusogenic function, then there is the possibility of antigenic evolution, and the possibility 
that an antigenic region will develop in the locality of their epitopes. In this section I examine 
the arguments and analysis presented by researchers of such antibodies (Table 5.4), in particular 
of those antibodies that feature in crystal studies, as those studies provide the most specific 
information relating to epitopes and therefore allow for in-depth analysis.  
In the studies considered in this section, the case for broad-spectrum binding is generally 
developed along the following lines: 
- Assays are used to demonstrate neutralising action or binding strength of the antibody 
to various strains (typically one strain of each subtype in the relevant groups); 
- The epitope (i.e., the precise atomic contacts) is determined from crystal studies of the 
affected subtypes; 
- The conservation of each epitopic residue is analysed; 
- Follow-up assays are conducted of wild-type amino acid variants revealed by the 
conservation analysis that were not covered by the first set of assays; 
- Escape mutants are cultured, both to identify critical residues and also to assess the 
likelihood of escape in the wild. 
We will address each topic in turn, looking both at the evidence presented in published studies 
and also at its limitations. 
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Antibody PDB 
Structure(s) 
Reference 
C179 None Okuno et al., (1993) 
CR6261 3GBN (H1) 
3GBM (H5) 
Throsby et al. (2008), 
Ekiert et al., (2009) 
D8 
F10 
A66 
3FKU  
(F10, H5) 
Sui et al., (2009) 
7A7 
12D1 
39A4 
None Wang et al., (2010) 
PN-SIA28 None Clementi et al., (2011) 
CR8020 3SDY (H3) Ekiert et al., (2011) 
FI6 3ZTN (H1) 
3ZTJ (H3) 
Corti et al., (2011) 
CR9114 4FQI (H5) 
4FQY (H3) 
4FQV (H7) 
Dreyfus et al., (2012) 
Table 5.4: Broad-spectrum antibodies whose descriptions are considered in this section. 
 
 Assays Employed In Binding Studies 
As the neutralising action of the antibodies in question is related to fusogenic activity rather 
than the inhibition of cell attachment, the HI assay cannot be used to quantify their efficiency. 
Neutralisation assays, accompanied by assays of antibody binding strength, are typically 
employed. Neutralisation assays determine the titre at which an antibody will reduce viral 
plaque formation to a given percentage of that achieved by a control. When conducted with 
human or animal serum, they are generally regarded as representative of viral activity in vivo, as 
evidenced by their presence in recent WHO surveillance reports. The concentrations at which 
stem-binding antibodies might be naturally present in human serum are not well understood, 
although Sui et al. (2011) estimate that they are present in concentrations of up to 0.1μg/ml. The 
best (lowest) IC50 neutralising concentrations obtained from assays of stem binding antibodies 
are between 0.1 and 1.0 μg/ml: however many subtypes to which broad-spectrum antibodies 
bind only neutralise at much higher concentrations (Table 5.5). This suggests that the 
neutralising action of broad-spectrum stalk-binding antibodies against some cited strains and 
subtypes is weak at physiological levels. In addition, one study utilised artificial cell constructs, 
which may not accurately mimic natural conditions, such as the dense packing of 
haemagglutinin on the viral membrane and could therefore exaggerate neutralising activity 
(Wang et al., 2011).  
Neutralisation assays were conducted with whole antibody IgG with the exception of antibody 
F10, for which Fab fragments were used. Lee at al. (2012) found that the bivalent binding of 
IgG to an RBS epitope, in which the immunoglobulin is thought to span two HA trimers, can 
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increase apparent affinity compared to a monovalent Fab fragment by roughly three orders of 
magnitude and reduce neutralization IC50 concentrations by roughly two orders of magnitude. 
The same effect may apply to stalk binding IgG. On the other hand, the more demanding 
packing requirements close to the viral membrane, which were noted in the previous section as 
resulting in only partial occupancy of stalk epitopes, may reduce or eliminate the effect: Ekiert 
et al. (2009) note that Fab fragments of antibody CR6261 neutralise as potently as intact IgG.  
Antibody IC50 <  10 μg/ml IC50 > 10 μg/ml 
CR6261 H1, H5, H6, H8, H9  H2  
CR8020 H3 H7 
7A7 H3  
12D1 H3  
39A4 H3  
A06* H1pdm H1, H5 
PN-SIA28 H1, H2, H5, H9 H3, H3 
FI6  H1, H3 
CR9114 H1, H2, H4, H8, H9, H12 H3, H5, H6, H7, H10, 
H11, H14 
F10
+
 H5  
Table 5.5: IC50 neutralisation concentrations for each subtype neutralised by a stalk-bonding antibody, for those 
antibodies and subtypes for which figures are available. Where more than one strain of a subtype was tested, the 
highest IC50 concentration is used. The physiological concentration is estimated to be approximately  0.1 μg/ml, 
hence for those subtypes in the second column in particular, the naturally occurring antibody may not be fully 
neutralising  in vivo. Figures are taken from the references cited in Table 5.4. Figures for CR6261 are from Throsby 
et al. *Figures for A06 are minimal inhibitory concentrations. +Antibodies tested are whole antibody IgG apart from 
F10 which is represented as a Fab fragment. 
Determination of the Epitope 
The specific residues involved in interactions between HA and antibody are inferred from 
crystal structures by using software to predict hydrogen-bonds and van der Waals interactions. 
The results obtained are subject to error in the crystal determination, variation in the crystal 
structure compared to the shape under physiological conditions, and also depend upon the 
software and parameters employed for the calculation (which are rarely stated). My own 
analyses (presented in Chapter 3) are in general agreement with experimental reports, but in 
most cases I identify some participating residues that are not identified in the study, and vice 
versa. In all the studies reviewed, researchers identified, from a single analysis, a single set of 
epitopic residues. A more comprehensive examination, utilising multiple software packages or 
multiple sets of parameters, would yield a larger set of residues, more accurately reflecting the 
set whose variation could impact antibody binding. 
Analysis of the Conservation of Each Epitopic Residue 
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The purpose of the conservation analysis employed in these studies is to determine the 
likelihood of antigenic escape by assessing the degree to which each residue in the epitope has 
varied in the past, as evidenced from available amino acid sequences. As we saw in the above 
section, one problem with this approach is that the epitope is defined narrowly, so that some 
atomic interactions are likely to be missed. A further problem is that escape can be influenced 
by residues that are not part of the epitope per se. For example, an escape mutant raised against 
antibody CR6261 in an H5 strain exhibited the single substitution H111L in HA2. Residue 111 
is buried in the pre-fusion state and is unlikely to be identified as an epitopic residue in any 
analysis, but the substitution is believed to cause a reorientation of the antibody binding pocket 
(Throsby et al., 2008). For these reasons, the studies may overlook important variation in other 
nearby residues. 
Attention is often focussed on the ‘highly conserved’ A chain of HA2. Ekiert et al. (2009) assert 
high conservation of 11 residues on the chain (41, 42, 45, 46, 48, 49, 52, 53, 55, 56, 57). In 8 
residues, the conservation quoted is > 99%, based on an analysis of available sequences across 
all subtypes. This analysis, and a similar analysis of residues 30-36 (Ekiert et al., 2011), is based 
on groupings of similar amino acids, with transitions within a group being classed as conserved. 
The groups used are: 1) Asp/Asn/Glu/Gln; 2) Phe/Tyr; 3) Ile/Leu/Val/Met; 4) Lys/Arg; 5) 
Ser/Thr (Ekiert et al., 2011).  
The antibody/protein interface is subtle, and the precise nature of the atomic interactions 
involved can impact the conservation of substitutions. In particular, both hydrophobic and polar 
interactions can play a part (Xia et al., 2012). A simplistic division into groups is questionable. 
The definition of the first group above (group 1) has specific difficulties in the light of 
substitution studies and known escape substitutions. Ekiert et al., in the same studies, report 
Asp19Asn in H3 and H7 strains leading to a 30-fold increase in CR9114 Kd, and Glu15Gln 
leading to a tenfold reduction in affinity. The following ‘group-conserved’ escape mutants in 
influenza glycoproteins are reported by other researchers: Ile244Met (Yewdell, Caton, and 
Gerhard, 1986); Asp190Asn (Tsibane et al., 2012); Asp127Glu (Schmeisser et al., 2012). In 
addition, Wang et al. (2011) report Ile89Leu as an escape mutant, but it is not clear whether this 
residue is part of the epitope, or induces a conformational change elsewhere that induces escape. 
Returning to the ‘highly conserved’ A chain of Ekiert et al. (2009), if we remove group 1  
(Asp/Asn/Glu/Gln) given the 5 counter-examples cited above, 4 of the 11 residues become 
variable rather than conserved. HA2 46, for example, which is reported as 99.6% conserved in 
the study, has undergone two frequency switches in H3 strains: D46N in 1995/96 and a 
reversion N46D in 2005/07. 
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Follow-up assays of wild-type amino acid variants revealed by the conservation analysis 
The preceding points will serve to highlight key potential deficiencies in such follow-up assays: 
namely that they are unlikely to address all amino acid locations that could be involved in 
interactions, and that questionable assumptions of conservative similarity may lead to some 
substitutions being overlooked. Dreyfus et al. (2012) provide a particularly thorough analysis, 
covering nearly all substitutions observed in the wild in all identified epitopic residues of 
antibody CR9114. Interestingly, some substitutions outside the deduced epitope are considered, 
some of which (such as Q34T and Q34R) are seen to have a significant impact on Kd – findings 
that would appear to cast doubt on the completeness of epitope discovery. However, even this 
extensive analysis, covering 58 isolates, features only a small subset of the combinatorial 
possibilities. Such analyses can provide valuable insight, but they cannot provide a 
comprehensive understanding of the likelihood of escape. 
 
Culture of escape mutants 
Researchers have attempted to breed escape mutants in seven of the studies considered, and 
such mutants have been successfully bred in four (Table 5.6). It is interesting to note that Okuno 
et al. attempted to breed mutants from 10 base strains, and were only successful with 2. 
Antibody Escape Mutant bred 
successfully? 
Base Strain(s) 
C179 Yes A/Suita/1/89 (H1), 
A/Izumi/5/65 (H2) 
(8 other strains were tried 
unsuccessfully) 
CR6261 Yes RG-A/Indonesia/5/05 (H5) 
12D1 
39A4 
No A/Hong Kong/1/1968 (H3) 
A06 No Not stated 
D8 
F10 
A66 
No A/Vietnam/1203/04 (H5) 
PN-SIA28 Yes. A/PR/8/34 (H1) 
CR8020 Yes. A/Hong Kong/1/1968 (H3) 
FI6 n.d.  
CR9114 n.d.  
Table 5.6: Escape Mutants against broad-spectrum antibodies, from the studies considered in this section. n.d.= not 
done. 
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It is therefore possible that escape mutants to antibodies with negative results in the studies 
could be bred from a different base strain to those employed. 
Conclusion 
While the affinity spectrum of broad-binding antibodies to the HA stalk is impressive, the 
experimental and analytical evidence reviewed in this section demonstrates that their action is 
not universal. Furthermore, when considering strains beyond those directly assayed, researchers 
have made simplifying assumptions relating to epitope coverage and amino acid similarity 
which are likely to over-state the binding breadth of the antibodies in question and to under-
state the extent to which evolutionary variation in the stalk is possible. Even where 
neutralisation can be demonstrated in vitro, in over half the subtypes considered the 
concentration present in vivo is sufficiently low, on the basis of current understanding, as to cast 
doubts on the neutralising ability of the antibody. Returning to the question at the start of this 
section, it is clear from this analysis that there is scope even for the broad binding antibodies to 
present evolutionary pressure that the virus could reasonably be expected to overcome by 
evolution. Indeed, this is evidenced by the culture in vitro of escape mutants against such 
antibodies in four out of seven studies in which it was attempted.  
5.6 Characterisation of the H3 Stalk Antigenic Regions 
I will focus now on H3 because of the much larger number of HA2 sequences available 
compared to other subtypes. I first develop a list of residue locations comprising the antigenic 
sites in the stalk, following a similar process to that previously used to develop lists for sites A 
to E (Bush et al., 1999). That analysis built on earlier descriptions derived from substitutions in 
escape mutants (Wiley, Wilson, and Skehel, 1981; Wiley and Skehel, 1987; Wilson and Cox, 
1990). Bush et al. used a set of 357 HA1 sequences to identify residues undergoing variation in 
the period 1968 to 1999. Where such residues were located directly in the area of an antigenic 
site and were not buried, they assigned them to the antigenic site, thus providing a broader and 
more comprehensive understanding of the delineation of the sites than could be obtained from 
escape substitutions alone. From a nucleotide-level analysis of the 357 sequences, 18 amino 
acid locations were found to have been under positive selective pressure during the period. All 
18 are located within the identified antigenic sites, providing some confidence in the approach 
used to assign residues to sites. It is important to note that in the characterisation by Bush et al. 
only residues seen to vary between the strains under study were considered (this was clearly 
sufficient for the retrospective study in which the results were employed). Subsequent to the 
study period, variations occurred at many other locations that would otherwise have met the 
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criteria for assignment (Lees, Moss, and Shepherd, 2010). In characterising the stalk antigenic 
regions, I will consider both varying and to-date invariant locations. 
The characterisation of sites in H3 HA2 is made easier by the availability of the three crystal 
structures of stalk-binding broadly neutralising antibodies bound to H3 HA2 (PDB codes 3SDY, 
3ZTJ, 4FQY). These allow us to infer a more complete list of participating residues than would 
be available from the study of escape mutants alone, but the caveats noted in the previous 
section relating to epitope identification  apply here also.  To obtain a comprehensive view of 
the epitopes in these three structures, I took both the epitopic residues inferred by PDBsum from 
the three PDB structures (Table 3.1) and 13 additional residues listed by authors of the three 
studies, to create the combined view shown in Figure 5.4A. From this view, and from Figure 
5.4B, it can be seen that antibodies FI6 and CR9114 (PDB codes 3ZTJ and 4FQY) bind in a 
similar location, while CR8020 (PDB reference 3SDY) binds in a separate location, closer to 
the viral membrane, with just four residues being shared across all three epitopes. I therefore 
mapped the locations listed in the figure into two antigenic sites: site F, embodying the epitope 
of FI6 and CR9114, and site G, embodying the epitope of CR8020 (Figure 5.4C). The 
overlapping locations were assigned to the closest of the two sites. Four residues were classified 
as ‘outliers’ and not assigned to either site F or site G. Two of these, HA1 277 and 278, lie in 
site C, while the other two, HA2 7 and 11, lie in an adjacent monomer (see Figure 3.1A). 
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Figure 5.4: Epitopes deduced from three crystal structures of antibodies binding to the H3 stalk (PDB codes 3SDY, 
3ZTJ and 4FQY). (A) Summary: Locations coloured black are inferred by PDBsum. Locations coloured grey are 
additional locations described by authors of the crystal studies. Residue locations highlighted yellow are those 
exhibiting variation amongst the H3 sequences in the database. The locations are assigned to stalk antigenic sites F 
and G on the basis of their location.  (B) Epitopes of the three crystal structures shown on a single HA monomer: 
combined epitope of 3ZTJ and 4FQY in dark blue, epitope of 3SDY in dark red, common residues in pink. Canonical 
sites A-E are also shown: A-pale red, B-pale blue, C-green, D-yellow, E-orange. Other residues of HA1 are in pale 
grey, HA2 in dark grey. (C) Site F (blue) and site G (red), as described in the text and as assigned in 5.4A. Other 
colours as (B). 
The majority of contacts in site F are in Helix A of HA2 (Figure 5.5A). HA1 and HA2 loops 
provide additional contacts. Antibody binding to Helix A (across all subtypes) is often, although 
not exclusively, associated with descent from the VH1-69 germline (see Section 5.4). CR9114 is 
a descendent of this germline, while FI6 is not.  
Site G is composed primarily of contacts in the outermost strand of a beta sheet at the base of 
HA2; contacts in a nearby short alpha helix (Figure 5.5B), and contacts in the fusion peptide 
(HA2 15-19). While the precise neutralising action of stalk-binding antibodies is not well 
understood, and more than one mechanism may contribute (Corti et al., 2011), binding to this 
latter set of contacts is likely to be important. Note that contacts to HA2 18 and 19 are common 
to all three antibodies. 
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Figure 5.5: Detailed structure of site F (A, blue) and site G (B, red). HA1 in light grey, HA2 in dark grey. 
5.7 Detection of Evolutionary Change in the Stalk   
Recent statistical methods have extended standard approaches based on the ratio of synonymous 
to non-synonymous mutations (Bush et al., 1999) to take into account directional evolution 
towards "target" residues (Kosakovsky Pond et al., 2006) and the spatial clustering of mutations 
(Tusche, Steinbrück, and McHardy, 2012). However, all these approaches lack discriminatory 
power in regions such as the stalk where mutation rates are low: in Appendix A, I describe an 
application of the methods of Kosakovsky Pond et al. to the H3 stalk, and examine its power in 
further detail. 
For this study I develop an approach for assessing the true degree of mutability in the stalk 
region, and draw conclusions relevant to broad spectrum antibody and vaccine development. In 
Chapter 3, I presented a method for predicting B-cell epitopes on the surface of HA1 that 
involved the identification of clusters consistent with the known dimensions of known B-cell 
epitopes; many clusters in regions of HA that mutate rapidly (notably the canonical antigenic 
sites) were detected between successive dominant seasonal strains, whereas clusters in other 
regions were rarely detected and only when mutations accumulated in dominant strains 
separated by much longer periods of time. Here I build on this approach in ways that are 
specifically designed to maximize the chances of detecting antigenic pressure in the H3 stalk 
region, where the overall mutation rate is generally low. Whereas the previous study considered 
simply the substitutions and fixations occurring between the dominant strains of the population, 
here I consider additional categories of mutation event occurring within the population, looking 
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for fixations and other variations that are co-ordinated both in distance and time, and compare 
the frequency of such events within the identified antigenic sites F and G, and outside them. 
Viewed in isolation, mutations that never become universal in the global population provide 
relatively weak evidence of evolutionary pressure. However, multiple mutation events (both 
fixations and polymorphic events), occurring within close spatial and temporal proximity, 
provide strong evidence of selective pressure rather than hitchhiking. On the grounds that HA1 
fixations are observed within the antigenic sites at a much greater frequency than outside them, 
hitchhiking is thought to be rare in HA1 (Shih et al., 2007). I make a similar argument here: 
given the low rate of fixation in the stalk, it is unlikely that fixations occurring closely together 
in space and time are caused by hitchhikers, which would be expected to be much more evenly 
distributed across the protein. In the following section, we will consider the non-uniform 
distribution of fixations in the stalk, which provides further substance to this argument. 
The question remains as to whether co-ordinated events in the stalk can be attributed to 
antigenic pressure as opposed to adaptive mutations. Within the fusogenic region, adaptive 
mutations are known to change the pH of activation (Daniels et al., 1985; Thoennes et al., 2008; 
Reed et al., 2009; Reed et al., 2010), and such changes have been associated with the adaption 
of H5N1 strains to transmission in mammals, and the associated structurally substantial changes 
to receptor binding (Imai et al., 2012; Herfst et al., 2012). Adaptive changes to other aspects of 
membrane kinetics may also occur. It is therefore not possible to state with certainty whether a 
particular mutation is related to antigenic escape. In this analysis I present evidence of 
temporally co-ordinated mutations at multiple locations within epitope-sized patches in a region 
that is known to bind antibodies, which provides a strong overall case for antigenic pressure 
being one of the factors at work. Supporting evidence comes from Wang et al. (2011), who 
identify a mutation in this region in wild-type H1N1 strains leading to a reduction in the 
effectiveness of cross-neutralising antisera.  
Daniels et al. (1985) bred viral mutants of the H3N2 X-31 strain in conditions of raised 
endosomal pH. Across the mutants sampled, they identified mutations at the following 13 
locations: HA1 17, 102, 207 and HA2 6, 9, 47, 54, 57, 81, 105, 112, 114, 163. Of these, all but 
three are invariant in H3 samples, the three showing variation being HA1 207 and HA2 57, 114. 
If compensatory changes to regulate activation pH were a major factor in H3, we would expect 
to see more of the locations identified in the X-31 experiments mutating in wild-type samples. 
Of the 13 residues identified in the experiments, only HA2 57 lies within the stalk-based 
antigenic sites (in site F).   
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5.8 Fixations and Polymorphism in the HA Stalk 
Both unvaried and mutable locations are found in all regions of HA. One common pattern of 
mutability is an abrupt fixation, in which the consensus residue at a location changes rapidly at a 
particular point in time (Figure 5.6A). This pattern, which above the stalk is almost exclusively 
found in the antigenic sites, has previously been associated with positive selective pressure, as 
discussed above and in Shih et al. (2007). Another pattern is that of transient polymorphism 
(Figure 5.6B). The punctuated nature of these events is again suggestive of selective pressure, 
although in this case, as the mutation does not become fixed in the population, it is likely that a 
separate mutation, providing greater fitness, emerges to take its place, or that the evolutionary 
pressure is either transitory or balanced out by other factors. In this analysis, in order to 
differentiate strong and weaker signals, the dominant amino acid must be present in less than 
80% of samples in a year for a period to be classified as one of transient polymorphism, other 
periods of polymorphism that do not meet this threshold are classified as ‘intermediate’ (Figure 
5.6C). Finally, any location at which the dominant amino acid is identical in all years and 
present in at least 95% of samples is classified as ‘invariant’. 
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Figure 5.6: Patterns of mutability in selected HA locations: (A) – fixation, (B) – transient polymorphism, (C) – 
intermediate variation. 
I classified each location in H3 HA based on observed activity across all years. Locations in 
which one or more fixations occurred over the period 1968-2009 were classed as ‘Switchers’, 
while locations exhibiting transient polymorphism but no fixations were classed as 
‘Polymorphic’. Likewise further sites were classified as ‘Intermediate’ or ‘Invariant’ (Table 
5.7). 
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Classification HA1 Residues HA2 Residues 
Switcher 2, 3, 25, 31, 50, 53, 57, 62, 63, 75, 78, 
82, 83, 94, 122, 124, 126, 131, 133, 135, 
137, 140, 142, 143, 144, 145, 146, 155, 
156, 157, 158, 159, 163, 172, 186, 188, 
189, 190, 192, 193, 196, 197, 202, 207, 
213, 217, 222, 225, 227, 242, 244, 260, 
262, 275, 276, 278, 299 
2, 32, 46, 55, 57, 121, 150 
Polymorphic 5, 8, 9, 10, 16, 33, 34, 47, 54, 67, 81, 88, 
92, 95, 96, 98, 106, 112, 121, 138, 160, 
164, 167, 173, 174, 182, 185, 199, 201, 
209, 216, 219, 226, 230, 247, 248, 257, 
271, 273, 280, 294, 304, 307, 323 
18, 56, 58, 66, 97, 102, 110, 
123, 124, 126, 150, 158 
Intermediate 4, 6, 7, 13, 19, 23, 27, 44, 45, 48, 49, 55, 
79, 80, 103, 105, 118, 120, 128, 129, 
132, 141, 162, 169, 171, 175, 176, 179, 
187, 194, 198, 208, 212, 214, 218, 220, 
223, 229, 232, 233, 236, 240, 245, 246, 
252, 261, 264, 265, 267, 268, 269, 279, 
282, 291, 292, 297, 298, 303, 308, 309, 
310, 312, 322, 325, 326, 327 
4, 11, 27, 43, 44, 45, 49, 51, 59, 
71, 79, 82, 84, 98, 100, 103, 
106, 113, 114, 120, 139, 143, 
155, 156, 171 
Invariant 1, 11, 12, 14, 15, 17, 18, 20, 21, 22, 24, 
26, 28, 29, 30, 32, 35, 36, 37, 38, 39, 40, 
41, 42, 43, 46, 51, 52, 56, 58, 59, 60, 61, 
64, 65, 66, 68, 69, 70, 71, 72, 73, 74, 76, 
77, 84, 85, 86, 87, 89, 90, 91, 93, 97, 99, 
100, 101, 102, 104, 107, 108, 109, 110, 
111, 113, 114, 115, 116, 117, 119, 123, 
125, 127, 130, 134, 136, 139, 147, 148, 
149, 150, 151, 152, 153, 154, 161, 165, 
166, 168, 170, 177, 178, 180, 181, 183, 
184, 191, 195, 200, 203, 204, 205, 206, 
210, 211, 215, 221, 224, 228, 231, 234, 
235, 237, 238, 239, 241, 243, 249, 250, 
251, 253, 254, 255, 256, 258, 259, 263, 
266, 270, 272, 274, 277, 281, 283, 284, 
285, 286, 287, 288, 289, 290, 293, 295, 
296, 300, 301, 302, 305, 306, 311, 313, 
314, 315, 316, 317, 318, 319, 320, 321, 
324, 328 
1, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14, 
15, 16, 17, 19, 20, 21, 22, 23, 
24, 25, 26, 28, 29, 30, 31, 33, 
34, 35, 36, 37, 38, 39, 40, 41, 
42, 47, 48, 50, 52, 53, 54, 60, 
61, 62, 63, 64, 65, 67, 68, 69, 
70, 72, 73, 74, 75, 76, 77, 78, 
80, 81, 83, 85, 86, 87, 88, 89, 
90, 91, 92, 93, 94, 95, 96, 99, 
101, 104, 105, 107, 108, 109, 
111, 112, 115, 116, 117, 118, 
119, 122, 125, 127, 128, 129, 
130, 131, 132, 133, 134, 135, 
136, 137, 138, 140, 141, 142, 
144, 145, 146, 147, 148, 149, 
151, 152, 153, 154, 157, 159, 
160, 161, 162, 163, 164, 165, 
166, 167, 168, 169, 170, 172, 
173, 174, 175 
 Table 5.7: H3 HA locations classified by mutability. Locations in antigenic sites F are shown in bold blue and those 
in site G in bold red. 
Figure 5.7A illustrates the distribution of these classifications across the H3 HA structure, and 
in Figure 5.7B I show a similar analysis of H1 locations for comparison, although it should be 
noted that there is only limited availability of H1 sequences for years before 2000, meaning that 
there is a greater likelihood of classification error, probably accounting for the larger number of 
switcher and polymorphic locations. 
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Invariant residues are found in all regions of the molecule. In H3 HA1 they delineate the 
antigenic sites. In H3 HA2, while the overall level of mutability is reduced compared to that in 
HA1, mutable locations do occur, and are grouped in specific locations. If mutations in HA2 
were purely hitchhikers, one would expect a random distribution. This grouping is therefore 
indicative of selective pressure.  While, in other areas of H2, some invariance is mandated by 
structural or functional considerations, in other cases it may be attributable to weak (or absent) 
selective pressure.  
Fixations have occurred at 7 locations in HA2, of which 4 are located in the antigenic sites F 
and G. If fixations were distributed evenly in HA2, such a concentration in these sites is 
unlikely (p < 0.03
2
). Two of the remaining three fixations, HA2 55 and HA2 121, occur close to 
the sites. HA2 55 is immediately adjacent to HA2 56, which is located in site F. It is a ‘buried’ 
residue, but, as evidenced by the escape mutation raised against CR6261 by Throsby et al. 
(2008), buried residues can elicit antigenic escape. HA2 121 lies near to the boundary of both 
antigenic sites and is surface-exposed in the trimeric structure (Figure 5.8). Its Cα atom lies at 
10Å from HA2 153, the nearest residue in site G, and 12Å from HA2 39, the closest residue in 
site F. It is sufficiently close to participate in the epitope of antibodies binding in either site F or 
site G, although its orientation on the three-dimensional molecule makes the former more likely 
than the latter as it is roughly co-planar with regions of site F, but lies over a ridge from site G. 
                                                     
 
2
 As there are 175 locations in HA2 and 34 of them are in the sites F and G, the probability of four 
fixations lying in sites F and G, and three fixations lying outside the sites, assuming a random 
distribution, is 
 
                         
                             
             
 
and the probability of four or more fixations lying in the sites is 0.027. 
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Figure 5.7: Locations in H3 HA (A) and H1 HA (B) classified by mutability. Blue – switcher; red – polymorphic; 
pink – intermediate; grey – invariant. 
 
Figure 5.8: Fixations occur at HA2 locations 55 (brown) and 121(green), which lie outside but adjacent to the 
characterised antigenic sites F and G. The residues are shown in two views of the HA monomer. Site F is shown in 
blue and site G in red: other residues in white.  
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N-glycosylation sites are known to interfere with the attachment of antibodies (Skehel et al., 
1984). They are characterised by the motif Asn-X-Ser/Thr (where X is not Pro), but the 
likelihood of such a motif being populated with a glycan is dependent on the specific sequence 
and its context. The server NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc), which 
employs artificial neural networks, is widely used to predict populated sites, and is claimed to 
have 76% accuracy when tested against known populated and non-populated sites (Gupta, Jung, 
and Brunak, 2004). When the server is run against the full-length HA sequences of A/Hong 
Kong/1/1968 and A/Perth/16/2009, with a potential in excess of 0.5, which is the default 
threshold, it predicts the same four sites in the stalk of each protein. The asparagine residues of 
the sites are at HA1 8, 22, 38 and HA2 154 (Figure 5.9). The residues HA1 8-10 display some 
polymorphism between 1971-1972 and 1980-1982. Other constituent residues of these N-
glycosylation sites are invariant, apart from some slight mutability in HA2 155 in 2004-2005. 
The four sites are therefore likely to be permanent in H3, apart from some exceptions during the 
polymorphic years of HA1 8-10. Experimental evidence confirms that all four sites are occupied 
in A/Hong Kong/1/1968 and A/Aichi/1/1968 (Wilson, Skehel, and Wiley, 1981; Gallagher et 
al., 1988). 
Figure 5.9: N-glycosylation sites of the HA H3 stalk, predicted by the NetNGlyc server from full-length sequences of 
A/Hong Kong/1/1968 and A/Perth/16/2009, shown on the HA trimer. Asparagine residues of the glycosylation sites 
are shown in yellow. Antigenic site F is in blue and site G in red. Other HA1 residues are white, HA2 grey. 
Despite the known ability of N-glycosylation sites to interfere with antibody binding, HA1 38 
and 39 are included in antigenic site F, and HA2 154 is immediately adjacent to site G. It is 
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unlikely that an antibody could bind across a populated N-glycosylation site (this was the 
specific point established experimentally by Skehel et al.). If we assume that neutralising 
antibodies in HA2 must bind to the fusion peptide, the two N-glycosylation sites with 
asparagines at HA1 22 and 38 would serve to prevent neutralising antibody binding extending 
to the left of site F or above the top of site G, thus explaining the demarcation of the sites. This 
in turn could explain the lack of mutability in HA2 in the region beyond the two N-
glycosylation sites: while it may be possible for antibodies to bind there, their binding would be 
unable to extend across the sites to reach the fusion peptide. They would therefore not have a 
neutralising action and so would not exert evolutionary pressure. 
5.9 Antigenic Transition in Antigenic Sites F and G 
In this section, we will examine mutability in antigenic sites F and G, and in the two 
neighbouring switcher locations. We will see that, at various points since the introduction of H3 
to the human population in 1968, change has occurred across multiple locations in the sites, in a 
manner that is co-ordinated in time, and that the affected locations form clusters whose 
dimensions are consistent with the dimensions and spatial constraints of B-cell epitopes. 
Figure 5.10 shows a timeline of mutable events in the antigenic sites and the two neighbouring 
switcher locations. We shall consider these events in chronological order, considering the 
possibility of linkage between events that are both spatially and temporally close. 
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Figure 5.10: Year-by-year variation in mutable residues of antigenic sites F and G, and in the nearby locations HA2 
55 and 121 where fixations occur. The dominant residue in 1968 and in 2010 is shown in the ‘Dominant’ columns at 
each end of the table. Fixations are shown in blue, together with the code of the newly fixed residue. Periods of 
transient polymorphism (where the frequency of the dominant residue falls below 80%) are shown in dark red. Other 
periods of polymorphism (where the frequency of the dominant residue falls below 95% but not as low as 80%) are 
shown in pink. In cases of polymorphism, the code of the minority residue is shown. Because of the low number of 
HA2 sequences in early years, the frequency switch in HA2 150 in 1971/72 identified from available sequences does 
not pass the test for statistical significance (Shih et al., 2007). We can be confident that the dominant residue was E 
(Glutamic Acid) in 1968 samples, as A/Hong Kong/1/1968 is well documented, and G (Glycine) from 1972 onwards, 
as there are sequences available for 10 strains that year and all have 150G, but the exact point of transition cannot be 
reliably determined as there are only 4 HA2 sequences available for each year from 1969 to 1971. 
In the period 1971-1983, a fixation in site F is co-ordinated with four polymorphisms in the 
same site. A period of polymorphism in the adjacent location HA2 55 occurs between 1971 and 
1974 during which the minority residue is isoleucine, and the period ends with a fixation in that 
location to leucine. A fixation also occurs at HA2 150, but this location is towards the bottom of 
site G and therefore unlikely to be part of a linked antigenic cluster. Excluding HA2 150, the 
cluster distance of the other 6 residues is 30Å, which is consistent with the dimension 
established in Chapter 3 for a B-cell epitope (Figure 5.11A). The temporal co-ordination 
between changes at locations HA2 18 and HA2 55 is striking (Figures 5.11B, C).  There is 
polymorphism at both locations in 1972. Following the fixation in HA2 I18V in 1978, the 
fixation HA2 55 in 1982 is accompanied by a 25% reversion to isoleucine at HA2 18. 
Site Domain Location Dominant 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 Dominant
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Figure 5.11: Locations displaying variation in the period 1971-83: (A) fixations in blue, others in red. (B),(C) Amino 
acid frequency charts for this period for locations HA2 18 and HA2 55 respectively. 
Following 10 years in which little activity is seen, a fixation HA2 K121R in 1993 is followed by 
transient polymorphism at HA2 49 and 56 in 1993-1994, and then by the fixation HA2 D46N in 
1996. Three of the affected locations are in antigenic site F, while the fourth is the neighbouring 
residue HA2 121. The locations are roughly collinear, with a cluster distance of 34Å, which is 
again consistent with the dimensions of a B-cell epitope (Figure 5.12). 
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Figure 5.12: Locations displaying variation in the period 1993-96: fixations in blue, others in red. 
In 1999, polymorphic activity is seen in site F at HA1 291 and HA2 18 (Figure 5.13). This is 
followed in 2000 by a fixation in HA2 57, the period of fixation extending over four years, 
during which time there is continued polymorphism at the first two locations. The activity in 
site F concludes with the fixation HA2 N46D: this is a reversion of the fixation observed in the 
previous period.  
Coincident activity in site G starts with a small transient polymorphism in HA2 150 in 2003, 
following which there are two fixations at HA2 32: T32I in 2004/5 and I32R in 2007/8. These 
changes are quite distant from the changes in site F – the overall cluster size is 45Å, and so (on 
the assumption that the changes are indeed related to antigenic escape) are likely to be 
independent.  
Also on this period, there is a fixation neighbouring the antigenic sites: HA2 R121K. This is a 
reversion of the second fixation observed in the previous period. As noted in the previous 
section, HA2 121 is close to both sites F and G, but a ridge separates it from site G, so that it is 
more likely to be part of an epitope with antibodies binding in site F. It also seems most likely 
that the two reversions occurring in this period are related rather than independent, particularly 
as the two fixations are closely associated.  
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Figure 5.13: Locations displaying variation in the period 1999-2008: fixations in blue, others in red. 
The reversions at HA2 46 and 121 suggest a relaxation of the evolutionary pressure under which 
the substitutions developed, but, if we assume that this pressure was imposed by a neutralising 
antibody, one would expect the antibody to persist. One alternative scenario is as follows. In the 
period 1993-96, antigenic pressure from an antibody binding in the site induced two 
substitutions (in HA2 46 and 121), leading to escape but reducing fitness. In the period 1999-
2008, pressure from a further antibody induced further substitutions, in HA2 46 and 57. If these 
new substitutions also provide escape from the first antibody, the substitutions at HA2 46 and 
121 can be reversed, increasing overall fitness. Another possibility is simply that the 
substitution at HA2 57 emerged as a fitter alternative to the previous two substitutions, which 
still provided for antigenic escape. 
5.10 Discussion 
In this study I have presented evidence of directed evolution in the H3 stalk. Crucially, this 
evidence draws on factors that are not considered by existing statistical approaches, extending 
the analysis of Shih et al. (2007) to HA2 and extending it to include consideration of the 
temporal coordination of fixations and polymorphisms and their locations with respect to known 
epitopes.  
Some authors have expressed hope that the elicitation of broadly-based anti-stalk antibodies can 
provide universal immunity against influenza (Russell, 2011; Nabel and Fauci, 2010), however 
those antibodies discovered to date may be more restricted in their binding ability at 
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physiological concentrations. In addition, the assumption that a ‘conserved’ substitution will not 
impact antibody binding has led to unwarranted assumptions concerning the stalk’s level of 
conservation. That HA escape mutants to broadly binding antibodies have been bred 
successfully in four cases also sounds a note of concern. I have reviewed evidence from a 
number of studies that neutralising stalk binding antibodies – albeit not so broadly-binding – are 
widely present in the human population. Taken together, these points suggest that neutralising 
stalk binding antibodies form a continuum of binding ranges and neutralising abilities. The 
broad-binding examples from the literature may lie towards one end of this continuum, but they 
are not essentially different. Extending vaccination techniques to elicit a greater quantity of 
stalk-binding antibodies is worthwhile, but it is not obvious that such antibodies will meet the 
very high expectations being placed on them in some quarters.  
Within H3 strains, neutralising anti-stalk antibodies have been found to bind in two sites, which 
I have termed sites F and G. These sites overlap with the functionally active ‘fusogenic region’ 
of HA, and, while the exact neutralisation mechanism of such antibodies is uncertain, it is 
reasonable to assume that interference with this function is key to their neutralising capability. It 
is notable that mutable activity (in the form of fixations and polymorphisms) is significantly 
more frequent in sites F and G than in other regions of HA2. This provides strong evidence that 
such activity is directed and not simply the result of hitchhiking. We cannot with certainty 
ascribe any particular mutation or set of mutations to antigenic pressure – but, with the known 
presence of antigenic activity in the region, and the documented possibility of antigenic escape, 
there is a strong case for antigenic pressure to be considered as one factor. I have presented a 
possible explanation of the mutable activity observed in the H3 stalk that is consistent with 
antigenic pressure as a primary cause. This argument cannot be conclusive, but deserves further 
study. 
These results have consequences for influenza surveillance, vaccine selection, and vaccine 
design. 
It is important to monitor the development of polymorphism in the stalk, as it may be indicative 
of antigenic escape with implications for sections of the population that have developed 
protection via relatively broadly protective antibodies binding there. Supporting evidence comes 
from studies of pandemic H1N1 strains, where the mutation E374K in the stalk has been 
associated with vaccine breakouts (Maurer-Stroh et al., 2010; Strengell et al., 2011).  As an 
associated point, serological surveillance has tended to focus on changes in HA1. It would be 
helpful to develop assays that will identify antigenic escape from stalk-binding antibodies, 
which could be indicative of strains to which the wider population has reduced immunity. 
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Assays based on artificial or augmented constructs (Martínez-Sobrido et al., 2010; Pica et al., 
2012) may help in this respect. 
It is unlikely that a single human antibody to the HA stalk could confer universal protection. 
Even if such an antibody could be isolated or developed, despite the points above on relative 
conservation and binding strength, there would still remain the difficulty of eliciting that precise 
antibody in all human phenotypes. There appear to be two approaches to developing a universal 
vaccine. One is to target a single epitope that, for functional reasons, is truly conserved across 
strains and subtypes of interest. The other is to develop antigenic ‘defence in depth’ in which 
antibody response is elicited to a number of relatively well conserved epitopes, such that escape 
from any one antibody will not of itself confer evolutionary advantage. On the basis of the 
analysis in this chapter, the HA stalk is not a good candidate for the first approach, but it has 
potential for the second. When eliciting antibodies to the HA stalk in a vaccine, it would be 
advisable to present multiple stalk antigens, representing the variation found in strains to date. 
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6 Conclusions and Areas for Further Study 
6.1 Conclusions 
A rich collection of influenza sequences, covering the past 45 years, is publicly available via 
GenBank (http://www.ncbi.nlm.nih.gov/GenBank) and specialist influenza resources. The body 
of knowledge continues to grow. In particular, the US National Institute of Allergy and 
Infectious Diseases has conducted, since 2005, a project to provide whole-genome sequences of 
early strains, for which, previously, only an HA1 sequence was available (National Institute of 
Allergy and Infectious Diseases, 2013). Where multiple sequences of the same strain exist in 
GenBank, correspondence is generally good. Exceptions exist for some early strains, where 
some erroneous sequences have been used in earlier studies (Section 2.4.1). 
To my knowledge, no public database of antigenic data exists. The combination of sequence 
and antigenic data is valuable, as evidenced by this study, and I am exploring options to make 
the data publicly available to other researchers. The systematic collection of antigenic data has 
made it possible to examine the repeatability and accuracy of HI assay results. Where there are 
multiple measurements of the same strain/serum pair, the standard deviation is generally below 
one unit of antigenic distance, and the generally accepted view that assay results are accurate to 
within +/– 1 unit of distance is reasonable. ‘Two-way’ Archetti-Horsfall distances have greater 
precision (Tables 2.1-2.4). 
I have demonstrated the use of substitution analysis in combination with an understanding of the 
three dimensional structure of HA to predict the location of those epitopes in wild-type human 
HA which have driven antigenic evolution. While experimental work would be needed to 
confirm the accuracy of these predictions, the good correspondence between ‘immunoactive’ 
locations in HA1 identified by this method and by other methods (Section 3.4) is encouraging.  
A simple predictive model of antigenic distance, based on changes at the immunoactive 
locations identified via this analysis, is capable of matching or exceeding the predictive powers 
of other models published to date, while encapsulating a greater degree of generality, which 
may lead to superior performance when addressing novel strains (Section 3.8). Such predictive 
models may prove of value where a rapid determination is required, where difficulties are 
encountered with conventional assays (Section 2.2), or where such a large-scale analysis is 
required that laboratory assays would be impractical (Section 6.4). 
Results from the analysis support the view that, in general, antibodies to H3N2 HA1 bind in the 
five ‘canonical’ antigenic sites A-E. The survey of HI assay quality demonstrates that the 
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immune response across a number of individual animal hosts (in this case, ferrets) is, at a gross 
level, reasonably consistent. These points suggest that, firstly, epitope-bearing surfaces of 
proteins do have some distinguishing properties, and, secondly, that the antibody germline has a 
strong influence on locational response. 
The epitopes predicted by substitution analysis were grouped in two key regions in H3 HA1 
(Section 3.3). Through the use of an antigenic map simulation, I provided support for the 
hypotheses that either this property, or the tendency in some epitopes for the binding energy to 
be concentrated in a small number of residues, could lead to the clustering phenomenon seen in 
H3N2 antigenic maps and that the two could act in combination (Section 4.5). In the course of 
this work, I demonstrated the use of density-based clustering algorithms in antigenic maps, and 
introduced a Silhouette-based metric for determining the degree of cluster quality. 
Although HA1 and HA2 overlap in the membrane-proximal region of the globular head, HA2 
residues play only a small part in the epitopes predicted by substitution analysis (Section 5.3). A 
number of antibodies to the HA stalk have recently been characterised, and I map their binding 
locations to the H3 stalk to two new antigenic regions, F and G (Section 5.6). These broadly-
binding antibodies may not be broadly neutralising at physiological concentrations, and, while 
the regions in which they bind are conserved in comparison to the HA head, substitutions 
observed in the wild may be sufficient to allow antigenic escape (Section 5.5). Their existence 
therefore does not rule out the possibility of antigenic evolution in regions F and G, and, while 
other evolutionary factors are likely to be at work in the region, the possibility of antigenic 
evolution should not be ruled out (Section 5.9). Such antigenic evolution would have significant 
consequences for the development of vaccines based on the elicitation of broadly-binding anti-
stalk antibodies (Section 5.10). 
6.2 Areas for Further Study 
6.2.1  Epitope Prediction 
 The techniques used in this study identify clusters of substitutions that are plausible as epitopes 
in terms of their spatial and temporal grouping. It is unlikely that all locations identified within 
the identified clusters are epitopic. The technique could be refined further by checking the 
predicted epitope for structural plausibility, and by checking it against the known general 
properties of epitopes, such as planarity and linearity (Rubinstein et al., 2008; Kringelum et al., 
2013). Some caution would be necessary, however: as discussed in Sections 3.2 and 5.4 and in 
the cited studies, antibody binding is opportunistic in its nature, and many binding 
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configurations are possible. It might be possible to develop a probabilistic approach, in which 
the properties of a predicted epitope are compared against a database of known structures in 
order to give a likelihood score.  This approach would assume, though, that anti-HA antibodies 
conform to a general norm of epitopes in other proteins. It could be that the shape of the protein 
is atypical when compared to other antibody targets. Likewise, it may turn out that an 
antibody’s germline descent has a significant bearing on the properties of its epitopes – as was 
suggested for the IGHV1-69 germline in Section 5.4, in which case a generic approach may not 
be meaningful. 
Another enhancement that could add specificity would be to examine the fitness cost of a 
particular substitution, in the absence of antigenic activity, by measuring the change in free 
energy caused by the substitution, or by assessing the novelty of the substituted residue in that 
location. Again, though, some caution would be necessary: as noted in Section 5.5, even 
apparently conservative substitutions can elicit escape.  
6.2.2 Simulated Mutagenesis 
A wider study of epitope mutagenesis is needed in order to fully understand the scope of the 
identified broad-binding antibodies and the possibilities for escape (Section 5.5). The large 
number of HA/antibody structures now available, together with experimental mutagenesis 
studies to date, would provide a useful starting point for simulated mutagenesis studies using 
molecular dynamics (MD).  While such studies are notoriously computationally expensive - one 
HA/antibody MD study was conducted on an IBM supercomputer (Zhou, Das, and Royyuru, 
2008) – computational power continues to increase. Specialist hardware is available (Shaw et 
al., 2007), as are increasingly large clusters of conventional computers. The available 
experimental data could provide a useful platform for testing algorithms and optimisations, 
either generic or problem-specific. 
6.2.3 dN/dS Studies 
The study of nucleotide synonymous and non-synonymous mutation rates is a widely accepted 
approach for identifying locations or regions under positive or negative selective pressure; 
however, as discussed in Appendix A, as generally developed the approach lacks sensitivity 
when applied to the sequence data available for HA, and embodies some questionable 
assumptions. Refinements highlighted and suggested in the Appendix, in particular applying a 
dN/dS approach to a sliding window of isolation years, might address the sensitivity issue to 
some extent by giving greater prominence to fast-moving events such as rapid fixations.  
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6.2.4 Neuraminidase 
Although antibodies binding to NA do not appear to impede viral cell entry, they select for 
escape mutants (Webster, Hinshaw, and Laver, 1982), indicating that they have some 
neutralising action. It has been suggested that including NA in vaccines provides enhanced 
protection, although evidence is mixed (Johansson and Brett, 2008; Nayak et al., 2010). There is 
support for the occurrence of antigenic drift in NA: the substitution rate is similar to HA, and a 
crystal study exists of an antibody which binds close to the active site, in a region known to 
have undergone significant variation in wild-type strains (Venkatramani et al., 2006; Air, 2011). 
Extension of the analysis to NA could provide some useful insight into its antigenic activity, for 
example in determining the extent of antigenic sites and the typical protection period. I have 
already started some work in this direction: the database contains a collection of N2 sequences, 
and a visualisation of sequence differences on the NA head is available. 
6.2.5 Other Viruses 
The techniques developed in this study are potentially extensible to other RNA-based viruses 
that exhibit antigenic drift, and for which there are sizable sequence data sets available. 
Hepatitis C virus (HCV) and HIV are possible candidates, each having well in excess of 
100,000 sequences in GenBank (http://www.ncbi.nlm.nih.gov/GenBank/). In contrast to 
influenza, these two viruses cause persistent infection in humans. Study of sequences obtained 
from individual patients over time with these techniques might provide insights into antibody 
and viral development. Kwong and Wilson (2009) provide an interesting summary of antibody 
recognition of HIV and parallels with broad-spectrum influenza HA recognition. While the 
humoral response plays a clear role in HIV infection, its role in HCV infection is not well 
understood. Rapid viral clearance in some individuals is associated with the T-cell response. 
While B-cells are elicited, particularly in later infection, the majority of antibodies secreted are 
not HCV specific (Rehermann, 2009): HCV may therefore not prove to be a good candidate for 
discovery of antibody-induced evolutionary pressure. 
6.3 Laboratory Investigations 
A number of laboratory investigations, which would help to advance the overall aim of this 
work, are highlighted in this section.  
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6.3.1 Assays 
The HI assay, widely used in surveillance, is only useful for detecting the neutralising action of 
antibodies that sterically block host cell binding. In recent years, the assay has suffered from 
problems: in particular the H3N2 subtype’s gradual loss of affinity to avian red blood cells, and 
a receptor binding site in N2 neuraminidase (see Section 2.2.3). As a result, for H3 strains, 
WHO collaborating centres have started to introduce the microneutralisation assay alongside the 
HI assay. The WHO protocol for the microneutralisation assay is a two-step process (World 
Health Organization, 2011). In the first step, virus is mixed with dilutions of serum, and time is 
allowed for binding to take place. In the second step, MDCK cells are added, and time is 
allowed for viral infection. At the end of this second step, an ELISA assay is used to identify 
infected cells. The protocol is designed to assay the effectiveness of antibodies that act on the 
virus before cell entry. It is evidently less sensitive to those that act on budding – a mechanism 
that has been suggested both for stalk binding anti-HA antibodies (Corti et al., 2011) and for 
anti-NA antibodies (Air, 2011). A modified assay, which could be run at high throughput for 
surveillance purposes, but was equally sensitive to neutralisation at any point in the replication 
cycle, would facilitate the identification of such antibodies and provide a more complete picture 
of the neutralising potential of antisera. An early step in this direction was undertaken in 
collaboration between Birkbeck and the UK WHO CC at the suggestion of Dr John McCauley 
and under the supervision of Dr John McCauley and Dr Adrian Shepherd, but the results were 
inconclusive in the identification of such antibodies (Akere, 2012). 
6.3.2 The Role of Stalk Binding Antibodies in Seasonal Infection 
The prevalence and action of stalk binding antibodies in seasonal infections is not well 
understood (Section 4.4), and focus of study has so far been given to broad-binding examples, 
which appear to be extremely rare. A greater understanding of less broadly binding types – both 
their prevalence and their action – for example whether or not they are neutralising, and whether 
or not they lessen the virulence of infection – is needed in order to build a better understanding 
of the role of stalk binding antibodies and their effectiveness in vivo. 
6.3.3 Determination of Physiological Concentrations of Antibody 
The current, limited, understanding of physiological levels of antibody suggests that broad 
spectrum stalk-binding anti-HA antibodies identified to date may not be present in sufficiently 
high concentrations in vivo to have a neutralising effect (Section 5.5). Further studies are needed 
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in order to understand whether the binding strengths being observed would be sufficient to 
provide protection in humans. 
6.3.4 Mutagenesis 
The mutagenesis studies carried out in the studies of broadly-binding stalk antibodies, while 
extensive, do not cover all possibilities for escape (Section 5.5). It would be useful to attempt to 
breed escape mutants against antibodies FI6 and CR9114, and to attempt to culture escape 
mutants against antibodies D8/F10/A66 using additional base strains (Table 5.6). Such escape 
mutants, if bred successfully, would be helpful in understanding the critical residues of the 
epitope. Ideally one would wish, through mutation analysis or some other means, to understand 
the binding energy of each member of the epitope. This would enable a much more informed 
analysis of the likelihood of escape. If such an analysis proves impractical in the laboratory, 
computational methods may offer an alternative approach (Section 6.2.2).   
6.4 The Changing Nature of Sequence Data 
At the time of writing, the Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU) holds 9,358 sequences for HA for strains isolated 
between 1
st
 January 2009 and 31
st
 December 2009: that is, over twice the number of isolates it 
holds for H1N1 and H3N2 combined in all years prior to 2009. The numbers have since fallen 
substantially: a total of 1387 human HA sequences (across all subtypes) were deposited for 
2010, and 899 for 2011. The peak was undoubtedly caused by increased surveillance following 
the emergence of the pandemic: nevertheless, overall, the number of sequences added annually 
is likely to trend upwards, following the same trend that has been observed since the early 1990s 
(Figure 5.1).  
While the increasing volume of data poses a computational challenge, it will provide new 
opportunities. It remains to be seen how much the volume will, of itself, help in the overall 
understanding of the mechanisms which allow apparently simple behaviour, such as antigenic 
behaviour, to emerge from the overall complexity of a system consisting of a virus that 
interacts, at any one time, with tens of millions of hosts (Bedford, Rambaut, and Pascual, 2012). 
It may well exacerbate problems of phylogeny, which are touched on in Appendix A. Bush et al. 
(1999) identified an excess of mutations on the terminal branches of the phylogenetic tree, and 
recommended that studies of positive selection should be confined to internal branches. This, 
and other methods that focus on the mainstream evolution of the virus, may become 
increasingly necessary as the volume of data increases. 
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The increasing volume of data may help us to identify subtler patterns underneath the apparently 
simple progression of influenza’s evolution today – for example a prevalence of particular 
strains in particular geographies, propensities linked to host genetic factors, and the presence of 
sub-populations of subtypes. It should enable the rather general descriptions of dominant strains 
worldwide (see Section 2.4.1) to be replaced by a more meaningful and numerically precise 
account. However, if such an account is to include descriptions of antigenic relatedness, a 
computational model of such relatedness will be needed, given the very large number of 
sequences that will be involved. 
Deep sequencing offers the possibility of studying viral evolution within the host as well as 
between hosts, as we do now. Whether or not influenza follows the quasi-species model is 
contentious (Holmes, 2009), nevertheless it seems likely that the virus will adapt to the host 
environment once infection is established, and study of such adaptions should provide 
interesting insights into viral and host mechanisms. Variation of adaption between hosts could 
provide indications of genetic determinants of virulence.  Intra-host transmission bottlenecks 
may help elucidate the determinants. 
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Appendix A - An Investigation of Nucleotide Mutation Rates in Influenza A H3N2 
Haemagglutinin 
A.1 Introduction 
Our recent research has utilised a method developed by Shih et al. (2007) to infer selective 
pressure at a single amino acid site by identifying frequency switches: a method which I have 
extended to include subtler signs of pressure such as transient polymorphism, and applied to 
infer co-ordinated selective pressure amongst a number of amino acid sites in the HA2 
polypeptide chain of Influenza A HA, as described in Chapter 5. 
Researchers in many fields, including that of influenza evolution, have developed techniques to 
infer the action of selective pressure by comparing the ratio of non-synonymous to synonymous 
nucleotide substitutions (dN/dS). The large number of sequences available for influenza HA has 
made it a common target for such work. Typically, in such an approach, a nucleotide 
substitution model is calibrated against the history of the protein. A phylogenetic tree is inferred 
in order to account for intermediate ancestral states not represented in the available samples. 
The ratio of non-synonymous to synonymous nucleotide substitutions is then calculated, and 
compared to the value expected from the substitution model.  A significantly high value implies 
positive selective pressure, while a significantly low value implies negative selective pressure.  
Traditionally, for reasons related to calculation time and sample size, the calculation is 
aggregated over a number of sites and along all branches of the phylogenetic tree. Hence 
selective pressure at a small number of individual sites, or along a single branch of the 
phylogenetic tree, may be missed. Methods do exist that attempt to overcome these restrictions, 
and a useful account may be found in Chapter 8 of Yang (2006).  
Existing Studies 
Table A.1 summarises methods broadly based on this approach which have been applied to 
influenza H3 haemagglutinin and attempt to identify individual residues under selective 
pressure or to distinguish between pressure in antigenic and non-antigenic regions. 
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Study Method Extent 
Ina and Gojobori (1994) Analysis of antigenic site members vs. non-
members 
HA1 
Fitch et al. (1997) Single site analysis. Tree reconstructed by 
parsimony, changes counted at each site 
along each branch of the tree 
HA1 
Suzuki and Gojobori  (1999) Same approach and data set as Fitch et al. 
(1997) but a more stringent criterion for 
positive selection 
HA1 
Bush et al. (1999) Single site analysis. Differentiation between 
mutations on terminal and nonterminal 
branches of the phylogenetic tree. 
HA1 
Yang (2000) Tree and substitution model inferred by 
Maximum Likelihood (ML) 
HA1 
Suzuki (2004) Grouping of amino acid locations via three 
dimensional window analysis utilising 
information on protein structure 
HA1 
Suzuki (2006) Single site analysis Entire 
genome 
Wolf et al. (2006) Analysis of antigenic site members 
compared to other regions  
Entire 
genome 
Suzuki (2008) Analysis of antigenic sites A-E along 
grouped phylogenetic tree branches 
HA1 
Kosakovsky Pond et al.  
(2008) 
Tree inferred by ML.  Evidence is then 
explored for a directional substitution model 
which favours substitutions towards a 
specific amino acid at a particular site 
Entire gene 
segment 
Suzuki (2011) Analysis of locations grouped around 
glycosylation sites 
Entire gene 
segment 
Chen and Sun (2011) Parallel single-site analysis from multiple 
datasets 
HA1 
Murrell et al. (2012) Single site analysis, episodic pressure HA1 
Tusche et al. (2012) Detection of patches containing close 
residues with evidence of positive selection 
Entire gene 
segment 
Suzuki (2013) Single site analysis, correcting for 
energetically unstable amino acid mutations 
Entire gene 
segment 
Table A.1: Published Analyses of H3 sequences using nucleotide substitution methods  
 
In viral surface proteins, evolution at a single amino acid site is rapid and transient, as evidenced 
by the rapid changes observed in amino acid frequency plots. Single-site models may lack the 
sensitivity to identify changes of this nature. To address this, sliding window analyses have 
been developed that consider changes in locations closely located in the three-dimensional 
structure and hence can relax the criterion for positive selection at any single location. Suzuki 
(2004), employed windows of fixed size. Tusche et al. (2012) searched for continuous patches 
with a heightened dN/dS ratio, testing this approach on H3 HA1 and HA2 among other proteins. 
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A.2 HA2 Results from Published Studies 
Approaches based on dN/dS are known to be conservative (Suzuki, 2013). Typically a dN/dS 
analysis will identify a small set of locations under positive or negative selective pressure, and a 
large number for which the analysis is inconclusive.  
Study H3 HA2 sites/regions under 
positive pressure 
Suzuki (2006) None 
Kosakovsky Pond et al.  (2008) 1 
Suzuki (2011) None 
Tusche et al. (2012) None 
Suzuki (2013) None 
Table A.2: HA2 sites reported in those analyses from Table A.1 that cover HA2. None of these analyses list sites 
determined to be under negative selective pressure, although Figure 1 in Suzuki (2006) suggests that approximately 
10% of HA2 locations satisfy the 95% likelihood criterion for negative selection. 
 
Of the studies considered above, five cover H3 HA2 (Table A.2). Kosakovsky Pond et al.  
(2008) identified one HA2 location under pressure, with a whole-segment numbering of 347 
corresponding to an HA2 numbering of 2. Tusche et al. (2012) do not identify any HA2 patches. 
While the latter result is perhaps unsurprising given the relative sparsity of substitutions in HA2, 
it is interesting that the former study only identifies one of the fixations in HA2 as being in a 
location undergoing positive selective pressure (Figure A.1). It is possible that the analysis in 
that study is influenced by the reversals at locations 32, 46, and 121. The three single-site dN/dS 
studies covered HA1 only: furthermore,  all three are based on the dataset of Bush et al. (1999) 
and therefore cover a period when comparatively limited samples were available. 
Figure A.1: HA2 locations undergoing fixations, of which only location 2 is identified as a location under positive 
selective pressure in Kosakovsky Pond et al.  (2008). 
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A.3 An Investigation of H3 HA2 Selective Pressure Inferred From Nucleotide 
Substitution Rates 
I decided to investigate positive selection in H3 HA2 using the single-site dN/dS calculation. I 
chose to run the calculation in strain samples isolated between 1999 and 2008, split into two 
groups (Table  A.3). The period under study was chosen to match a period in which I had 
observed significant fixation activity (see Figure 5.10), and was split into two sets partly for 
reasons of computational economy and partly to reflect the division of activity observed in that 
period. It was anticipated that a focus on a relatively limited period in which specific directional 
activity could be observed in the fixation analysis would provide a clearer signal for the dN/dS 
calculations. 
As an additional investigation, I repeated the directional substitution analysis of Kosakovsky 
Pond et al. (2008) focussing on the same period as above. Again it was anticipated that this 
focus might provide a clearer signal than the original broader-ranging analysis. 
A.4 Methods 
All available full-length human H3N2 HA nucleotide sequences were downloaded from the 
Influenza Virus Resource (Bao et al., 2008), and aligned with Muscle (Edgar, 2004). Sequences 
with gaps were eliminated.  Sequences for HA2 were extracted, and duplicates removed (Table 
A.3). Selection analyses were performed in HyPhy v2.1.1 (Kosakovsky Pond and Frost, 2005). 
Isolation Dates Number of unique 
HA2 nucleotide 
sequences 
Number of unique 
HA2 AA sequences 
HA2 Events inferred 
from frequency 
analysis 
June 1999 – May 
2004 
348 108 18, E57G, 123 
June 2004 – May 
2008 
316 100 I32R, N46D, R121K 
Table A.3: Number of sequences used in the HA2 studies, and the HA2 fixations inferred from frequency analysis in 
the periods under study. In the right-hand column, fixation events are shown as a transition between two amino acids 
(e.g. E57G) while polymorphisms are indicated purely by the location (e.g. 18) 
 
For the dN/dS study, phylogenetic trees were estimated in HyPhy with the neighbour joining 
method, using the REV substitution model (Yang, 1994) and the TN93 distance model (Tamura 
and Nei, 1993) using global parameters.  Nucleotide substitution biases were then estimated 
using the inferred tree by fitting the Generalised Time-Reversible model  (Tavaré, 1986) with 
global parameters.  dN/dS values were then estimated by HyPhy’s Single Most-Likely Ancestor 
Counting  (SLAC) method, applied to the whole tree at once, with ambiguities in reconstructed 
 132 
 
codons averaged over possible codon states. This pipeline follows the approach recommended 
by the authors of HyPhy for a SLAC analysis. 
HA1 sites were excluded from the above analysis in the expectation that this would allow a 
clearer signal to be obtained from the slower changing HA2 chain. To provide a comparison, a 
SLAC analysis was also conducted against full-length HA1 and HA2 sequences, using the 
above methods. The main reason for conducting this comparative analysis was a concern that 
that it might not be possible to obtain a representative phylogenetic tree from the HA2 
sequences alone. The number of distinct full-length nucleotide sequences used in this analysis 
was 787 for the period 1999 –2004 and 593 for the period 2004 –2008.  
For the directional substitution analyses, the nucleotide sequence of A/Hong Kong/1/1968 was 
added to each collection. Amino acid sequences were inferred from the nucleotide sequences 
and duplicates removed.  Phylogenetic trees were then estimated from the remaining 
corresponding nucleotide sequences using the neighbour joining method as above, and the trees 
were rooted on A/Hong Kong/1/1968. 
A.5 Results 
SLAC Analysis of HA2 Sequences 
At the default confidence level of p < 0.05, the SLAC method did not identify any sites under 
positive selection in HA2. 43 sites in the period 1999-2004 and 39 in the period 2004-2008 were 
identified as under negative selection: 17 of these were identified in both periods.  
Results for sites of interest from the fixation analysis in Chapter 5 are shown in Table A.4 
. 
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Site 
 
1999 to 2004 2004 to 2008  
1999-
04 sel 
 
2004-
08 sel 
 
Events 
Observed 
S 
Changes 
Observed 
NS 
Changes 
dS dN 
P{S leq. 
observed} 
P{S geq. 
observed} 
Observed 
S 
Changes 
Observed 
NS 
Changes 
dS dN 
P{S leq. 
observed} 
P{S geq. 
observed} 
18 1 5 1.29 2.25 0.51 0.83 2 5 2.03 2.48 0.58 0.73 neut neut Polymorphism 
between 2000 
and 2003 
32 1 2 1.00 1.00 0.74 0.70 2 12 5.40 4.57 0.75 0.53 neut neut Fixations in 
2004 and 2009 
46 4 0 5.52 0.00 1.00 0.00 3 9 5.54 3.66 0.84 0.37 -ve neut Fixation in 2006 
57 2 5 2.37 2.50 0.65 0.66 2 2 2.03 1.00 0.89 0.40 neut neut Fixation in 
2002/2003 
121 3 6 3.31 2.99 0.70 0.57 3 5 3.26 2.66 0.75 0.52 neut neut Fixation in 
2006/2007 
123 2 3 2.90 1.34 0.91 0.34 8 4 11.72 1.77 1.00 0.00 neut -ve Polymorphism 
in 2000-2002 
Table A.4: Results of single-site SLAC analysis of HA2 sequences isolated in the two periods studied, for events of interest identified from fixation and polymorphism analysis. For each of the two 
periods, the following information is provided: 
Observed S/NS Changes – a count of silent and nonsilent changes observed at the site  
dS, (dN) – The number of observed synonymous (non-synonymous) substitutions per synonymous (non-synonymous) site, as calculated by the SLAC model 
P{S leq observed) – The probability (calculated from a continuous extension of a binomial distribution) of observing this or a greater number of synonymous changes on the assumption that the 
selection is neutral – this is the p-value of positive selection at the site 
P{S geq observed) – As above, the p-value of negative selection at the site  
1999-04, 2004-08 selection – Selection applying at the site (neutral or negative) 
Fixation or Polymorphism Events – Events as inferred from amino acid frequency analysis 
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The results in Table A.4 suggest a lack of predictive power compared to the amino acid 
frequency analysis. The two models are not in conflict in the sense of one predicting negative 
selection where the other predicts positive selection, but the SLAC analysis appears to have less 
sensitivity to the presence of positive selection.  
Period Location Observed S 
changes 
Observed 
NS 
changes 
P{S leq. 
observed} 
1999-2004 18 1 5 0.51 
27 3 5 0.69 
32 1 2 0.74 
50 1 2 0.74 
57 2 5 0.65 
94 0 1 0.73 
97 0 1 0.75 
98 1 4 0.46 
100 0 1 0.67 
121 3 6 0.70 
143 0 1 0.72 
147 0 6 0.09 
150 2 5 0.58 
160 0 3 0.64 
163 0 1 0.69 
172 0 3 0.35 
2004-2008 18 2 5 0.58 
32 2 12 0.75 
71 1 2 0.69 
84 1 2 0.74 
99 0 1 0.67 
101 1 2 0.74 
104 0 1 0.77 
121 3 5 0.75 
139 0 1 0.72 
155 1 2 0.68 
168 0 1 0.77 
172 0 4 0.25 
173 0 2 0.44 
Table A.5: Locations in each examined period that were assigned a p-value for positive selection less than 0.8. 
Locations at which the amino acid frequency model identified events in the period are shaded. 
 
Table A.5 lists all locations with a p-value for positive selection < 0.8: this includes 4 out of the 
6 locations identified by amino acid frequency analysis, along with a further 25 hits. Many of 
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these have low observed N and S changes (Figure A.2). Interestingly, the four locations 
identified by amino acid frequency analysis have relatively high observed N and S changes, the 
lowest total being 6.  
Figure A.2: Frequency of the total observed N and S counts seen in the results listed in Table A.5. 
Of the results listed in Table A.5 which are not identified in the amino acid frequency analysis, 
the two with the highest total observed N and S counts are 121 in 1999-2004 (9) and 27 in 1999-
2004 (8).  While location 121 underwent fixations in 1992/1993 and 2006/2007 it displays only 
a low degree of polymorphism in 1999-2004. Location 27 shows little polymorphism in the 
period. Likewise the two locations with the lowest p-values for positive selection:  147 in 1999-
2004 (0.9) and 172 in 2004-2008 (0.25) display only modest polymorphism (Figure A.3). 
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Figure A.3: Amino acid frequency charts for four residues identified by SLAC analysis as being under positive 
selection in the periods shown. 
SLAC Analysis of Full-length HA Sequences 
Once again, at the default confidence level of p < 0.05, the SLAC method did not identify any 
sites under positive selection in HA2.  6 locations in HA1 were identified as being under 
positive selective pressure in the period 1999-2004 and 9 in the period 2004-2008. (Table A.6). 
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Period Location P{S leq. 
observed} 
Antigenic 
Site 
1999-2004 45 0.01 C 
50 0.01 C 
92 0.04 E 
220 0.0 - 
226 0.05 D 
229 0.00 D 
2004-2008 3 0.01 - 
50 0.04 C 
53 0.00 C 
142 0.02 A 
157 0.01 B 
173 0.03 D 
194 0.01 B 
223 0.03 - 
261 0.02 E 
Table A.6: HA1 locations identified by SLAC analysis as being under positive selective pressure 
 
For HA2 sites of interest identified from frequency analysis, counts of silent and nonsilent 
changes obtained from the full-length SLAC analysis are broadly in line with those obtained 
from the HA2-only analysis (Table A.7), indicating that the phylogenetic trees are similar. From 
the point of view of inferring sites under selective pressure, neither method seems preferable: 
however it would be worthwhile to conduct a more detailed examination of the inferred 
phylogenetic trees for HA2 and full-length HA, for example using bootstrap analysis to examine 
stability.  
A.6 Directional Evolution Study of Full-Length Sequences 
The 2008 study published by Kosakovsky Pond et al. was based on full-genome sequences of 
strains isolated between 1968 and 2005. For HA, 284 unique full-length sequences were 
available.  Software used for the study was provided publicly in version 1.0 of the HyPhy 
software package (www.hyphy.org). The sequence datasets used in the study are published. 
The analysis requires a rooted tree, and for this purpose the sequence of A/Hong Kong/1/1968 
was included in the 2000 and 2004 sequence sets. Analysis of the HA2 sequence sets using the 
provided  H5N1 substitution model in the current version of HyPhy, 2.1.1, yielded no results. 
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Site 
 
1999 to 2004 2004 to 2008 
HA2-only Analysis Full-length Analysis HA2-only Analysis Full-length Analysis 
Observed 
S 
Changes 
Observed 
NS 
Changes  
P{S leq. 
observed} 
Observed 
S 
Changes  
Observed 
NS 
Changes  
P{S leq. 
observed} 
Observed 
S 
Changes  
Observed 
NS 
Changes  
P{S leq. 
observed} 
Observed 
S 
Changes  
Observed 
NS 
Changes  
P{S leq. 
observed} 
18 1 5 0.51 1 6 0.44 2 5 0.58 2 6 0.47 
32 1 2 0.74 1 2 0.74 2 12 0.75 1.5 14.5 0.51 
46 4 0 1.00 4 0 1.00 3 9 0.84 3 4 0.92 
57 2 5 0.65 2 6 0.49 2 2 0.89 2 2 0.89 
121 3 6 0.70 2 6 0.52 3 5 0.75 1.9 5.5 0.58 
123 2 3 0.91 2 1 0.97 8 4 1.00 8 4 1.00 
Table A.7: Comparison of Silent and nonsilent changes, and derived p-value of positive selective pressure, for identified sites of interest, showing values obtained both from the HA2-only SLAC 
analysis and the Full-length SLAC analysis. 
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Site (Segment 
numbering) 
Chain Site (H3  
Numbering) 
Antigenic 
Site 
Preferred 
AA 
Estimated Bayes Factor 
Published 
Figures 
My Figures 
H5N1 model REV model 
5      I 
 
2695 639 
10    I >100000 704848 23875 
32 H
A
1 
16  G 
 
1092 693 
48 32  D 
 
2427 
 
61 45 C S 338 
  
74 58  I 
 
360 385 
94 78 E G 
 
3525 343 
101 85  D 
 
945 
 
151 135 A T 2109 
  
161 145 A K 1936 
  
171 155 B H 3047 
  
174 158 B K 212 
  
190 174 D F 
 
4040 
 
191 175 D D 
 
415 
 
230 214 D I 
 
320 594 
233 217 D I 
  
135 
236 220  R 
 
>1000
00  
245 229 D R 
>100000 
>1000
00  
246 230 D I 
 
714 438 
252 236  I 
 
179 196 
264 248 D T 1112 
  
347 H
A
2 
2  I 102 
  
395 50  G 
 
873 264 
434 89  I 
 
179 195 
453 108  I 
 
1683 1220 
477 132  D 
 
417 
 
483 138  F 
 
3178 
 
490 145  D 
 
239 
 
494 149  I 
 
711 435 
505 160  D 
 
238 
 
520 175  G 
 
187 296 
566      I 
 
118 130 
Table A.8: Sites identified as undergoing directional evolution identified using the method of Kosakovsky Pond et al. 
(2008). The Estimated Bayes Factor is returned by the model, and is a measure of the power of a directional model 
favouring the preferred amino acid compared to a neutral model. 
 
I attempted to reproduce the results originally published by Kosakovsky Pond et al. for H3N2 
HA in order to confirm that I was running the analysis correctly, but obtained quite different 
results (Table A.8). In correspondence with the author, it transpired that the results were 
obtained with the REV substitution model rather than H5N1. Using this model, I obtained a 
close subset of my earlier results. It is striking that, across these two results sets, 11 of the 25 
identified sites have leucine as the preferred residue. 
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A.7 Discussion 
The inference of selective pressure from synonymous and nonsynonymous nucleotide 
substitution rates has, since its inception (Miyata and Yasunaga, 1980), become sufficiently 
ubiquitous that it is tempting to regard a divergence in substitution rates as the definitive 
indicator of evolutionary pressure.  As evidenced in this study, however, the application of the 
technique to the analysis of single site mutations in a rapidly changing organism such as 
influenza presents several difficulties. 
Firstly, even with the high degree of change seen in influenza haemagglutinin, and with the 
large number of samples available, the number of changes at any one site is small, and the 
variation in the number of silent changes comparatively large. For example in the five year HA2 
samples used in this study, in the sites identified in Table A.4, the number of silent changes at a 
site ranges from 1 to 8, while the number of nonsilent changes ranges from 1 to 12, with 12 
being a notable outlier. In such circumstances, it is difficult to separate signal from noise and 
the predictive power of the approach becomes limited. 
While it may be possible to improve the signal-to-noise ratio by sampling over a larger time 
period, such an approach will exacerbate another problem encountered in this study, which is 
that selective pressure at a site may change over time. Consider the ‘directional sweep’ 
exemplified by site 2 in Figure A.1, in which isoleucine is completely replaced in the population 
by leucine. As noted by Kosakovsky Pond et al. (2008), selective pressure at such a site may be 
highly negative in the period before the change (when isoleucine dominates) and in the period 
after the change (when leucine dominates) but is highly positive during the change itself. 
Averaging over too long a time period is likely to miss events such as this one, which occurs 
over a short time period in a manner characteristic of changes in influenza HA. 
The directional evolution technique of Kosakovsky Pond et al. was introduced to detect just 
such switches, by focussing on directed change at the amino acid level. This method, however, 
has drawabacks of its own. Because it works at the amino acid level, the small numbers problem 
is even more acute. Also, if the site experiences reversals during the sample period (such as 
those seen in sites 46 and 121 in Figure A.1), both switches are likely to be missed due to 
averaging. Kosakovsky and Pond identify 7 sites in HA1 undergoing directional evolution 
compared at the 63 sites identified by Shih et al. (2007) in the same period. While it is possible 
that not all the switches were apparent in the 284 samples used by Kosakovsky Pond et al. 
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compared to the 2,248 samples used by Shih et al., reproducing the directional evolution 
analysis on a four node high performance compute cluster took approximately five days of 
computational time whereas running the Shih analysis on my database of over 10,000 sequences 
completes in a few seconds and is run on-the-fly in the course of requesting a page on the web 
site. 
The techniques applied in Chapters 3-5 aggregate effects across all branches of the phylogenetic 
tree. This highlights an important consideration in the study of the phylogeny of highly mutable 
organisms such as viruses as opposed to the study of larger and more stable organisms such as 
plants or animals. The samples we collect of the former, particularly under the intense scrutiny 
of surveillance programmes such as that in place for influenza, map out evolutionary ‘dead 
ends’ throughout the history of the phylogenetic tree. Over the time period for which data exists, 
we have not witnessed the evolution of differentiated organisms via genetic drift. These factors 
account for the topology of the tree, with wide branches and a single mainline trunk. In contrast, 
when we examine the phylogeny of more stable organisms, we typically only have samples of 
the evolutionarily successful ‘endpoints’, of which there may be many. We can infer common 
ancestors, but we will typically have no sight of evolutionary dead ends that occurred in the 
past. These factors influence the questions of interest and the approach that should be taken. For 
example, in the case of a virus, if we are interested in directed evolution of the organism over a 
representative period, we may wish to study evolution along the main branch alone, as in 
Chapter 3.  
Another issue observed with viral samples is the presence of inter-host adaptive mutations, for 
example the substitutions that are likely to occur if mammalian influenza is grown in eggs, or 
mutations observed in samples from severely ill patients where the virus has adapted to culture 
in lung tissue. Such mutations are not linked to a specific evolutionary pattern, and may be 
found in samples from many branches of the phylogenetic tree. A current example is in sites 
153 to 157 of H1N1pdm HA1, which have been seen to vary in some samples since the 
beginning of the pandemic. The cause of this variation is unknown, but it occurs in 
phylogenetically distinct samples in many branches (McCauley et al., 2012). Such adaptive 
mutations will be given prominence by mutation rate analyses, due to their presence in multiple 
branches, and this may account for the identification of sites such as those highlighted in Figure 
A.3. 
 142 
 
 
Suzuki (2013) identifies a further problem with the dN/dS approach, which is that, in 
calculating the ratio, all amino acid locations reachable by a single nucleotide mutation are 
considered physiologically plausible. In practice, some will not be, and the discrepancy means 
that the approach will under-estimate the significance of such substitutions as are observed. He 
attempts to address this by removing from consideration substitutions that would violate a free 
energy criterion. While this does allow a greater number of positively selected locations to be 
identified, there are problems with the approach. Firstly, the free energy calculations and the 
free energy threshold for each location have to be derived via approximations from the 
substitution history available for the location, and from the limited number of crystal structures 
available for the protein. Secondly, the approach will not take account of functional limitations 
on allowed substitutions, which, in the case of functional regions of a protein, such as the RBS 
and fusogenic region of HA, may impose additional limitations that will be missed by 
consideration of free energy calculations alone. 
dN/dS predictions of selective pressure are based on the assumption that synonymous codon 
mutations are not subject to selective pressure, however codon bias has been identified in 
influenza A PB2 (Marsh et al., 2008) and in other RNA viruses (Holmes, 2009). The argument 
has been put forward that selective pressures relating to plasticity are at work in HA, in addition 
to widely acknowledged host pressure relating to tRNA abundance and other host factors 
(Plotkin and Dushoff, 2003). The fundamental assumption of synonymous mutation neutrality is 
therefore questionable.  
Initial results from directional evolution analysis suggest that this method loses power when 
confined to a small run of years, possibly because such a sample does not provide enough data 
to accurately calibrate the substitution model. The SLAC analysis, on the other hand, appears to 
perform well with a five year window. One possible avenue to explore is a time-based sliding 
window SLAC analysis, which could reveal variation in selective pressure at individual sites 
when events such as frequency switches occur. A concern with this approach is the stability of a 
phylogenetic tree derived from samples from a small number of years. Bootstrapping techniques 
could be utilised to investigate the stability of such trees and hence derive an understanding of 
the minimum window period that is likely to produce acceptable results. 
Bootstrapping of phylogenetic trees would also provide an understanding of the most stable 
branches. Confining analyses (SLAC, directional selection and frequency analyses) to these 
branches may eliminate noise sourced from adaptive mutations and evolutionary dead ends. 
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Appendix B – Software Used In This Study 
B.1 Overview 
In previous work (Lees, 2009), I created a database of H3N2 sequences and HI assay 
information, collected from published sources. I created a web-based front-end through which 
consolidated information could be viewed: for example summarizing all assays relating to a 
particular strain. 
For this work, I extended the database to cover H1 strains as well as neuraminidase N2 
sequences, and different assay types, such as neutralisation, and HI in the presence of 
oseltamivir. In addition, I developed a ‘visualisation workbench’, which can be used to explore 
the spatial distribution of mutations, fixation events and mutation clusters. I include in this 
chapter an analysis of sequence and assay data quality, and a brief explanation of the functions 
and rationale of the web site. 
B.1.1 Scientific Aims 
The database and web site were developed to address the following scientific objectives: 
To provide a representative set of H1, H3 and N2 sequences covering the recorded 
period of activity. While large, publicly available sources exist, none are 
comprehensive, particularly in coverage of strains isolated before 1990. For this work, I 
wished to assemble as representative as possible a set of sequences covering the 
recorded active period of those subtypes.  
To improve sequence quality and matches between sequences and assay information 
through consensus and curation. In the course of assembling the sequence data, I 
encountered classification issues, naming issues (for example inconsistent abbreviation) 
and a small number of low-quality sequences. By developing my own database, I could 
bring together sequences from various sources, and pay careful attention to 
classification and consensus. 
To provide a consistent, curated set of HI assay information. In contrast to the sequence 
data, no publicly accessible database of HI assay data exists. By consolidating assays 
from numerous published sources, I aimed to create a significantly larger body of data 
than has previously been used for modelling purposes. 
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To facilitate the study of HA sequence evolution. While many general-purpose sequence 
analysis tools exist, I wished to make it easy to identify differences between specific 
sequences, or trends across the entire population, by referring conveniently and directly 
to the underlying sequence database. 
To visualise evolutionary trends on the structure. I wished to examine the location of 
evolutionary events such as substitutions and fixations on the protein structure, in a way 
that would facilitate interactive discovery and hence build knowledge of patterns and 
trends. 
Pages in addition to those provided on the website today were developed during the course of 
the research, for example to test particular techniques for substitution cluster identification, to 
classify substitutions in particular ways, and to test computational models linking antigenic and 
sequence development. The website as it stands includes those pages that I feel are of general 
interest, or which support specific results described in this work. 
B.2 The Web Site and Database 
Here I briefly describe the functionality offered from the home page of the web site (Figure 
B.1). The pages listed under ‘About the Database’ and ‘Basic Reports’ were first developed for 
my previous work, while the remaining pages were developed for this work. 
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Figure B.1: The Web Site Home Page 
 
B.2.1 About The Database 
The Source Papers and Reports and Papers and Reports by Institution pages provide details of 
all sources from which HI data has been extracted. The individual reports are clickable, 
providing a summary of the data extracted from each one. 
The Database Statistics page provides an overview of the data held within the system. At the 
time of writing, this encompasses HA sequences for 15,826 unique strains, 9678 H3N2 and 
6148 H1N1; and 28,677 HI assays, extracted from 57 papers and reports. 
The Assay Statistics page (newly developed for this work) provides some statistics on 
commonly conducted assays, for which multiple results are held in the database (Figure B.2). 
These statistics are discussed in Section 2.1. 
 147 
 
 
Figure B.2: Assay Statistics for frequently occurring strain pairs 
B.2.2 Basic Reports 
The Composite Assay Report merges HI assay data from all available reports for selected strains 
and antisera. 
The Virus Strain Report provides information held in the database for the specified strain, 
including a summary if its inclusion in HI assays, consolidated assay results, and available 
sequences. 
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B.2.3 Visualisation Workbench 
The web site embodies a flexible tool for visualising sequence differences on the HA molecule 
(Figure B.3). A similar facility exists for visualising N2 sequence differences. In the Compare 
Strains tab (shown in the figure), the user enters two strains of the same subtype. Type-ahead is 
provided, so that after typing the first few characters, matching strains with sequences present in 
the database are provided as a dropdown. Amino acid differences between the two strains are 
highlighted on a visualisation of the HA molecule rendered in Jmol (Hanson, 2010), using PDB 
structure 1RU7 (A/Puerto Rico/1934)  (Gamblin et al., 2004) for H1 strains and 1HGD 
(A/Aichi/2/1968) (Sauter et al., 1992) for H3 strains. The structures chosen have good 
resolution (2.6 and 2.7 Å respectively) and were taken of the protein in complex with the sialic 
acid receptor. These were chosen in preference to structures of the protein complexed with 
antibodies, as the structural shape of the HA molecule in the latter structures may be more 
grossly affected by binding to the antibody, given its much larger size and surface of interaction 
compared to the sialic acid complex. 
Through checkboxes, the user can elect to display a single monomer or the whole trimeric 
structure, can show or hide the HA2 chain, and can colour those locations comprising the RBS 
in yellow. Residues differing between the two strains are coloured red on the structure. Those 
which constitute fixations (i.e. the substitution observed in the later of the two strains becomes 
fixed across the whole population) can optionally be coloured in blue: here I take Shih’s 
definition of an “effective switch” (Shih et al., 2007), which includes a statistical test of 
significance, as constituting a fixation. In addition, the entire facilities of Jmol (for example to 
select a different display style or to measure distances between residues) are available by 
clicking or right-clicking on the display. 
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Figure B.3: Structural and Amino Acid comparison of HA strains from the web site (the Jalview amino acid 
sequence display has been omitted for brevity) 
A further checkbox enables the display of substitution clusters. A substitution cluster is defined 
as a set of three or more substitutions where all members of the set are within a specified 
distance of each other. In this visualisation tool, the distance is set to 35Å. The biological 
significance of substitution clusters is discussed in Chapter 3. 
Underneath the Jmol display is a quick summary of residue differences, including charge 
differences. Fixations are indicated. Below this (not shown in the figure) is a rendition of the 
two sequences in Jalview (Waterhouse et al., 2009) in which sequence differences are 
highlighted. 
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Other tabs on the screen provide additional visualisations superimposed onto the HA structure 
as follows (Figure B.4): 
Epitopes – Indicates (in red) the B-cell epitopes from selected influenza A / antibody 
complexes in the PDB (the residues comprising the epitope are those identified in the 
published article accompanying the structure). 
Site Variation – Shows visually the degree of polymorphism at each location in strains 
from the selected year, where white (for HA1) or grey (for HA2) indicate no variation, 
and shades from light yellow through to red indicate progressively greater degrees of 
variation. Fixations occurring that year are indicated in blue, if the ‘Show Frequency 
Switches’ option in the Control Panel is selected. 
Strain Transitions – Shows substitutions and fixations occurring between successive 
dominant H3N2 strains. A particular strain transition can be selected, or the sequence 
can be cycled through with the arrow buttons. 
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Figure B.4: Additional visualisations of HA available from the Visualisation Workbench. (A) – epitopes of selected 
structures; (B) – site variation heat map for a selected year; (C) – substitutions between two successive H3 dominant 
strains. 
The Antigenic Map Simulator generates simulated antigenic maps based on mutation 
characteristics provided by the user. It is discussed in detail in Chapter 4. 
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B.2.4 Fixation and Polymorphism 
The Amino Acid Frequency Chart provides a chart showing the relative frequency at which 
specific amino acids are observed at the specified location in each year for which samples are 
available, and a second chart showing the number of sequences available in each year (Figure 
B.5). 
 
The Fixation Report lists the year and location of all fixations identified in the H1 and H3 
sequence collections, using the method previously described by Shih et al. (2007).  The report is 
sortable by column header and can be exported to Excel. 
Figure B.5: Amino Acid Frequency Chart Web Page, showing the frequency chart for H3N2 HA1 location 222, and 
underneath a count of the number of H3N2 sequences available in each year. 
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The report indicates the perpendicular distance of the location at which the fixation occurs along 
the axis of the molecule (a precise definition is provided on the page). This distance can be used 
to identify fixations in the fusogenic region, using the definition of that region provided in 
Chapter 5. 
 
The Polymorphism Report lists the location and year of polymorphisms in a format similar to 
the fixation report. Here a polymorphism is defined as a location in which, across all the 
sequences available for a particular year, no one amino acid type is present in more than a 
threshold percentage of sequences. The threshold can be set on the page, but defaults to 80%. 
Polymorphisms By Year And Region generates a chart showing the number of fixations and 
polymorphisms occurring in each year in selected regions: antigenic sites A and B (as a single 
region), antigenic sites C and E (as a single region), and the fusogenic region (defined as in 
Chapter 5). The analysis is confined to H3 sequences. The plot can be restricted to particular 
data series of interest via the checkboxes (Figure B.6). 
Figure B.6: Polymorphism chart for H3 sequences, showing in this case the number of polymorphisms and fixations 
in each year in antigenic sites C and E. 
H3 Polymorphisms and Fixations by Year and Site tabulates the information displayed by 
Polymorphisms By Year And Region in a form convenient for import into Excel or other 
applications. 
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H1 and H3 Locations classified by Mutability classifies each location according to the 
mutability observed:  
- Switchers are those locations which have undergone a fixation event;  
- Polymorphic locations are those which have not, but have undergone a period of 
polymorphism as defined in the Polymorphism Report;  
- Invariant locations are those which always have the same dominant amino acid, and 
where the dominant amino acid is present in at least 95% of samples each year; 
- Intermediate locations are other locations not falling in to one of the above 
classifications.  
The HA2 Seeker lists strains for which an entire HA2 sequence is available which are 
genetically similar to a nominated target strain. Its use is explained in Section 2.4.2.  
Selective Pressure at Single HA Locations allows the user to compare an amino acid frequency 
analysis for a given H1 or H3 location with selective pressure estimates obtained from counts of 
nonsilent and silent mutations, using the Single Likelihood Ancestor Counting Method 
(Kosakovsky Pond and Frost, 2005). This analysis is discussed further in Appendix A. 
B.3 Software Used in this Study 
B.3.1 The Web Server 
The web server is built on open source components and will run on Linux or Microsoft 
Windows. Software components of the web server are shown in Table B.1. 
Name Purpose Developed By 
Apache HTTP Server 2.2 Web Server The Apache Foundation 
PHP 5.4 Server-side scripting The PHP Group 
MySQL Server 5.1 Database Oracle, Inc 
Table B.1: Server Software Components 
 
B.3.2 The Web Client 
The web client is also built on open source components. It has been tested with Mozilla Firefox 
v20, Google Chrome v27, and Microsoft Internet Explorer v10. Adobe Flash and Oracle Java 
must be installed in the browser for full functionality. Software components are shown in Table 
B.2. 
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Name Purpose Developed By 
Ext JS 3 Client-side scripting Sencha, Inc 
Jmol 13 Visualisation of protein 
structures 
www.jmol.org 
Jalview  Sequence visualisation Waterhouse et al. (2009) 
Table B.2: Web Client Software Components 
 
B.3.3 Other Software 
Other software used in the course of this study is listed in Table B.3. 
Name Purpose Developed By 
R 2.11 Statistical analysis http://www.r-project.org/ 
Muscle  Sequence alignment Edgar (2004) 
HyPhy 2.1 Phylogenetic Analysis Kosakovsky Pond et al. 
(2005) 
Word 2010 Word processing Microsoft, Inc 
Excel 2010 Data manipulation Microsoft, Inc 
PSPad Source code editing Jan Fiala 
Perl 5 Data manipulation www.perl.org 
Dropbox Backup and replication www.dropbox.com 
Unfuddle Source control and defect 
tracking 
www.unfuddle.com 
Table B.3: Web Client Software Components 
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